Methods of using activin receptor type ii variants

Extracellular activin receptor type II variants fused to an Fc domain monomer are used to treat ADPKD, lupus nephritis, and IgA nephropathy by reducing fibrosis and inflammation, effectively slowing disease progression and improving kidney function.

WO2026236607A1PCT designated stage Publication Date: 2026-11-12KEROS THERAPEUTICS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/027264
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-08
Filing Date
2026-05-08
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Current treatments for autosomal dominant polycystic kidney disease (ADPKD), lupus nephritis, ANCA-associated vasculitis, and IgA nephropathy are limited, leading to severe kidney damage and end-stage renal disease, with existing therapies like tolvaptan having significant side effects and limited efficacy.

Method used

Polypeptides comprising extracellular activin receptor type II variants, such as ActRII chimera or ActRIIB variants, fused to an Fc domain monomer, are administered to reduce kidney fibrosis and inflammation, thereby slowing disease progression and improving kidney function.

Benefits of technology

These polypeptides effectively reduce kidney fibrosis and inflammation, delay the onset of end-stage renal disease, and improve kidney function, reducing the need for dialysis or transplant in patients with ADPKD, lupus nephritis, or IgA nephropathy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000005_0001
    Figure IMGF000005_0001
  • Figure IMGF000018_0001_TABLE
    Figure IMGF000018_0001_TABLE
  • Figure IMGF000020_0001_TABLE
    Figure IMGF000020_0001_TABLE
Patent Text Reader

Abstract

The invention features methods for the treatment of autosomal dominant polycystic kidney disease (ADPKD), lupus nephritis, antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, and immunoglobulin A (IgA) nephropathy using a polypeptide containing an extracellular ActRII variant, such as a polypeptide containing an extracellular ActRII chimera or an extracellular ActRIIB variant. The polypeptide may include an extracellular ActRII chimera or an extracellular ActRIIB variant fused to an Fc domain monomer. Treatment of ADPKD, lupus nephritis, ANCA-associated vasculitis, and IgA nephropathy with a polypeptide described herein may reduce kidney inflammation, reduce kidney fibrosis, slow disease progression, and / or improve kidney function, which may reduce or delay the need for a kidney transplant or dialysis.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] PATENT

[0002] ATTORNEY DOCKET NO.: 51184-064WO2

[0003] METHODS OF USING ACTIVIN RECEPTOR TYPE II VARIANTS

[0004] Sequence Listing

[0005] The instant application contains a Sequence Listing which has been submitted electronically in XML file format and is hereby incorporated by reference in its entirety. Said XML copy, created on April 28, 2026, is named 51184-064WO2_Sequence_Listing_4_28_26 and is 421 ,636 bytes in size.

[0006] Background of the Invention

[0007] Autosomal dominant polycystic kidney disease (ADPKD) is the 4thleading cause of end stage renal disease (ESRD). In the United States about 500,000 people have ADPKD as well as 1 in every 400-1000 people worldwide. Approximately 75% of patients affected by ADPKD will develop ESRD by 70 years of age and require renal replacement therapy.

[0008] ADPKD is a genetic kidney disorder, characterized by the progressive formation and growth of bilateral fluid-filled cysts in the kidneys. As the disease progresses normal functional nephrons are crowded out by proliferating and growing cysts accompanied by inflamed and fibrotic tissue, resulting in progressive loss of kidney function and eventually ESRD. Mutations in the PKD1 or PKD2 genes, which encode polycystin-1 (PC1) and PC2, respectively, are the primary drivers of the disease.

[0009] The vasopressin receptor 2 antagonist Tolvaptan is the only approved treatment for ADPKD. Tolvaptan was only shown to delay ESRD by 3.1 years in patients with rapidly progressing ADPKD and has a high discontinuation rate due to polyuria (urinate 5-6 L / d) and polydypsia (drink 4-6 L / d) and a black box warning for liver failure.

[0010] Lupus nephritis is a kidney disease caused by systemic lupus erythematosus (SLE). SLE is an autoimmune disease that occurs when autoantibodies attack body tissues, leading to inflammation and tissue damage. In lupus nephritis, inflammation of the kidneys occurs as a result of autoantibodies attacking cells in the kidney due to SLE, which can result in kidney damage, inflammation, and kidney failure.

[0011] Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis is an autoimmune condition in which autoantibodies attack proteins found in neutrophils, leading to neutrophil activation and inflammation in blood vessels. In particular, the kidneys are most commonly and severely affected in ANCA-associated vasculitis. When blood vessels in the kidney are affected, it can cause glomerular inflammation and injury, ultimately leading to ESRD.

[0012] Immunoglobulin A (IgA) nephropathy is a condition in which IgA accumulates in the glomerulus of the kidneys, leading to damage, inflammation and gradual loss of the kidney’s ability to filter blood. As the disease progresses blood and proteins spill into the urine and may ultimately lead to ESRD.

[0013] Accordingly, the severe pathologies associated with these diseases and the limited treatment options available indicate a need for new treatments for ADPKD, lupus nephritis, ANCA-associated vasculitis, and IgA nephropathy.

[0014] Summary of the Invention

[0015] The present invention features polypeptides that include an extracellular activin receptor type II (ActRII) variant, such as an extracellular ActRIIB variant or an extracellular ActRII chimera. In somePATENT

[0016] ATTORNEY DOCKET NO.: 51184-064WO2

[0017] embodiments, a polypeptide of the invention includes an extracellular ActRII variant fused to the N- or C-terminus of an Fc domain monomer (e.g., by fusion of the C-terminus of the ActRII variant to the N-terminus of an Fc domain monomer by way of a linker), which may be attached by amino acid or other covalent bonds and increase stability of the polypeptide. A polypeptide including an extracellular ActRII variant fused to an Fc domain monomer may also form a dimer (e.g., a homodimer or heterodimer) through the interaction between two Fc domain monomers. The polypeptides of the invention may be used to treat a subject having autosomal dominant polycystic kidney disease (ADPKD), lupus nephritis, antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, and immunoglobulin A (IgA) nephropathy. The polypeptides described herein may treat ADPKD, lupus nephritis, ANCA-associated vasculitis, or IgA nephropathy by reducing kidney fibrosis and / or kidney inflammation, by slowing or inhibiting the progression kidney fibrosis and / or kidney inflammation, or by delaying the development of kidney fibrosis and / or kidney inflammation. The polypeptides described herein may also improve kidney function, slow or inhibit a decline in kidney function, delay or prevent the onset of end stage renal disease, delay or prevent the need for dialysis, delay or prevent the need for continuous renal replacement therapy, or delay or prevent the need for a kidney transplant in a subject having ADPKD, lupus nephritis, ANCA-associated vasculitis, or IgA nephropathy.

[0018] Exemplary embodiments of the invention are described in the enumerated paragraphs below. E1. A method of treating ADPKD in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a composition of Table 7 or a composition of Table 8.

[0019] E2. The method of E1 , wherein the method reduces kidney cyst volume, hepatic cyst volume, or pancreatic cyst volume.

[0020] E3. The method of E1 or E2, wherein the subject has a mutation in polycystin 1 (PKD1) or polycystin 2 (PKD2).

[0021] E4. The method of any one of E1-E3, wherein the method slows or inhibits progression of cardiovascular disease.

[0022] E5. The method of E4, wherein the cardiovascular disease is hypertension, an aneurysm, mitral valve prolapse, aortic dissection, atrial fibrillation, left ventricular hypertrophy, aortic calcification, soft tissue calcification, cardiomyopathy, vasculitis, or left-sided heart failure.

[0023] E6. The method of any one of E1-E5, wherein the method slows or inhibits progression of bone disease.

[0024] E7. The method of E6, wherein the bone disease is osteoporosis, bone pain, bone fracture, soft tissue calcification, osteopenia, osteopetrosis, bone cancer or cancer metastasis-related bone loss, Paget’s disease, renal osteodystrophy, treatment-related bone loss, osteogenesis imperfecta, neuromuscular disease-related bone loss, burn-induced bone loss, anorexia-related bone loss, diet-related bone loss, bone loss associated with the treatment of obesity, low gravity- related bone loss, or immobility-related bone loss.

[0025] E8. The method of E7, wherein the cancer is multiple myeloma, osteosarcoma, breast cancer, prostate cancer, lung cancer, or kidney cancer.

[0026] E9. The method of any one of E1-E8, wherein the method slows or inhibits progression of diverticular disease.PATENT

[0027] ATTORNEY DOCKET NO.: 51184-064WO2

[0028] E10. The method of any one of E1 -E9, wherein the method prevents urinary tract infections or decreases the frequency or severity of urinary tract infections.

[0029] E11. The method of any one of E1 -E10, wherein the method reduces kidney weight.

[0030] E12. The method of any one of E1 -E11 , wherein the method reduces expression of a SMAD2 / 3 target gene.

[0031] E13. The method of E12, wherein the SMAD2 / 3 target gene is Col1a1 , Fn1 (EDA), or PAH .

[0032] E14. A method of treating lupus nephritis in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a composition of Table 7 or a composition of Table 8.

[0033] E15. The method of E14, wherein the method slows or inhibits progression of cardiovascular disease. E16. The method of E15, wherein the cardiovascular disease is hypertension or left ventricular hypertrophy.

[0034] E17. The method of any one of E14-E16, wherein the method slows or inhibits progression of bone disease.

[0035] E18. The method of E17, wherein the bone disease is osteoporosis, bone pain, bone fracture, soft tissue calcification, osteopenia, osteopetrosis, bone cancer or cancer metastasis-related bone loss, Paget’s disease, renal osteodystrophy, treatment-related bone loss, osteogenesis imperfecta, neuromuscular disease-related bone loss, burn-induced bone loss, anorexia-related bone loss, diet-related bone loss, bone loss associated with the treatment of obesity, low gravity- related bone loss, or immobility-related bone loss.

[0036] E19. The method of E18, wherein the cancer is multiple myeloma, osteosarcoma, breast cancer, prostate cancer, lung cancer, or kidney cancer.

[0037] E20. A method of treating ANCA-associated vasculitis in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a composition of Table 7 or a composition of Table 8.

[0038] E21. The method of E20, wherein the method slows or inhibits progression of cardiovascular disease. E22. The method of E21 , wherein the cardiovascular disease is hypertension or left ventricular hypertrophy.

[0039] E23. The method of any one of E20-E22, wherein the method slows or inhibits progression of bone disease.

[0040] E24. The method of E23, wherein the bone disease is osteoporosis, bone pain, bone fracture, soft tissue calcification, osteopenia, osteopetrosis, bone cancer or cancer metastasis-related bone loss, Paget’s disease, renal osteodystrophy, treatment-related bone loss, osteogenesis imperfecta, neuromuscular disease-related bone loss, burn-induced bone loss, anorexia-related bone loss, diet-related bone loss, bone loss associated with the treatment of obesity, low gravity- related bone loss, or immobility-related bone loss.

[0041] E25. The method of E24, wherein the cancer is multiple myeloma, osteosarcoma, breast cancer, prostate cancer, lung cancer, or kidney cancer.

[0042] E26. A method of treating IgA nephropathy in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a composition of Table 7 or a composition of Table 8.PATENT

[0043] ATTORNEY DOCKET NO.: 51184-064WO2

[0044] E27. The method of E26, wherein the method slows or inhibits progression of cardiovascular disease. E28. The method of E27, wherein the cardiovascular disease is hypertension or left ventricular hypertrophy.

[0045] E29. The method of any one of E26-E28, wherein the method slows or inhibits progression of bone disease.

[0046] E30. The method of E29, wherein the bone disease is osteoporosis, bone pain, bone fracture, soft tissue calcification, osteopenia, osteopetrosis, bone cancer or cancer metastasis-related bone loss, Paget’s disease, renal osteodystrophy, treatment-related bone loss, osteogenesis imperfecta, neuromuscular disease-related bone loss, burn-induced bone loss, anorexia-related bone loss, diet-related bone loss, bone loss associated with the treatment of obesity, low gravity- related bone loss, or immobility-related bone loss.

[0047] E31 . The method of E30, wherein the cancer is multiple myeloma, osteosarcoma, breast cancer, prostate cancer, lung cancer, or kidney cancer.

[0048] E32. The method of any one of E1 -E31 , wherein the subject is male.

[0049] E33. The method of any one of E1 -E31 , wherein the subject is female.

[0050] E34. The method of any one of E1 -E33, wherein the method reduces kidney fibrosis or slows or inhibits progression of kidney fibrosis.

[0051] E35. The method of any one of E1-E34, wherein the method reduces kidney inflammation or slows or inhibits progression of kidney inflammation.

[0052] E36. The method of any one of E1 -E35, wherein the method improves kidney function or slows or inhibits a decline in kidney function.

[0053] E37. The method of E36, wherein improving kidney function or slowing or inhibiting a decline in kidney function results in improved glomerular filtration rate (GFR) or slowing or stopping a progressive decline in GFR, improved protein-to-creatinine ratio (PCR), albumin-to-creatinine ratio (ACR), or urinary albumin-creatinine-ratio (UACR) or slowing or stopping a progressive increase in PCR, ACR or UACR, reduced blood urea nitrogen, reduced creatinine in blood, improved creatinine clearance, reduced proteinuria, reduced hematuria, or reduced albuminuria.

[0054] E38. The method of E37, wherein the method improves GFR or slows or inhibits a decline in GFR. E39. The method of any one of E1 -E38, wherein the method delays or prevents the onset of end stage renal disease.

[0055] E40. The method of any one of E1 -E39, wherein the method delays or prevents a need for dialysis, continuous renal replacement therapy, or a kidney transplant.

[0056] E41 . The method of any one of E1 -E40, wherein the method improves life expectancy for the subject. E42. The method of any one of E1 -E41 , wherein the method comprises administering to the subject a therapeutically effective amount of a composition of Table 7.

[0057] E43. The method of any one of E1 -E42, wherein the composition of Table 7 is a polypeptide comprising an extracellular ActRII chimera having a sequence of any one of SEQ ID NOs: 1 -21 , wherein Xi is D or R, X2 is I, F, E, D, Y, S, N, Q, or T, X3 is N or T, X4 is A or E, X5 is T or K, Xe is E or K, X7 is E or D, Xs is N or S, and X9 is Q, E, K, R, D, or N, optionally wherein the chimera is truncated from the N-terminus by deletion of 1 , 2, 3, 4, 5, 6, 7, 8, or 9 amino acids, wherein the chimera retains the two amino acids before the first cysteine.PATENT

[0058] ATTORNEY DOCKET NO.: 51184-064WO2

[0059] E44. The method of E43, wherein the chimera has the sequence of SEQ ID NO: 19.

[0060] E45. The method of E43, wherein the chimera has the sequence of SEQ ID NO: 12.

[0061] E46. The method of E43, wherein the chimera has the sequence of SEQ ID NO: 5.

[0062] E47. The method of any one of E43-E46, wherein Xi is D, X2 is I, F, or E, X3 is N or T, X4 is A or E, X5 is T or K, Xe is E or K, X7 is E or D, Xs is N or S, and X9 is E or Q.

[0063] E48. The method of E47, wherein Xi is D, X2 is I or F, X3 is N, X4 is A or E, X5 is T or K, Xe is E or K, X7 is E or D, Xs is N or S, and X9

[0064]

[0065] is E or Q. E49. The method of E48, wherein Xi is D, X2 is F, X3 is N, X4 is E, X5 is K, Xe is K, X7 is D, Xs is S, and X9 is Q.

[0066] E50. The method of E43, wherein the chimera has the sequence of any one of SEQ ID NOs: 22-43. E51. The method of E50, wherein the chimera has the sequence of SEQ ID NO: 41.

[0067] E52. The method of E50, wherein the chimera has the sequence of SEQ ID NO: 25.

[0068] E53. The method of E50, wherein the chimera has the sequence of SEQ ID NO: 40.

[0069] E54. The method of any one of E43-E53, wherein the polypeptide further includes an Fc domain monomer fused to the C-terminus of the polypeptide (e.g., the C-terminus of the chimera) by way of a linker.

[0070] E55. The method of E54, wherein the polypeptide is in the form of a dimer (e.g., a homodimer).

[0071] E56. The method of E54, wherein the polypeptide has the sequence of any one of SEQ ID NOs: 107- 110 and SEQ ID NOs: 184-263.

[0072] E57. The method of E56, wherein the polypeptide has the sequence of SEQ ID NO: 216.

[0073] E58. The method of E56, wherein the polypeptide has the sequence of SEQ ID NO: 110.

[0074] E59. The method of E56, wherein the polypeptide has the sequence of SEQ ID NO: 215.

[0075] E60. The method of any one of E56-E59, wherein the polypeptide is in the form of a homodimer.

[0076] E61. The method of any one of E1 -E41 , wherein the method comprises administering to the subject a therapeutically effective amount of a composition of Table 8.

[0077] E62. The method of any one of E1 -E41 and E61 , wherein the composition of Table 8 is a polypeptide comprising an extracellular activin receptor type I IB (ActRIIB) variant, the variant having one or more amino acid substitutions relative to the sequence of GRGEAETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIELVKKGCWLDDF NCYDRQECVATEENPQVYFCCCEGNFCNERFTHLPEAGGPEVTYEPPPTAPT (SEQ ID NO: 45), wherein the variant comprises one or more amino acid substitutions that impart reduced BMP9 binding relative to wild type extracellular ActRIIB and one or more additional amino acid substitutions, wherein the substitutions that reduce BMP9 binding comprise one or more of:

[0078] a) amino acid substitution E75K;

[0079] b) amino acid substitutions Q69T and E70D; or

[0080] c) amino acid substitutions Q69D and E70T,

[0081] optionally wherein the variant is truncated from the N-terminus by deletion of 1 , 2, 3, 4, 5, 6, or 7 amino acids.

[0082] E63. The method of E62, wherein the variant comprises amino acid substitutions 111 L, L27V, Q34K, T50S, 151 L, L53I, Q69D, E70T, E75K, and F89M or amino acid substitutions 111 L, L27V, Q34K, T50S, 151 L, L53I, Q69T, E70D, E75K, and F89M.PATENT

[0083] ATTORNEY DOCKET NO.: 51184-064WO2

[0084] E64. The method of E62, wherein the variant has the sequence of any one of SEQ ID NOs: 270-283. E65. The method of E64, wherein the variant has the sequence of SEQ ID NO: 283.

[0085] E66. The method of any one of E62-E65, wherein the polypeptide further includes an Fc domain monomer fused to the C-terminus of the polypeptide (e.g., the C-terminus of the variant) by way of a linker.

[0086] E67. The method of E66, wherein the polypeptide is in the form of a dimer (e.g., a homodimer).

[0087] E68. The method of E66, wherein the polypeptide has the sequence of SEQ ID NO: 284.

[0088] E69. The method of E68, wherein the polypeptide is in the form of a homodimer.

[0089] E70. The method of any one of E1-E69, wherein the composition is administered in an amount sufficient to reduce kidney fibrosis, delay the development of kidney fibrosis, slow or inhibit the progression of kidney fibrosis, reduce kidney inflammation, slow or inhibit the progression of kidney inflammation, improve kidney function, slow or inhibit a decline in kidney function, improve GFR, slow or stop a progressive decline in GFR, improve PCR, ACR, or UACR, slow or stop a progressive increase in PCR, ACR or UACR, reduce blood urea nitrogen, reduce creatinine in the blood, improve creatinine clearance, reduce proteinuria, delay or inhibit the onset of end-stage renal disease, treat, prevent, delay the onset of, slow the progression of, or reduce the risk of hematuria, proteinuria, delay or prevent a need for dialysis, continuous renal replacement therapy, or a kidney transplant, or improve life expectancy.

[0090] E71. The method of any one of E1 -E70, wherein the subject is a human.

[0091] Definitions

[0092] To facilitate the understanding of this invention, a number of terms are defined below. Terms defined herein have meanings as commonly understood by a person of ordinary skill in the areas relevant to the invention. Terms such as “a”, “an,” and “the” are not intended to refer to only a singular entity but include the general class of which a specific example may be used for illustration. The terminology herein is used to describe specific embodiments of the invention, but their usage does not limit the invention, except as outlined in the claims.

[0093] As used herein, the term “about” refers to a value that is within 10% above or below the value being described.

[0094] As used herein, any values provided in a range of values include both the upper and lower bounds, and any values contained within the upper and lower bounds.

[0095] As used herein, the terms “extracellular activin receptor type II (ActRI I) chimera,” “extracellular ActRII chimera,” and “ActRI I chimera” refer to a polypeptide including a soluble, extracellular portion of the single transmembrane receptor ActRIIB and a soluble, extracellular portion of the single transmembrane receptor ActRIIA. The ActRII chimeras described herein result from joining an N-terminal portion of extracellular ActRIIB to a C-terminal portion of extracellular ActRIIA such that the sequences are contiguous (e.g., the ActRIIA sequence continues where the ActRIIB sequence left off, starting with the next the amino acid located in the corresponding position of ActRIIA). The extracellular ActRII chimera may also include one or more amino acid substitutions in the portion of the chimera that corresponds to the sequence of ActRIIB compared to a wild-type extracellular ActRIIB (e.g., bold portion of the sequence of SEQ ID NO: 46 shown below) and / or one or more amino acid substitutions in thePATENT

[0096] ATTORNEY DOCKET NO.: 51184-064WO2

[0097] portion of the chimera that corresponds to the sequence of ActRIIA compared to a wild-type extracellular ActRIIA (e.g., bold portion of the sequence of SEQ ID NO: 47 shown below). The extracellular ActRII chimera may also have an N-terminal truncation of 1-9 amino acids relative to the extracellular portion of ActRIIB or ActRIIA. The sequences of wild-type, human ActRIIB (SEQ ID NO: 46) and wild-type, human ActRIIA (SEQ ID NO: 47) are shown below, in which the signal peptide is italicized and the extracellular portion is bold.

[0098] Wild-type human ActRIIB (SEQ ID NO: 46):

[0099] MTAPWV44MU.WGSZ.CAGSGRGEAETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYAS WRNSSGTIELVKKGCWLDDFNCYDRQECVATEENPQVYFCCCEGNFCNERFTHLPEAGGPEV TYEPPPTAPTLLTVLAYSLLPIGGLSLIVLLAFWMYRHRKPPYGHVDIHEDPGPPP PSPLVGLKPLQLLEIKARGRFGCVWKAQLMNDFVAVKIFPLQDKQSWQSEREIFSTPGMK HENLLQFIAAEKRGSNLEVELWLITAFHDKGSLTDYLKGNIITWNELCHVAETMSRGLSY LHEDVPWCRGEGHKPSIAHRDFKSKNVLLKSDLTAVLADFGLAVRFEPGKPPGDTHGQVG TRRYMAPEVLEGAINFQRDAFLRIDMYAMGLVLWELVSRCKAADGPVDEYMLPFEEEIGQ HPSLEELQEVVVHKKMRPTIKDHWLKHPGLAQLCVTIEECWDHDAEARLSAGCVEERVSL IRRSVNGTTSDCLVSLVTSVTNVDLPPKESSI

[0100] Wild-type, human ActRIIA precursor protein (SEQ ID NO: 47):

[0101] MGAAAKiLAFAI / FE / SCSSGAILGRSETQECLFFNANWEKDRTNQTGVEPCYGDKDKRRHCFAT WKNISGSIEIVKQGCWLDDINCYDRTDCVEKKDSPEVYFCCCEGNMCNEKFSYFPEMEVTQPT SNPVTPKPPYYNILLYSLVPLMLIAGIVICAFWVYRHHKMAYPPVLVPTQDPGPPPPSPLLGLKPL QLLEVKARGRFGCVWKAQLLNEYVAVKIFPIQDKQSWQNEYEVYSLPGMKHENILQFIGAEKRG TSVDVDLWLITAFHEKGSLSDFLKANVVSWNELCHIAETMARGLAYLHEDIPGLKDGHKPAISHR DIKSKNVLLKNNLTACIADFGLALKFEAGKSAGDTHGQVGTRRYMAPEVLEGAINFQRDAFLRID MYAMGLVLWELASRCTAADGPVDEYMLPFEEEIGQHPSLEDMQEVVVHKKKRPVLRDYWQKH AGMAMLCETIEECWDHDAEARLSAGCVGERITQMQRLTNIITTEDIVTVVTMVTNVDFPPKESSL

[0102] An extracellular ActRII chimera may have the sequence of any one of SEQ ID NOs: 1-43. In particular embodiments, an extracellular ActRII chimera has the sequence of any one of SEQ ID NOs: 22-43 (Table 2).

[0103] As used herein, the terms “extracellular activin receptor type IIB (ActRIIB) variant” and “ActRIIB variant” refer to a polypeptide including a soluble, extracellular portion of the single transmembrane receptor, ActRIIB, that has at least one amino acid substitution relative to a wild-type extracellular ActRIIB (e.g., bold portion of the sequence of SEQ ID NO: 46, shown above). An extracellular ActRIIB variant may have a sequence of any one of SEQ ID NOs: 269-283. In particular embodiments, an extracellular ActRIIB variant has a sequence of any one of SEQ ID NOs: 270-283 (Table 6). In some embodiments, an extracellular ActRIIB variant may have at least 85% (e.g., at least 85%, 87%, 90%, 92%, 95%, 96%, 97%, 98%, 99%, or greater) amino acid sequence identity to the sequence of a wild-type extracellular ActRIIB (SEQ ID NO: 45). The extracellular ActRIIB variant may also have an N-terminal truncation of 1 -7 amino acids relative to the extracellular portion of ActRIIB.PATENT

[0104] ATTORNEY DOCKET NO.: 51184-064WO2

[0105] As used herein, the term “extracellular activin receptor type II (ActRI I) variant” refers to an extracellular ActRIIB variant or an extracellular ActRI I chimera described herein.

[0106] As used herein, the term “N-terminal truncation” refers to a deletion of 1 -7 amino acids (e.g., 1 , 2, 3, 4, 5, 6, or 7 amino acids) from the N-terminus of an extracellular ActRIIB variant (e.g., an extracellular ActRIIB variant having the sequence of any one of SEQ ID NOs: 269-283 (e.g., SEQ ID NOs: 270-283)) or a deletion of 1 -9 amino acids (e.g., 1, 2, 3, 4, 5, 6, 7, 8, or 9 amino acids) from the N-terminus of an extracellular ActRI I chimera (e.g., an extracellular ActRI I chimera having the sequence of any one of SEQ ID NOs: 1-43 (e.g., SEQ ID NOs: 22-43)). The N-terminal truncation can remove amino acids up to two amino acids before the first cysteine (e.g., the two amino acids before the first cysteine (RE) are retained in an N-terminally truncated extracellular ActRIIB variant and the two amino acids before the first cysteine (RE or QE) are retained in an N-terminally truncated extracellular ActRII chimera).

[0107] As used herein, the term “linker” refers to a linkage between two elements, e.g., peptides or protein domains. A polypeptide described herein may include an extracellular ActRII variant (e.g., an extracellular ActRII chimera having the sequence of any one of SEQ ID NOs: 1-43 (e.g., SEQ ID NOs: 22-43) or an extracellular ActRIIB variant having the sequence of any one of SEQ ID NOs: 269-283 (e.g., SEQ ID NOs: 270-283)) fused to an Fc domain monomer, which increases stability or improves pharmacokinetic properties of the polypeptide. The Fc domain monomer may be fused to the polypeptide by way of a linker. A linker can be a covalent bond or a spacer. The term “bond” refers to a chemical bond, e.g., an amide bond or a disulfide bond, or any kind of bond created from a chemical reaction, e.g., chemical conjugation. The term “spacer” refers to a moiety (e.g., a polyethylene glycol (PEG) polymer) or an amino acid sequence (e.g., a 1-200 amino acid sequence) occurring between two elements, e.g., peptides or protein domains, to provide space and / or flexibility between the two elements. An amino acid spacer is part of the primary sequence of a polypeptide (e.g., fused to the spaced peptides via the polypeptide backbone). The formation of disulfide bonds, e.g., between two hinge regions that form an Fc domain, is not considered a linker.

[0108] As used herein, the term “Fc domain” refers to a dimer of two Fc domain monomers. An Fc domain has at least 80% sequence identity (e.g., at least 85%, 90%, 95%, 97%, or 100% sequence identity) to a human Fc domain that includes at least a CH2 domain and a CH3 domain. An Fc domain monomer includes second and third antibody constant domains (CH2 and CH3). In some embodiments, the Fc domain monomer also includes a hinge domain. An Fc domain does not include any portion of an immunoglobulin that is capable of acting as an antigen-recognition region, e.g., a variable domain or a complementarity determining region (CDR). In the wild-type Fc domain, the two Fc domain monomers dimerize by the interaction between the two CH3 antibody constant domains, as well as one or more disulfide bonds that form between the hinge domains of the two dimerizing Fc domain monomers. In some embodiments, an Fc domain may be mutated to lack effector functions, typical of a “dead Fc domain.” In certain embodiments, each of the Fc domain monomers in an Fc domain includes amino acid substitutions in the CH2 antibody constant domain to reduce the interaction or binding between the Fc domain and an Fey receptor. In some embodiments, the Fc domain contains one or more amino acid substitutions that reduce or inhibit Fc domain dimerization. An Fc domain can be any immunoglobulin antibody isotype, including IgG, IgE, IgM, IgA, or IgD. Additionally, an Fc domain can be an IgG subtypePATENT

[0109] ATTORNEY DOCKET NO.: 51184-064WO2

[0110] (e.g., lgG1 , lgG2a, lgG2b, lgG3, or lgG4). The Fc domain can also be a non-naturally occurring Fc domain, e.g., a recombinant Fc domain.

[0111] As used herein, the term “endogenous” describes a molecule (e.g., a polypeptide, nucleic acid, or cofactor) that is found naturally in a particular organism (e.g., a human) or in a particular location within an organism (e.g., an organ, a tissue, or a cell, such as a human cell, e.g., a human red blood cell, platelet, neutrophil, or muscle cell).

[0112] As used herein, the term “fused” is used to describe the combination or attachment of two or more elements, components, or protein domains, e.g., peptides or polypeptides, by means including chemical conjugation, recombinant means, and chemical bonds, e.g., amide bonds. For example, two single peptides in tandem series can be fused to form one contiguous protein structure, e.g., a polypeptide, through chemical conjugation, a chemical bond, a peptide linker, or any other means of covalent linkage. In some embodiments of a polypeptide described herein, an extracellular ActRII variant (e.g., an extracellular ActRII chimera having the sequence of any one of SEQ ID NOs: 1-43 (e.g., SEQ ID NOs: 22-43) or an extracellular ActRIIB variant having the sequence of any one of SEQ ID NOs: 269-283 (e.g., SEQ ID NOs: 270-283)) may be fused in tandem series to the N- or C-terminus of an Fc domain monomer (e.g., the sequence of SEQ ID NO: 48, SEQ ID NO: 100, SEQ ID NO: 264, or SEQ ID NO: 285) by way of a linker. For example, an extracellular ActRII variant is fused to an Fc domain monomer by way of a peptide linker, in which the N-terminus of the peptide linker is fused to the C-terminus of the extracellular ActRII variant through a chemical bond, e.g., a peptide bond, and the C-terminus of the peptide linker is fused to the N-terminus of the Fc domain monomer through a chemical bond, e.g., a peptide bond.

[0113] As used herein, the terms “increasing” and “decreasing” refer to modulating resulting in, respectively, greater or lesser amounts, of function, expression, or activity of a metric relative to a reference. For example, subsequent to administration of a polypeptide described herein including an extracellular ActRII variant in a method described herein, the amount of a marker of a metric (e.g., kidney fibrosis) as described herein may be increased or decreased in a subject relative to the amount of the marker prior to administration. Generally, the metric is measured subsequent to administration at a time that the administration has had the recited effect, e.g., at least one week, one month, 3 months, or 6 months, after a treatment regimen has begun.

[0114] As used herein, the term “fibrosis” refers to the pathological process of formation of excess fibrous connective tissue in an organ or tissue. Fibrosis is characterized by fibroblast accumulation and collagen deposition in excess of normal deposition in any particular tissue. In response to inflammation or an injury to a tissue, nearby fibroblasts can migrate into the wound, proliferate, and produce large amounts of collagenous extracellular matrix. When fibrosis occurs in response to injury, the term “scarring” can be used as synonym.

[0115] As used herein, the term “autosomal dominant polycystic kidney disease” (ADPKD) refers to a genetic disorder characterized by the progressive formation and growth of bi-lateral fluid filled cysts in the kidneys. As cysts accumulate and grow, they compress and damage normal functioning nephrons, creating an environment of progressive injury, inflammation and fibrosis. As the disease progresses, kidney function declines until patients reach end-stage renal disease. ADPKD is the result of mutations in PKD1 or PKD2, coding for polycystin-1 (PO1) or polycystin-2 (PC2), respectively.PATENT

[0116] ATTORNEY DOCKET NO.: 51184-064WO2

[0117] As used herein, the term “lupus nephritis” refers to a kidney disease caused by systemic lupus erythematosus (SLE). SLE is an autoimmune disease that occurs when autoantibodies attack body tissues, leading to inflammation and tissue damage. In lupus nephritis, inflammation of the kidneys occurs as a result of autoantibodies attacking cells in the kidney due to SLE, which can result in kidney damage, inflammation, and kidney failure.

[0118] As used herein, the term “antineutrophil cytoplasmic antibody-associated vasculitis” (ANCA-associated vasculitis) refers to an autoimmune condition in which autoantibodies attack proteins associated with neutrophils, leading to neutrophil activation and inflammation in blood vessels. In particular, the kidneys are most commonly and severely affected in ANCA-associated vasculitis. When blood vessels in the kidney are affected, it can cause glomerular inflammation and injury, ultimately leading to ESRD.

[0119] As used herein, the term “immunoglobulin A nephropathy” (IgA nephropathy) refers to a condition in which IgA accumulates in the glomeruli of the kidneys, resulting in damage, inflammation, and loss of kidney function, which can lead to ESRD.

[0120] As used herein, the term “bone disease” refers to a condition characterized by bone damage (e.g., decreased bone mineral density, decreased bone strength, and / or bone loss). Such diseases or conditions may be caused by an imbalance in osteoblast and / or osteoclast activity (e.g., increased bone resorption or reduced bone formation). Bone diseases include osteoporosis (e.g. primary or secondary osteoporosis), osteopenia, osteopetrosis, bone pain, bone fracture, soft tissue calcification, bone cancer or cancer metastasis-related bone loss (e.g., bone loss associated with multiple myeloma, osteosarcoma, breast cancer, prostate cancer, lung cancer, or kidney cancer), Paget’s disease, renal osteodystrophy, osteogenesis imperfecta, neuromuscular disease-related bone loss, burn-induced bone loss, anorexia-related bone loss, treatment-related bone loss, diet-related bone loss, bone loss associated with the treatment of obesity, low gravity-related bone loss, and immobility-related bone loss.

[0121] As used herein, the term “cardiovascular disease” refers to any disease or disorder of the heart or blood vessels (e.g., arteries and veins) or any symptom thereof, or any disease or condition that causes or contributes to a cardiovascular disease. Non-limiting examples of cardiovascular diseases include hypertension, an aneurysm, mitral valve prolapse, aortic dissection, atrial fibrillation, left ventricular hypertrophy, aortic calcification, soft tissue calcification, cardiomyopathy, vasculitis, and left-sided heart failure.

[0122] As used herein, the term “diverticular disease” refers to a disease where small pouches (i.e., diverticula) form in the colon. Diverticular disease includes diverticulosis, in which one or more diverticula form in the colon. Diverticular disease also includes diverticulitis, in which diverticula become inflamed, and diverticular bleeding, in which a small blood vessel in a pouch breaks open and bleeds.

[0123] As used herein, the term “SMAD2 / 3 target gene” refers to a gene whose expression is activated by phosphorylated SMAD2 and SMAD3. SMAD2 / 3 target genes include, for example, Col1a1 , Fn1(EDA), and PAH .

[0124] As used herein, the term “albuminuria” refers to a condition in which more than the normal amount of albumin is present in the urine. Normally, the glomerular filtration permeability barrier, which is composed of podocytes, glomerular basement membrane, and endothelial cells, prevents serum protein from leaking into urine. Albuminuria may reflect injury of the glomerular filtration permeability barrier.PATENT

[0125] ATTORNEY DOCKET NO.: 51184-064WO2

[0126] Albuminuria may be calculated from a 24-hour urine sample, an overnight urine sample or a spot-urine sample. Albuminuria can be determined by the albumin excretion rate (AER) and / or the albumin-to-creatine ratio (ACR) in the urine (also referred to as UACR). “Albumin / creatinine ratio” refers to the ratio of urine albumin (mg / dL) per urine creatinine (g / dL) and is expressed as mg / g. In certain embodiments, albumin / creatinine ratio may be calculated from a spot-urine sample and may be used as an estimate of albumin excretion over a 24-hour period.

[0127] As used herein, the term “blood urea nitrogen” refers to a measure of the amount of nitrogen in the blood in the form of urea. The liver produces urea in the urea cycle as a waste product of the digestion of protein, and the urea is removed from the blood by the kidneys. Normal human adult blood may contain between 7 to 21 mg of urea nitrogen per 100 ml (7-21 mg / dL) of blood. Measurement of blood urea nitrogen is used as an indicator of renal health. If the kidneys are not able to remove urea from the blood normally, a subject's blood urea nitrogen rises.

[0128] As used herein, the term “end stage renal disease (ESRD)” refers to the complete or almost complete failure of kidney function.

[0129] As used herein the term “hematuria” refers to a condition characterized by the presence of red blood cells in the urine.

[0130] As used herein, the terms “estimated glomerular filtration rate (eGFR)” and “glomerular filtration rate (GFR)” refer to a measurement of how well the kidneys are filtering creatinine and are used as an estimate of how much blood passes through the glomeruli per minute. The estimated GFR may be calculated based on serum creatinine values, e.g., using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation, the Cockcroft-Gault formula, or the Modification of Diet in Renal Disease (MDRD) formula, which are all known in the art. Normal results may range from 90-120 mL / min / 1 .73 m2. Values of >60 to <90 mL / min / 1 .73 m2may indicate mild renal impairment, values of >30 to <60 mL / min / 1 .73 m2may indicate moderate renal impairment, and values of >15 to <30 mL / min / 1 .73 m2may indicate severe renal impairment. Levels below 60 mL / min / 1 .73 m2for three or more months may be an indicator of chronic kidney disease. Levels below 15 mL / min / 1 .73 m2may be an indicator of kidney failure.

[0131] As used herein the term “proteinuria” refers to a condition in which there is a presence of excess protein in the urine. The protein content in urine is usually measured as a concentration in mg / dL. The concentration of protein in the urine may be compared to the creatinine level in the urine sample. This is termed the protein / creatinine ratio (PCR). Usually, proteinuria is defined as a protein / creatinine ratio (PCR) greater than 45 mg / mmol, which is equivalent to an albumin-to-creatinine ration (ACR) of greater than 30 mg / mmol or approximately 300 mg / g. Proteinuria may also be characterized by the excretion of > 250 mg of protein into the urine per 24 hours and / or a urine protein to creatinine ratio of > 0.20 mg / mg.

[0132] As used herein, the term “C-terminal extension” refers to the addition of one or more amino acids to the C-terminus of an extracellular ActRII chimera (e.g., an extracellular ActRII chimera having the sequence of any one of SEQ ID NOs: 1-43 (e.g., SEQ ID NOs: 22-43)). The C-terminal extension can be one or more amino acids, such as 1 -6 amino acids (e.g., 1 , 2, 3, 4, 5, 6 or more amino acids). The C-terminal extension may include amino acids from the corresponding position of wild-type ActRIIA or ActRIIB. Exemplary C-terminal extensions are the amino acid sequence NP (a two amino acid C-terminalPATENT

[0133] ATTORNEY DOCKET NO.: 51184-064WO2

[0134] extension) and the amino acid sequence NPVTPK (SEQ ID NO: 104) (a six amino acid C-terminal extension). Any amino acid sequence that does not disrupt the activity of the polypeptide can be used.

[0135] As used herein, the term “percent (%) identity” refers to the percentage of amino acid (or nucleic acid) residues of a candidate sequence, e.g., an extracellular ActRIIB variant or an extracellular ActRII chimera, that are identical to the amino acid (or nucleic acid) residues of a reference sequence, e.g., a wild-type extracellular ActRIIA (e.g., SEQ ID NO: 44) or wild-type extracellular ActRIIB (e.g., SEQ ID NO: 45), after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent identity (i.e., gaps can be introduced in one or both of the candidate and reference sequences for optimal alignment and non-homologous sequences can be disregarded for comparison purposes). Alignment for purposes of determining percent identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, ALIGN, or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared. In some embodiments, the percent amino acid (or nucleic acid) sequence identity of a given candidate sequence to, with, or against a given reference sequence (which can alternatively be phrased as a given candidate sequence that has or includes a certain percent amino acid (or nucleic acid) sequence identity to, with, or against a given reference sequence) is calculated as follows:

[0136] 100 x (fraction of A / B)

[0137] where A is the number of amino acid (or nucleic acid) residues scored as identical in the alignment of the candidate sequence and the reference sequence, and where B is the total number of amino acid (or nucleic acid) residues in the reference sequence. In some embodiments where the length of the candidate sequence does not equal to the length of the reference sequence, the percent amino acid (or nucleic acid) sequence identity of the candidate sequence to the reference sequence would not equal to the percent amino acid (or nucleic acid) sequence identity of the reference sequence to the candidate sequence.

[0138] In particular embodiments, a reference sequence aligned for comparison with a candidate sequence may show that the candidate sequence exhibits from 50% to 100% identity across the full length of the candidate sequence or a selected portion of contiguous amino acid (or nucleic acid) residues of the candidate sequence. The length of the candidate sequence aligned for comparison purpose is at least 30%, e.g., at least 40%, e.g., at least 50%, 60%, 70%, 80%, 90%, or 100% of the length of the reference sequence. When a position in the candidate sequence is occupied by the same amino acid (or nucleic acid) residue as the corresponding position in the reference sequence, then the molecules are identical at that position.

[0139] As used herein, the term “serum half-life” refers to, in the context of administering a therapeutic protein to a subject, the time required for plasma concentration of the protein in the subject to be reduced by half. The protein can be redistributed or cleared from the bloodstream, or degraded, e.g., by proteolysis. Serum half-life comparisons can be made by comparing the serum half-life of Fc fusion proteins.

[0140] As used herein, the terms “affinity” and “binding affinity” refer to the strength of the binding interaction between two molecules. Generally, binding affinity refers to the strength of the sum total ofPATENT

[0141] ATTORNEY DOCKET NO.: 51184-064WO2

[0142] non-covalent interactions between a molecule and its binding partner, such as an extracellular ActRII chimera or an extracellular ActRIIB variant and BMP9, activin A, or activin B. Unless indicated otherwise, binding affinity refers to intrinsic binding affinity, which reflects a 1 :1 interaction between members of a binding pair. The binding affinity between two molecules is commonly described by the dissociation constant (KD) or the affinity constant (KA). TWO molecules that have low binding affinity for each other generally bind slowly, tend to dissociate easily, and exhibit a large KD. TWO molecules that have high affinity for each other generally bind readily, tend to remain bound longer, and exhibit a small KD. The KD of two interacting molecules may be determined using methods and techniques well known in the art, e.g., surface plasmon resonance. KD is calculated as the ratio of kotf / kon.

[0143] As used herein, the phrase “affecting myostatin, activin A, activin B, and / or BMP9 signaling” means changing the binding of myostatin, activin A, activin B, and / or BMP9 to their receptors, e.g., ActRIIA, ActRIIB, and BMPRII (e.g., ActRIIA or ActRIIB, e.g., endogenous ActRIIA or ActRIIB). In some embodiments, a polypeptide including an extracellular ActRII chimera or an extracellular ActRIIB variant described herein reduces or inhibits the binding of myostatin, activin A, activin B, and / or BMP9 to their receptors, e.g., ActRIIA, ActRIIB, and / or BMPRII (e.g., ActRIIA or ActRIIB, e.g., endogenous ActRIIA or ActRIIB).

[0144] As used herein, the term “polypeptide” describes a single polymer in which the monomers are amino acid residues which are covalently conjugated together through amide bonds. A polypeptide is intended to encompass any amino acid sequence, either naturally occurring, recombinant, or synthetically produced.

[0145] As used herein, the term “homodimer” refers to a molecular construct formed by two identical macromolecules, such as proteins or nucleic acids. The two identical monomers may form a homodimer by covalent bonds or non-covalent bonds. For example, an Fc domain may be a homodimer of two Fc domain monomers if the two Fc domain monomers contain the same sequence. In another example, a polypeptide described herein including an extracellular ActRII chimera or an extracellular ActRIIB variant fused to an Fc domain monomer may form a homodimer through the interaction of two Fc domain monomers, which form an Fc domain in the homodimer.

[0146] As used herein, the term “heterodimer” refers to a molecular construct formed by two different macromolecules, such as proteins or nucleic acids. The two monomers may form a heterodimer by covalent bonds or non-covalent bonds. For example, a polypeptide described herein including an extracellular ActRII chimera or an extracellular ActRIIB variant fused to an Fc domain monomer may form a heterodimer through the interaction of two Fc domain monomers, each fused to a different ActRII chimera or ActRIIB variant, which form an Fc domain in the heterodimer (e.g., a heterodimer can contain two different extracellular ActRIIB variants or two different extracellular ActRII chimeras).

[0147] As used herein, the term “host cell” refers to a vehicle that includes the necessary cellular components, e.g., organelles, needed to express proteins from their corresponding nucleic acids. The nucleic acids are typically included in nucleic acid vectors that can be introduced into the host cell by conventional techniques known in the art (transformation, transfection, electroporation, calcium phosphate precipitation, direct microinjection, etc.). A host cell may be a prokaryotic cell, e.g., a bacterial cell, or a eukaryotic cell, e.g., a mammalian cell (e.g., a CHO cell or a HEK293 cell).PATENT

[0148] ATTORNEY DOCKET NO.: 51184-064WO2

[0149] As used herein, the term “therapeutically effective amount” refers an amount of a polypeptide, nucleic acid, or vector described herein or a pharmaceutical composition containing a polypeptide, nucleic acid, or vector described herein effective in achieving the desired therapeutic effect in treating a patient having a or at risk of developing a disease, such as ADPKD, lupus nephritis, ANCA-associated vasculitis, or IgA nephropathy. In particular, the therapeutically effective amount of the polypeptide, nucleic acid, or vector avoids adverse side effects.

[0150] As used herein, the term “pharmaceutical composition” refers to a medicinal or pharmaceutical formulation that includes an active ingredient as well as excipients and diluents to enable the active ingredient suitable for the method of administration. The pharmaceutical composition of the present invention includes pharmaceutically acceptable components that are compatible with the polypeptide, nucleic acid, or vector. The pharmaceutical composition may be in tablet or capsule form for oral administration or in aqueous form for intravenous or subcutaneous administration.

[0151] As used herein, the term “pharmaceutically acceptable carrier or excipient” refers to an excipient or diluent in a pharmaceutical composition. The pharmaceutically acceptable carrier must be compatible with the other ingredients of the formulation and not deleterious to the recipient. In the present invention, the pharmaceutically acceptable carrier or excipient must provide adequate pharmaceutical stability to the polypeptide including an extracellular ActRII chimera or an extracellular ActRIIB variant, the nucleic acid molecule(s) encoding the polypeptide, or a vector containing such nucleic acid molecule(s). The nature of the carrier or excipient differs with the mode of administration. For example, for intravenous administration, an aqueous solution carrier is generally used; for oral administration, a solid carrier is preferred.

[0152] As used herein, “treatment” and “treating” in reference to a disease or condition, refer to an approach for obtaining beneficial or desired results, e.g., clinical results. Beneficial or desired results can include, but are not limited to, alleviation or amelioration of one or more symptoms or conditions; diminishment of extent of disease or condition; stabilized (i.e. , not worsening) state of disease, disorder, or condition; preventing spread of disease or condition; delay or slowing the progress of the disease or condition; amelioration or palliation of the disease or condition; and remission (whether partial or total), whether detectable or undetectable. “Ameliorating” or “palliating” a disease or condition means that the extent and / or undesirable clinical manifestations of the disease, disorder, or condition are lessened and / or time course of the progression is slowed or lengthened, as compared to the extent or time course in the absence of treatment. “Treatment” can also mean prolonging survival as compared to expected survival if not receiving treatment. Those in need of treatment include those already with the condition or disorder, as well as those prone to have the condition or disorder or those in which the condition or disorder is to be prevented.

[0153] As used herein, the term “subject” refers to a mammal, e.g., preferably a human. Mammals include, but are not limited to, humans and domestic and farm animals, such as monkeys (e.g., a cynomolgus monkey), mice, rats, dogs, cats, horses, sheep, goats, rabbits, and cows, etc.

[0154] As used herein, the term “cellular assay that measures inhibition of activin A signaling” refers to an in vitro cell-based assay that measures the amount of binding of activin A ligand to its receptors (e.g., ActRIIA, ActRIIB, and BMPRII). Cellular assays that measure inhibition of activin A signaling are known in the art (see, e.g., International Patent Application Publication No. WO2021189019, which is incorporatedPATENT

[0155] ATTORNEY DOCKET NO.: 51184-064WO2

[0156] herein by reference in its entirety). For example, the cellular assay may be a luciferase reporter assay in which activin A ligand is incubated with cells expressing a Smad binding element (SBE)-Luciferase reporter (BPS Bioscience), which activates the downstream signaling that results in luciferase expression. When activin A ligand is pre-incubated with a polypeptide including an extracellular ActRII chimera or an extracellular ActRIIB variant before being added to the cells, there is a loss of luciferase signal corresponding to the extent of activin A ligand inhibition. By testing a series of polypeptide concentrations ranging from no inhibition to complete inhibition of activin A signaling, the IC50 value may be calculated.

[0157] As used herein, the term “cellular assay that measures inhibition of activin B signaling” refers to an in vitro cell-based assay that measures the amount of binding of activin B ligand to its receptors (e.g., ActRIIA, ActRIIB, and BMPRII). Cellular assays that measure inhibition of activin B signaling are known in the art (see, e.g., International Patent Application Publication No. WO2021189019, which is incorporated herein by reference in its entirety). For example, the cellular assay may be a luciferase reporter assay in which activin B ligand is incubated with cells expressing an SBE-Luciferase reporter (BPS Bioscience), which activates the downstream signaling that results in luciferase expression. When activin B ligand is pre-incubated with a polypeptide including an extracellular ActRII chimera or an extracellular ActRIIB variant before being added to the cells, there is a loss of luciferase signal corresponding to the extent of activin B ligand inhibition. By testing a series of polypeptide concentrations ranging from no inhibition to complete inhibition of activin B signaling, the IC50 value may be calculated.

[0158] Brief Description of the Drawings

[0159] FIGS. 1A-1D are a series of graphs showing left kidney weight (FIG. 1A), right kidney weight (FIG. 1B), total kidney weight (FIG. 1C), and kidney / body weight (2KBW) (FIG. 1D) following a 12-week treatment regimen of one-month old doxycycline inducible PKD1 knockout (KO) mice (Pkd1 f / f; Pax8+; Tet-O-Cre+). Immediately following doxycycline administration, mice were dosed subcutaneously (5 mL / kg) with 10 mg / kg ActRIIB 2.12-mFc (a homodimer of SEQ ID NO: 283 linked to a mouse Fc domain monomer by a GGG linker) (n=5 mice), 3 mg / kg Chimera 1 / 2b-mFc (a homodimer of SEQ ID NO: 41 fused to a mouse Fc domain monomer by way of a GGG linker) (n=5 mice), or Tris(hydroxymethyl)aminomethane (Tris)-buffered saline (TBS) control (n=4 mice) twice weekly for twelve weeks. Statistics are shown using one way analysis of variance (ANOVA) with Dunnett’s post-hoc test for multiple comparisons. * p<0.05.

[0160] Detailed Description of the Invention

[0161] The invention features methods of treating autosomal dominant polycystic kidney disease (ADPKD), lupus nephritis, antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, or immunoglobulin A (IgA) nephropathy by administering to a subject a polypeptide including an extracellular activin receptor type II (ActRII) variant, such an extracellular ActRII chimera or an extracellular ActRIIB variant. In some embodiments, a polypeptide including an extracellular ActRII variant includes an extracellular ActRII variant fused to an Fc domain monomer. A polypeptide including an extracellular ActRII variant fused to an Fc domain monomer may form a dimer (e.g., homodimer or heterodimer) through the interaction between two Fc domain monomers. The ActRII variants described herein may bind to activins (e.g., activin A and / or activin B), myostatin, and GDF-11 , and may have weak bindingPATENT

[0162] ATTORNEY DOCKET NO.: 51184-064WO2

[0163] affinity or no binding affinity to bone morphogenetic protein 9 (BMP9). Treatment of ADPKD, lupus nephritis, ANCA-associated vasculitis, or IgA nephropathy with a polypeptide including an extracellular ActRII variant described herein may reduce kidney inflammation, reduce or reverse kidney fibrosis, slow or inhibit the progression of kidney fibrosis or kidney inflammation, delay the development of kidney fibrosis or kidney inflammation, slow or inhibit disease progression, improve kidney function, slow or inhibit a decline in kidney function, delay the onset of kidney failure or end stage renal disease, and / or delay or eliminate the need for dialysis or a kidney transplant.

[0164] Extracellular activin receptor type II variants

[0165] Activin type II receptors are single transmembrane domain receptors that modulate signals for ligands in the transforming growth factor p (TGF-p) superfamily. Ligands in the TGF-p superfamily are involved in a host of physiological processes, such as muscle growth, vascular growth, cell differentiation, homeostasis, hematopoiesis, and osteogenesis. Examples of ligands in the TGF-p superfamily include, e.g., activin A, activin B, inhibin, growth differentiation factors (GDFs) (e.g., GDF8, also known as myostatin, and GDF11), and bone morphogenetic proteins (BMPs) (e.g., BMP9).

[0166] There exist two types of activin type II receptors: ActRIIA and ActRIIB. Studies have shown that BMP9 binds ActRIIB with about 300-fold higher binding affinity than ActRIIA (see, e.g., Townson et al., J. Biol. Chem. 287:27313, 2012). ActRIIA-Fc is known to have a longer half-life compared to ActRIIB-Fc. Described herein are two types of ActRII variants: 1) extracellular ActRII chimeras that are constructed by combining portions of extracellular ActRIIA and ActRIIB with the goal of generating proteins that bind to ActRII ligands (e.g., activin A, activin B, myostatin, and GDF11) and retain the function of wild-type extracellular ActRII proteins; and 2) extracellular ActRIIB variants that are constructed by introducing amino acid residues of ActRIIA into ActRIIB, or by introducing novel amino acid substitutions, with the goal of reducing BMP9 binding to prevent or reduce disruption of endogenous BMP9 signaling.

[0167] ActRII chimeras

[0168] In some embodiments, the ActRII variant for use according to the methods described herein is an extracellular ActRII chimera constructed by combining portions of extracellular ActRIIA and ActRIIB with the goal of generating proteins that bind to ActRII ligands (e.g., activin A, activin B, myostatin, and GDF11) and retain or improve upon the function of wild-type extracellular ActRII proteins. In some embodiments, the ActRII chimeras exhibit reduced BMP9 binding relative to wild-type extracellular ActRIIB, which can prevent or reduce disruption of endogenous BMP9 signaling. In some embodiments, the chimeras have properties of both ActRIIA (e.g., low binding affinity to BMP9 and / or longer serum halflife as an Fc fusion protein) and ActRIIB (e.g., strong binding affinity to activins A and B). The ActRII chimeras may exhibit similar or improved binding to activins (e.g., activin A and / or activin B) and / or myostatin compared to wild-type extracellular ActRIIA and / or ActRIIB, allowing them to compete with endogenous activin receptors for ligand binding and reduce or inhibit endogenous activin receptor signaling. The wild-type amino acid sequences of the extracellular portions of human ActRIIA and ActRIIB are shown below.PATENT

[0169] ATTORNEY DOCKET NO.: 51184-064WO2

[0170] Human ActRIIA, extracellular portion (SEQ ID NO: 44):

[0171] GAILGRSETQECLFFNANWEKDRTNQTGVEPCYGDKDKRRHCFATWKNISGSIEIVKQGCWLD DINCYDRTDCVEKKDSPEVYFCCCEGNMCNEKFSYFPEMEVTQPTS

[0172] Human ActRIIB, extracellular portion (SEQ ID NO: 45):

[0173] GRGEAETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIELVKKGCWLDDF NCYDRQECVATEENPQVYFCCCEGNFCNERFTHLPEAGGPEVTYEPPPTAPT

[0174] In some embodiments, the polypeptide for use according to the methods described herein is a polypeptide including an extracellular ActRII chimera that contains sequence from both the extracellular portion of ActRIIB and the extracellular portion of ActRIIA. The ActRII chimeras described herein result from joining an N-terminal portion of extracellular ActRIIB (SEQ ID NO: 45 shown above) to a C-terminal portion of extracellular ActRIIA (SEQ ID NO: 44 shown above) such that the sequences are contiguous (e.g., the ActRIIA sequence continues where the ActRIIB sequence left off, starting with the next the amino acid located in the corresponding position of ActRIIA). In some embodiments, the N-terminus of the ActRII chimera includes the six amino acids found at the N-terminus of extracellular ActRIIA joined to the fifth amino acid of extracellular ActRIIB. In some embodiments, the N-terminus of the ActRII chimera begins with the first amino acid located at the N-terminus of extracellular ActRIIB. Accordingly, in some embodiments, the N-terminal portion of ActRIIB begins with the amino acid in the fifth position of SEQ ID NO: 45 (A), while in other embodiments (e.g., in embodiments in which the six amino acids found at the N-terminus of extracellular ActRIIA are not included in the chimera), the N-terminal portion of ActRIIB begins with the amino acid in the first position of SEQ ID NO: 45 (G). In some embodiments, the N-terminus of the ActRII chimera includes the first ten amino acids found at the N-terminus of extracellular ActRIIA joined to the ninth amino acid of extracellular ActRIIB, in which case the N-terminal portion of ActRIIB begins with the amino acid in the ninth position of SEQ ID NO: 45 (E). The extracellular ActRII chimera may also include one or more amino acid substitutions in the portion of the chimera that corresponds to the sequence of ActRIIB compared to wild-type extracellular ActRIIB (e.g., SEQ ID NO: 45 shown above) and / or one or more amino acid substitutions in the portion of the chimera that corresponds to the sequence of ActRIIA compared to wild-type extracellular ActRIIA (e.g., SEQ ID NO: 44 shown above). Amino acid substitutions at 9 different positions may be introduced into an extracellular ActRII chimera (Table 1). An extracellular ActRII chimera may have one or more (e.g., 1 , 2, 3, 4, 5, 6, 7, 8, or 9) amino acid substitutions relative the sequence of a wild-type sequence (e.g., relative to the sequence of wild-type extracellular ActRIIB (SEQ ID NO: 45) if the portion of the chimera corresponds to a region of wild-type extracellular ActRIIB, or relative to the sequence of wild-type extracellular ActRIIA (SEQ ID NO: 44) if the portion of the chimera corresponds to a region of wild-type extracellular ActRIIA). The positions at which amino acid substitutions may be made, as well as the amino acids that may be substituted at these positions, are listed in Table 1.

[0175] Amino acid substitutions can alter the activity and / or binding affinity of the extracellular ActRII chimeras. In some embodiments, the extracellular ActRII chimeras bind to activin A, activin B, myostatin, and / or GDF11 with sufficient affinity to compete with endogenous activin receptors for binding to one or more of these ligands. In some embodiments, the extracellular ActRII chimeras have reduced, weak, orPATENT

[0176] ATTORNEY DOCKET NO.: 51184-064WO2

[0177] no substantial binding to BMP9 (e.g., compared to wild-type ActRIIB). BMP9 binding may be reduced in extracellular ActRII chimeras containing the amino acid sequence TEEN (SEQ ID NO: 265) or TKEN (SEQ ID NO: 266) at positions X3, X4, X5, and Xe. In some embodiments, a polypeptide including an extracellular ActRII chimera (e.g., any one of SEQ ID NOs: 1-43 (e.g., SEQ ID NOs: 22-43)) with the sequence TEEN (SEQ ID NO: 265) at positions X3, X4, X5, and Xe can have a substitution of the amino acid K for the amino acid E at position X4. In some embodiments, a polypeptide including an extracellular ActRII chimera (e.g., any one of SEQ ID NOs: 1-43 (e.g., SEQ ID NOs: 22-43)) with the sequence TKEN (SEQ ID NO: 266) at positions X3, X4, X5, and Xe can have a substitution of the amino acid E for the amino acid K at position X4. The sequences TEEN (SEQ ID NO: 265) and TKEN (SEQ ID NO: 266) can be used interchangeably in the extracellular ActRII chimeras (e.g., the chimeras in Tables 1 and 2, e.g., SEQ ID NOs: 1 -43 (e.g., SEQ ID NOs: 22-43)). The extracellular ActRII chimeras may further include a C-terminal extension (e.g., additional amino acids at the C-terminus). The C-terminal extension can add one or more additional amino acids at the C-terminus (e.g., 1 , 2, 3, 4, 5, 6 or more additional amino acids) to any of the chimeras shown in Tables 1 and 2 (e.g., SEQ ID NOs: 1 -43 (e.g., SEQ ID NOs: 22-43)). The C-terminal extension may correspond to sequence from the same position in wild-type ActRIIA or ActRIIB. For example, C-terminal extensions that can be included in the extracellular ActRII chimeras of the invention are the amino acid sequence NP and the amino acid sequence NPVTPK (SEQ ID NO: 104), which correspond to sequence found in the same position in wild-type ActRIIA.

[0178] Table 1. Extracellular ActRII chimeras GAILGRAETRECIYYNANWELERTNQSGLERCEGEQX1KRRHCFATWKNISGSIEIVKQGCWLDDX2X3 CYDRTDCVX4X5X6X7X8PX9VYFCCCEGNMCNEKFSYFPEMEVTQPTS (SEQ ID NO: 1)

[0179] GAILGRAETRECIYYNANWELERTNQSGLERCEGEQX1KRLHCFATWKNISGSIEIVKQGCWLDDX2X3 CYDRTDCVX4X5X6X7X8PX9VYFCCCEGNMCNEKFSYFPEMEVTQPTS (SEQ ID NO: 2)

[0180] GAILGRAETRECIYYNANWELERTNQSGLERCEGEQX1KRLHCYASWKNISGSIEIVKQGCWLDDX2X3 CYDRTDCVX4X5X6X7X8PX9VYFCCCEGNMCNEKFSYFPEMEVTQPTS (SEQ ID NO: 3)

[0181] GAILGRAETRECIYYNANWELERTNQSGLERCEGEQX1KRLHCYASWRNSSGSIEIVKQGCWLDDX2 X3CYDRTDCVX4X5X6X7X8PX9VYFCCCEGNMCNEKFSYFPEMEVTQPTS (SEQ ID NO: 4)

[0182] GAILGRAETRECIYYNANWELERTNQSGLERCEGEQX1KRLHCYASWRNSSGTIEIVKQGCWLDDX2X 3CYDRTDCVX4X5X6X7X8PX9VYFCCCEGNMCNEKFSYFPEMEVTQPTS (SEQ ID NO: 5)

[0183] GAILGRAETRECIYYNANWELERTNQSGLERCEGEQX1KRLHCYASWRNSSGTIELVKKGCWLDDX2 X3CYDRTDCVX4X5X6X7X8PX9VYFCCCEGNMCNEKFSYFPEMEVTQPTS (SEQ ID NO: 6)

[0184] GAILGRAETRECIYYNANWELERTNQSGLERCEGEQX1KRLHCYASWRNSSGTIELVKKGCWLDDX2 X3CYDRQECVX4X5X6X7X8PX9VYFCCCEGNMCNEKFSYFPEMEVTQPTS (SEQ ID NO: 7)

[0185]

[0186] PATENT

[0187] ATTORNEY DOCKET NO.: 51184-064WO2

[0188] GRGEAETRECIYYNANWELERTNQSGLERCEGEQX1KRRHCFATWKNISGSIEIVKQGCWLDDX2X3C YDRTDCVX4X5X6X7X8PX9VYFCCCEGNMCNEKFSYFPEMEVTQPTS (SEQ ID NO: 8)

[0189] GRGEAETRECIYYNANWELERTNQSGLERCEGEQX1KRLHCFATWKNISGSIEIVKQGCWLDDX2X3C YDRTDCVX4X5X6X7X8PX9VYFCCCEGNMCNEKFSYFPEMEVTQPTS (SEQ ID NO: 9)

[0190] GRGEAETRECIYYNANWELERTNQSGLERCEGEQX1KRLHCYASWKNISGSIEIVKQGCWLDDX2X3C YDRTDCVX4X5X6X7X8PX9VYFCCCEGNMCNEKFSYFPEMEVTQPTS (SEQ ID NO: 10)

[0191] GRGEAETRECIYYNANWELERTNQSGLERCEGEQX1KRLHCYASWRNSSGSIEIVKQGCWLDDX2X3C YDRTDCVX4X5X6X7X8PX9VYFCCCEGNMCNEKFSYFPEMEVTQPTS (SEQ ID NO: 11)

[0192] GRGEAETRECIYYNANWELERTNQSGLERCEGEQX1KRLHCYASWRNSSGTIEIVKQGCWLDDX2X3C YDRTDCVX4X5X6X7X8PX9VYFCCCEGNMCNEKFSYFPEMEVTQPTS (SEQ ID NO: 12)

[0193] GRGEAETRECIYYNANWELERTNQSGLERCEGEQX1KRLHCYASWRNSSGTIELVKKGCWLDDX2X3 CYDRTDCVX4X5X6X7X8PX9VYFCCCEGNMCNEKFSYFPEMEVTQPTS (SEQ ID NO: 13)

[0194] GRGEAETRECIYYNANWELERTNQSGLERCEGEQX1KRLHCYASWRNSSGTIELVKKGCWLDDX2X3 CYDRQECVX4X5X6X7X8PX9VYFCCCEGNMCNEKFSYFPEMEVTQPTS (SEQ ID NO: 14)

[0195] GAILGRSETQECIYYNANWELERTNQSGLERCEGEQX1KRRHCFATWKNISGSIEIVKQGCWLDDX2X3 CYDRTDCVX4X5X6X7X8PX9VYFCCCEGNMCNEKFSYFPEMEVTQPTS (SEQ ID NO: 15)

[0196] GAILGRSETQECIYYNANWELERTNQSGLERCEGEQX1KRLHCFATWKNISGSIEIVKQGCWLDDX2X3 CYDRTDCVX4X5X6X7X8PX9VYFCCCEGNMCNEKFSYFPEMEVTQPTS (SEQ ID NO: 16)

[0197] GAILGRSETQECIYYNANWELERTNQSGLERCEGEQX1KRLHCYASWKNISGSIEIVKQGCWLDDX2X3 CYDRTDCVX4X5X6X7X8PX9VYFCCCEGNMCNEKFSYFPEMEVTQPTS (SEQ ID NO: 17)

[0198] GAILGRSETQECIYYNANWELERTNQSGLERCEGEQX1KRLHCYASWRNSSGSIEIVKQGCWLDDX2 X3CYDRTDCVX4X5X6X7X8PX9VYFCCCEGNMCNEKFSYFPEMEVTQPTS (SEQ ID NO: 18)

[0199] GAILGRSETQECIYYNANWELERTNQSGLERCEGEQX1KRLHCYASWRNSSGTIEIVKQGCWLDDX2 X3CYDRTDCVX4X5X6X7X8PX9VYFCCCEGNMCNEKFSYFPEMEVTQPTS (SEQ ID NO: 19)

[0200] GAILGRSETQECIYYNANWELERTNQSGLERCEGEQX1KRLHCYASWRNSSGTIELVKKGCWLDDX2 X3CYDRTDCVX4X5X6X7X8PX9VYFCCCEGNMCNEKFSYFPEMEVTQPTS (SEQ ID NO: 20)PATENT

[0201] ATTORNEY DOCKET NO.: 51184-064WO2

[0202] GAILGRSETQECIYYNANWELERTNQSGLERCEGEQX1KRLHCYASWRNSSGTIELVKKGCWLDDX2 X3CYDRQECVX4X5X6X7X8PX9VYFCCCEGNMCNEKFSYFPEMEVTQPTS (SEQ ID NO: 21)

[0203] Xi D or R x6E or K

[0204] I, F, E, D, Y, S, N, Q, or

[0205] x2x

[0206] T7E or D

[0207] X3N or T Xs N or S X4 A or E x9Q, E, K, R, D, or N x5T or K

[0208]

[0209] In some embodiments, in the extracellular ActRII chimeras of SEQ ID NOs: 1-21 (shown in Table 1) Xi is D, X2 is I, F, or E, X3 is N or T, X4 is A or E, X5 is T or K, Xe is E or K, X7 is E or D, Xs is N or S, and X9 is E or Q. In some embodiments, in the extracellular ActRII chimeras of SEQ ID NOs: 1-21 Xi is D, X2 is I or F, X3 is N, X4 is A or E, X5 is T or K, Xe is E or K, X7 is E or D, Xs is N or S, and X9 is E or Q.

[0210] In some embodiments, a polypeptide for use in the methods described herein includes an extracellular ActRII chimera having the sequence of any one of SEQ ID NOs: 22-43 (Table 2).

[0211] Table 2. Extracellular ActRII chimeras

[0212] SEQ ID NO: Amino Acid Sequence

[0213] 22 GAILGRAETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIV KQGCWLDDINCYDRTDCVATEENPQVYFCCCEGNMCNEKFSYFPEMEVTQPTS

[0214] 23 GRGEAETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVK QGCWLDDINCYDRTDCVEKKDSPEVYFCCCEGNMCNEKFSYFPEMEVTQPTS

[0215] 24 GRGEAETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVK QGCWLDDINCYDRTDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTS

[0216] 25 GRGEAETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVK QGCWLDDFNCYDRTDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTS

[0217] 26 GAILGRAETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIV KQGCWLDDFNCYDRTDCVATEENPQVYFCCCEGNMCNEKFSYFPEMEVTQPTS

[0218] 27 GRGEAETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVK QGCWLDDFNCYDRTDCVEKKDSPEVYFCCCEGNMCNEKFSYFPEMEVTQPTS

[0219] 28 GRGEAETRECIYYNANWELERTNQSGLERCEGEQDKRRHCFATWKNISGSIEIVKQ GCWLDDFNCYDRTDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTS

[0220] 29 GRGEAETRECIYYNANWELERTNQSGLERCEGEQDKRLHCFATWKNISGSIEIVKQ

[0221] GCWLDDFNCYDRTDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTS

[0222]

[0223] PATENT

[0224] ATTORNEY DOCKET NO.: 51184-064WO2

[0225] SEQ ID NO: Amino Acid Sequence

[0226] 30 GRGEAETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWKNISGSIEIVKQ GCWLDDFNCYDRTDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTS

[0227] 31 GRGEAETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGSIEIVK QGCWLDDFNCYDRTDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTS

[0228] 32 GRGEAETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIELVK KGCWLDDFNCYDRTDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTS

[0229] 33 GRGEAETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIELVK KGCWLDDFNCYDRQECVATKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTS

[0230] 34 GRGEAETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIELVK KGCWLDDFNCYDRQECVATEENPQVYFCCCEGNMCNEKFSYFPEMEVTQPTS

[0231] 35 GRGEAETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVK QGCWLDDNNCYDRTDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTS

[0232] 36 GRGEAETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVK QGCWLDDTNCYDRTDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTS

[0233] 37 GRGEAETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVK QGCWLDDETCYDRTDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTS

[0234] 38 GRGEAETRECIYYNANWELERTNQSGLERCEGEQRKRLHCYASWRNSSGTIEIVK QGCWLDDFNCYDRTDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTS

[0235] 39 GRGEAETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVK QGCWLDDFNCYDRTDCVETKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTS

[0236] 40 GAILGRAETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIV KQGCWLDDFNCYDRTDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTS

[0237] 41 GAILGRSETQECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIV KQGCWLDDFNCYDRTDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTS

[0238] 42 GRGEAETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIELVK KGCWLDDFNCYDRQECVATKDSPEVYFCCCEGNMCNEKFSYFPEMEVTQPTS

[0239] 43 GRGEAETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIELVK

[0240] KGCWLDDFNCYDRQECVATKENPQVYFCCCEGNMCNEKFSYFPEMEVTQPTS

[0241]

[0242] In some embodiments, the extracellular ActRII chimeras described herein have an N-terminal truncation of 1 -9 amino acids (e.g., 1 , 2, 3, 4, 5, 6, 7, 8, or 9 amino acids). The N-terminal truncation can involve the removal of 1 -9 amino acids from the N-terminus of any of the chimeras shown in Tables 1 and 2 (e.g., SEQ ID NOs: 1-43 (e.g., SEQ ID NOs: 22-43)). The N-terminal truncation can remove amino acids up to two amino acids before the first cysteine (e.g., the two amino acids before the first cysteine (RE or QE) are retained in the N-terminally truncated ActRII chimeras). Exemplary ActRII chimeras having N-terminal truncations are provided in Table 3, below.PATENT

[0243] ATTORNEY DOCKET NO.: 51184-064WO2

[0244] Table 3. Extracellular ActRII chimeras having N-terminal truncations SEQ ID NO: Amino Acid Sequence

[0245] 111 ILGRAETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQ GCWLDDINCYDRTDCVATEENPQVYFCCCEGNMCNEKFSYFPEMEVTQPTS

[0246] 112 RGEAETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQ GCWLDDINCYDRTDCVEKKDSPEVYFCCCEGNMCNEKFSYFPEMEVTQPTS

[0247] 113 RGEAETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQ GCWLDDINCYDRTDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTS

[0248] 114 RGEAETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQ GCWLDDFNCYDRTDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTS

[0249] 115 LGRAETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQ GCWLDDINCYDRTDCVATEENPQVYFCCCEGNMCNEKFSYFPEMEVTQPTS

[0250] 116 GEAETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQG CWLDDINCYDRTDCVEKKDSPEVYFCCCEGNMCNEKFSYFPEMEVTQPTS

[0251] 117 GEAETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQG CWLDDINCYDRTDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTS 118 GEAETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQG CWLDDFNCYDRTDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTS

[0252] 119 GRAETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQG CWLDDINCYDRTDCVATEENPQVYFCCCEGNMCNEKFSYFPEMEVTQPTS

[0253] 120 EAETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQGC WLDDINCYDRTDCVEKKDSPEVYFCCCEGNMCNEKFSYFPEMEVTQPTS

[0254] 121 EAETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQGC WLDDINCYDRTDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTS

[0255] 122 EAETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQGC WLDDFNCYDRTDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTS

[0256] 123 RAETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQGC WLDDINCYDRTDCVATEENPQVYFCCCEGNMCNEKFSYFPEMEVTQPTS

[0257] 124 AETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQGCW LDDINCYDRTDCVEKKDSPEVYFCCCEGNMCNEKFSYFPEMEVTQPTS

[0258] 125 AETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQGCW LDDINCYDRTDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTS

[0259] 126 AETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQGCW

[0260] LDDFNCYDRTDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTS

[0261]

[0262] PATENT

[0263] ATTORNEY DOCKET NO.: 51184-064WO2

[0264] SEQ ID NO: Amino Acid Sequence

[0265] 127 AETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQGCW LDDINCYDRTDCVATEENPQVYFCCCEGNMCNEKFSYFPEMEVTQPTS

[0266] 128 ETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQGCWL DDINCYDRTDCVEKKDSPEVYFCCCEGNMCNEKFSYFPEMEVTQPTS

[0267] 129 ETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQGCWL DDINCYDRTDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTS

[0268] 130 ETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQGCWL DDFNCYDRTDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTS

[0269] 131 ETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQGCWL DDINCYDRTDCVATEENPQVYFCCCEGNMCNEKFSYFPEMEVTQPTS

[0270] 132 TRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQGCWLD DINCYDRTDCVEKKDSPEVYFCCCEGNMCNEKFSYFPEMEVTQPTS

[0271] 133 TRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQGCWLD DINCYDRTDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTS

[0272] 134 TRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQGCWLD DFNCYDRTDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTS

[0273] 135 TRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQGCWLD DINCYDRTDCVATEENPQVYFCCCEGNMCNEKFSYFPEMEVTQPTS

[0274] 136 RECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQGCWLDD INCYDRTDCVEKKDSPEVYFCCCEGNMCNEKFSYFPEMEVTQPTS

[0275] 137 RECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQGCWLDD INCYDRTDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTS

[0276] 138 RECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQGCWLDD FNCYDRTDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTS

[0277] 139 RECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQGCWLDD INCYDRTDCVATEENPQVYFCCCEGNMCNEKFSYFPEMEVTQPTS

[0278] 140 RGEAETRECIYYNANWELERTNQSGLERCEGEQDKRRHCFATWKNISGSIEIVKQG CWLDDFNCYDRTDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTS

[0279] 141 RGEAETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQ GCWLDDETCYDRTDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTS

[0280] 142 ILGRAETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQ GCWLDDFNCYDRTDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTS

[0281] 143 ILGRSETQECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQ

[0282] GCWLDDFNCYDRTDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTS

[0283]

[0284] PATENT

[0285] ATTORNEY DOCKET NO.: 51184-064WO2

[0286] SEQ ID NO: Amino Acid Sequence

[0287] 144 RGEAETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIELVKK GCWLDDFNCYDRQECVATKDSPEVYFCCCEGNMCNEKFSYFPEMEVTQPTS

[0288] 145 RGEAETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIELVKK GCWLDDFNCYDRQECVATKENPQVYFCCCEGNMCNEKFSYFPEMEVTQPTS

[0289] 146 GEAETRECIYYNANWELERTNQSGLERCEGEQDKRRHCFATWKNISGSIEIVKQGC WLDDFNCYDRTDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTS

[0290] 147 GEAETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQG CWLDDETCYDRTDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTS

[0291] 148 LGRAETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQ GCWLDDFNCYDRTDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTS

[0292] 149 LGRSETQECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQ GCWLDDFNCYDRTDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTS

[0293] 150 GEAETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIELVKKG CWLDDFNCYDRQECVATKDSPEVYFCCCEGNMCNEKFSYFPEMEVTQPTS

[0294] 151 GEAETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIELVKKG CWLDDFNCYDRQECVATKENPQVYFCCCEGNMCNEKFSYFPEMEVTQPTS

[0295] 152 EAETRECIYYNANWELERTNQSGLERCEGEQDKRRHCFATWKNISGSIEIVKQGC WLDDFNCYDRTDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTS

[0296] 153 EAETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQGC WLDDETCYDRTDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTS

[0297] 154 GRAETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQG CWLDDFNCYDRTDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTS 155 GRSETQECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQG CWLDDFNCYDRTDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTS 156 EAETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIELVKKGC WLDDFNCYDRQECVATKDSPEVYFCCCEGNMCNEKFSYFPEMEVTQPTS

[0298] 157 EAETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIELVKKGC WLDDFNCYDRQECVATKENPQVYFCCCEGNMCNEKFSYFPEMEVTQPTS

[0299] 158 AETRECIYYNANWELERTNQSGLERCEGEQDKRRHCFATWKNISGSIEIVKQGCW LDDFNCYDRTDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTS

[0300] 159 AETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQGCW LDDETCYDRTDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTS

[0301] 160 RAETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQGC

[0302] WLDDFNCYDRTDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTS

[0303]

[0304] PATENT

[0305] ATTORNEY DOCKET NO.: 51184-064WO2

[0306] SEQ ID NO: Amino Acid Sequence

[0307] 161 RSETQECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQGC WLDDFNCYDRTDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTS

[0308] 162 AETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIELVKKGCW LDDFNCYDRQECVATKDSPEVYFCCCEGNMCNEKFSYFPEMEVTQPTS

[0309] 163 AETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIELVKKGCW LDDFNCYDRQECVATKENPQVYFCCCEGNMCNEKFSYFPEMEVTQPTS

[0310] 164 ETRECIYYNANWELERTNQSGLERCEGEQDKRRHCFATWKNISGSIEIVKQGCWL DDFNCYDRTDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTS

[0311] 165 ETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQGCWL DDETCYDRTDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTS

[0312] 166 AETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQGCW LDDFNCYDRTDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTS

[0313] 167 SETQECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQGCW LDDFNCYDRTDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTS

[0314] 168 ETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIELVKKGCWL DDFNCYDRQECVATKDSPEVYFCCCEGNMCNEKFSYFPEMEVTQPTS

[0315] 169 ETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIELVKKGCWL DDFNCYDRQECVATKENPQVYFCCCEGNMCNEKFSYFPEMEVTQPTS

[0316] 170 TRECIYYNANWELERTNQSGLERCEGEQDKRRHCFATWKNISGSIEIVKQGCWLD DFNCYDRTDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTS

[0317] 171 TRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQGCWLD DETCYDRTDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTS

[0318] 172 ETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQGCWL DDFNCYDRTDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTS

[0319] 173 ETQECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQGCWL DDFNCYDRTDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTS

[0320] 174 TRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIELVKKGCWLD DFNCYDRQECVATKDSPEVYFCCCEGNMCNEKFSYFPEMEVTQPTS

[0321] 175 TRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIELVKKGCWLD DFNCYDRQECVATKENPQVYFCCCEGNMCNEKFSYFPEMEVTQPTS

[0322] 176 RECIYYNANWELERTNQSGLERCEGEQDKRRHCFATWKNISGSIEIVKQGCWLDD FNCYDRTDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTS

[0323] 177 RECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQGCWLDD

[0324] ETCYDRTDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTS

[0325]

[0326] PATENT

[0327] ATTORNEY DOCKET NO.: 51184-064WO2

[0328] SEQ ID NO: Amino Acid Sequence

[0329] 178 TREOIYYNANWELERTNQSGLEROEGEQDKRLHOYASWRNSSGTIEIVKQGOWLD DFNCYDRTDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTS

[0330] 179 TQECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQGCWLD DFNCYDRTDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTS

[0331] 180 RECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIELVKKGCWLD DFNCYDRQECVATKDSPEVYFCCCEGNMCNEKFSYFPEMEVTQPTS

[0332] 181 RECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIELVKKGCWLD DFNCYDRQECVATKENPQVYFCCCEGNMCNEKFSYFPEMEVTQPTS

[0333] 182 RECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQGCWLDD FNCYDRTDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTS

[0334] 183 QECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQGCWLDD

[0335] FNCYDRTDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTS

[0336]

[0337] In some embodiments, a polypeptide including an extracellular ActRII chimera may further include an Fc domain monomer, which may be fused to the N- or C-terminus (e.g., C-terminus) of the extracellular ActRII chimera by way of a linker or other covalent bonds. A polypeptide including an extracellular ActRII chimera fused to an Fc domain monomer may form a dimer (e.g., homodimer or heterodimer) through the interaction between two Fc domain monomers, which combine to form an Fc domain in the dimer. Exemplary polypeptides containing an ActRII chimera, an Fc domain monomer, and a linker are provided in Table 4, below. In some embodiments, the terminal lysine is absent from the Fc domain monomer amino acid sequence included in the polypeptides of Table 4.

[0338] Table 4. Polypeptides containing an extracellular ActRII chimera fused to an Fc domain monomer SEQ ID NO: Amino Acid Sequence

[0339] 107 GAILGRAETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQGCWL DDINCYDRTDCVATEENPQVYFCCCEGNMCNEKFSYFPEMEVTQPTSGGGDKTHTCPPCP APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPR EEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPS RDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSR WQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

[0340] 108 GRGEAETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQGCWLD DINCYDRTDCVEKKDSPEVYFCCCEGNMCNEKFSYFPEMEVTQPTSGGGDKTHTCPPCPAP ELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREE QYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRD ELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQ QGNVFSCSVMHEALHNHYTQKSLSLSPGK

[0341]

[0342] PATENT

[0343] ATTORNEY DOCKET NO.: 51184-064WO2

[0344] SEQ ID NO: Amino Acid Sequence

[0345] 109 GRGEAETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQGCWLD DINCYDRTDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTSGGGDKTHTCPPCPA PELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPRE EQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR DELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW QQGNVFSCSVMHEALHNHYTQKSLSLSPGK

[0346] 110 GRGEAETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQGCWLD DFNCYDRTDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTSGGGDKTHTCPPCPA PELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPRE EQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR DELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW QQGNVFSCSVMHEALHNHYTQKSLSLSPGK

[0347] 184 ILGRAETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQGCWLDD INCYDRTDCVATEENPQVYFCCCEGNMCNEKFSYFPEMEVTQPTSGGGDKTHTCPPCPAPE LLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQ YNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDEL TKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQ GNVFSCSVMHEALHNHYTQKSLSLSPGK

[0348] 185 RGEAETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQGCWLDD INCYDRTDCVEKKDSPEVYFCCCEGNMCNEKFSYFPEMEVTQPTSGGGDKTHTCPPCPAPE LLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQ YNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDEL TKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQ GNVFSCSVMHEALHNHYTQKSLSLSPGK

[0349] 186 RGEAETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQGCWLDD INCYDRTDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTSGGGDKTHTCPPCPAPE LLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQ YNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDEL TKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQ GNVFSCSVMHEALHNHYTQKSLSLSPGK

[0350] 187 RGEAETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQGCWLDD FNCYDRTDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTSGGGDKTHTCPPCPAP ELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREE QYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRD ELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQ QGNVFSCSVMHEALHNHYTQKSLSLSPGK

[0351]

[0352] PATENT

[0353] ATTORNEY DOCKET NO.: 51184-064WO2

[0354] SEQ ID NO: Amino Acid Sequence

[0355] 188 LGRAETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQGCWLDDI NCYDRTDCVATEENPQVYFCCCEGNMCNEKFSYFPEMEVTQPTSGGGDKTHTCPPCPAPE LLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQ YNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDEL TKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQ GNVFSCSVMHEALHNHYTQKSLSLSPGK

[0356] 189 GEAETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQGCWLDDI NCYDRTDCVEKKDSPEVYFCCCEGNMCNEKFSYFPEMEVTQPTSGGGDKTHTCPPCPAPE LLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQ YNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDEL TKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQ GNVFSCSVMHEALHNHYTQKSLSLSPGK

[0357] 190 GEAETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQGCWLDDI NCYDRTDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTSGGGDKTHTCPPCPAPE LLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQ YNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDEL TKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQ GNVFSCSVMHEALHNHYTQKSLSLSPGK

[0358] 191 GEAETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQGCWLDDF NCYDRTDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTSGGGDKTHTCPPCPAPE LLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQ YNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDEL TKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQ GNVFSCSVMHEALHNHYTQKSLSLSPGK

[0359] 192 GRAETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQGCWLDDI NCYDRTDCVATEENPQVYFCCCEGNMCNEKFSYFPEMEVTQPTSGGGDKTHTCPPCPAPE LLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQ YNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDEL TKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQ GNVFSCSVMHEALHNHYTQKSLSLSPGK

[0360] 193 EAETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQGCWLDDIN CYDRTDCVEKKDSPEVYFCCCEGNMCNEKFSYFPEMEVTQPTSGGGDKTHTCPPCPAPELL GGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQY NSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELT KNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSPGK

[0361]

[0362] PATENT

[0363] ATTORNEY DOCKET NO.: 51184-064WO2

[0364] SEQ ID NO: Amino Acid Sequence

[0365] 194 EAETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQGCWLDDIN CYDRTDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTSGGGDKTHTCPPCPAPEL LGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQY NSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELT KNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSPGK

[0366] 195 EAETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQGCWLDDFN CYDRTDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTSGGGDKTHTCPPCPAPEL LGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQY NSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELT KNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSPGK

[0367] 196 RAETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQGCWLDDIN CYDRTDCVATEENPQVYFCCCEGNMCNEKFSYFPEMEVTQPTSGGGDKTHTCPPCPAPEL LGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQY NSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELT KNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSPGK

[0368] 197 AETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQGCWLDDINC YDRTDCVEKKDSPEVYFCCCEGNMCNEKFSYFPEMEVTQPTSGGGDKTHTCPPCPAPELL GGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQY NSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELT KNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSPGK

[0369] 198 AETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQGCWLDDINC YDRTDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTSGGGDKTHTCPPCPAPELL GGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQY NSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELT KNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSPGK

[0370] 199 AETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQGCWLDDFNC YDRTDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTSGGGDKTHTCPPCPAPELL GGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQY NSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELT KNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSPGK

[0371]

[0372] PATENT

[0373] ATTORNEY DOCKET NO.: 51184-064WO2

[0374] SEQ ID NO: Amino Acid Sequence

[0375] 200 AETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQGCWLDDINC YDRTDCVATEENPQVYFCCCEGNMCNEKFSYFPEMEVTQPTSGGGDKTHTCPPCPAPELL GGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQY NSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELT KNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSPGK

[0376] 201 ETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQGCWLDDINCY DRTDCVEKKDSPEVYFCCCEGNMCNEKFSYFPEMEVTQPTSGGGDKTHTCPPCPAPELLG GPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNS TYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKN QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNV FSCSVMHEALHNHYTQKSLSLSPGK

[0377] 202 ETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQGCWLDDINCY DRTDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTSGGGDKTHTCPPCPAPELLG GPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNS TYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKN QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNV FSCSVMHEALHNHYTQKSLSLSPGK

[0378] 203 ETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQGCWLDDFNCY DRTDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTSGGGDKTHTCPPCPAPELLG GPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNS TYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKN QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNV FSCSVMHEALHNHYTQKSLSLSPGK

[0379] 204 ETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQGCWLDDINCY DRTDCVATEENPQVYFCCCEGNMCNEKFSYFPEMEVTQPTSGGGDKTHTCPPCPAPELLG GPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNS TYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKN QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNV FSCSVMHEALHNHYTQKSLSLSPGK

[0380] 205 TRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQGCWLDDINCYD RTDCVEKKDSPEVYFCCCEGNMCNEKFSYFPEMEVTQPTSGGGDKTHTCPPCPAPELLGG PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNST YRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKN QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNV FSCSVMHEALHNHYTQKSLSLSPGK

[0381]

[0382] PATENT

[0383] ATTORNEY DOCKET NO.: 51184-064WO2

[0384] SEQ ID NO: Amino Acid Sequence

[0385] 206 TRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQGCWLDDINCYD RTDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTSGGGDKTHTCPPCPAPELLGG PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNST YRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKN QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNV FSCSVMHEALHNHYTQKSLSLSPGK

[0386] 207 TRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQGCWLDDFNCYD RTDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTSGGGDKTHTCPPCPAPELLGG PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNST YRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKN QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNV FSCSVMHEALHNHYTQKSLSLSPGK

[0387] 208 TRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQGCWLDDINCYD RTDCVATEENPQVYFCCCEGNMCNEKFSYFPEMEVTQPTSGGGDKTHTCPPCPAPELLGG PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNST YRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKN QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNV FSCSVMHEALHNHYTQKSLSLSPGK

[0388] 209 RECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQGCWLDDINCYDR TDCVEKKDSPEVYFCCCEGNMCNEKFSYFPEMEVTQPTSGGGDKTHTCPPCPAPELLGGP SVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQ VSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVF SCSVMHEALHNHYTQKSLSLSPGK

[0389] 210 RECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQGCWLDDINCYDR TDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTSGGGDKTHTCPPCPAPELLGGP SVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQ VSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVF SCSVMHEALHNHYTQKSLSLSPGK

[0390] 211 RECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQGCWLDDFNCYDR TDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTSGGGDKTHTCPPCPAPELLGGP SVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQ VSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVF SCSVMHEALHNHYTQKSLSLSPGK

[0391]

[0392] PATENT

[0393] ATTORNEY DOCKET NO.: 51184-064WO2

[0394] SEQ ID NO: Amino Acid Sequence

[0395] 212 RECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQGCWLDDINCYDR TDCVATEENPQVYFCCCEGNMCNEKFSYFPEMEVTQPTSGGGDKTHTCPPCPAPELLGGP SVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQ VSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVF SCSVMHEALHNHYTQKSLSLSPGK

[0396] 213 GRGEAETRECIYYNANWELERTNQSGLERCEGEQDKRRHCFATWKNISGSIEIVKQGCWLD DFNCYDRTDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTSGGGDKTHTCPPCPA PELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPRE EQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR DELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW QQGNVFSCSVMHEALHNHYTQKSLSLSPGK

[0397] 214 GRGEAETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQGCWLD DETCYDRTDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTSGGGDKTHTCPPCPA PELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPRE EQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR DELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW QQGNVFSCSVMHEALHNHYTQKSLSLSPGK

[0398] 215 GAILGRAETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQGCWL DDFNCYDRTDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTSGGGDKTHTCPPCP APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPR EEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPS RDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSR WQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

[0399] 216 GAILGRSETQECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQGCW LDDFNCYDRTDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTSGGGDKTHTCPPC PAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKP REEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPP SRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKS RWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

[0400] 217 GRGEAETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIELVKKGCWL DDFNCYDRQECVATKDSPEVYFCCCEGNMCNEKFSYFPEMEVTQPTSGGGDKTHTCPPCP APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPR EEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPS RDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSR WQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

[0401]

[0402] PATENT

[0403] ATTORNEY DOCKET NO.: 51184-064WO2

[0404] SEQ ID NO: Amino Acid Sequence

[0405] 218 GRGEAETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIELVKKGCWL DDFNCYDRQECVATKENPQVYFCCCEGNMCNEKFSYFPEMEVTQPTSGGGDKTHTCPPCP APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPR EEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPS RDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSR WQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

[0406] 219 RGEAETRECIYYNANWELERTNQSGLERCEGEQDKRRHCFATWKNISGSIEIVKQGCWLDD FNCYDRTDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTSGGGDKTHTCPPCPAP ELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREE QYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRD ELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQ QGNVFSCSVMHEALHNHYTQKSLSLSPGK

[0407] 220 RGEAETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQGCWLDD ETCYDRTDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTSGGGDKTHTCPPCPAP ELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREE QYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRD ELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQ QGNVFSCSVMHEALHNHYTQKSLSLSPGK

[0408] 221 ILGRAETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQGCWLDD FNCYDRTDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTSGGGDKTHTCPPCPAP ELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREE QYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRD ELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQ QGNVFSCSVMHEALHNHYTQKSLSLSPGK

[0409] 222 ILGRSETQECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQGCWLD DFNCYDRTDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTSGGGDKTHTCPPCPA PELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPRE EQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR DELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW QQGNVFSCSVMHEALHNHYTQKSLSLSPGK

[0410] 223 RGEAETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIELVKKGCWLDD FNCYDRQECVATKDSPEVYFCCCEGNMCNEKFSYFPEMEVTQPTSGGGDKTHTCPPCPAP ELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREE QYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRD ELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQ QGNVFSCSVMHEALHNHYTQKSLSLSPGK

[0411]

[0412] PATENT

[0413] ATTORNEY DOCKET NO.: 51184-064WO2

[0414] SEQ ID NO: Amino Acid Sequence

[0415] 224 RGEAETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIELVKKGCWLDD FNCYDRQECVATKENPQVYFCCCEGNMCNEKFSYFPEMEVTQPTSGGGDKTHTCPPCPAP ELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREE QYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRD ELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQ QGNVFSCSVMHEALHNHYTQKSLSLSPGK

[0416] 225 GEAETRECIYYNANWELERTNQSGLERCEGEQDKRRHCFATWKNISGSIEIVKQGCWLDDF NCYDRTDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTSGGGDKTHTCPPCPAPE LLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQ YNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDEL TKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQ GNVFSCSVMHEALHNHYTQKSLSLSPGK

[0417] 226 GEAETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQGCWLDDE TCYDRTDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTSGGGDKTHTCPPCPAPE LLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQ YNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDEL TKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQ GNVFSCSVMHEALHNHYTQKSLSLSPGK

[0418] 227 LGRAETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQGCWLDD FNCYDRTDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTSGGGDKTHTCPPCPAP ELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREE QYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRD ELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQ QGNVFSCSVMHEALHNHYTQKSLSLSPGK

[0419] 228 LGRSETQECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQGCWLDD FNCYDRTDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTSGGGDKTHTCPPCPAP ELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREE QYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRD ELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQ QGNVFSCSVMHEALHNHYTQKSLSLSPGK

[0420] 229 GEAETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIELVKKGCWLDDF NCYDRQECVATKDSPEVYFCCCEGNMCNEKFSYFPEMEVTQPTSGGGDKTHTCPPCPAPE LLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQ YNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDEL TKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQ GNVFSCSVMHEALHNHYTQKSLSLSPGK

[0421]

[0422] PATENT

[0423] ATTORNEY DOCKET NO.: 51184-064WO2

[0424] SEQ ID NO: Amino Acid Sequence

[0425] 230 GEAETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIELVKKGCWLDDF NCYDRQECVATKENPQVYFCCCEGNMCNEKFSYFPEMEVTQPTSGGGDKTHTCPPCPAPE LLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQ YNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDEL TKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQ GNVFSCSVMHEALHNHYTQKSLSLSPGK

[0426] 231 EAETRECIYYNANWELERTNQSGLERCEGEQDKRRHCFATWKNISGSIEIVKQGCWLDDFN CYDRTDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTSGGGDKTHTCPPCPAPEL LGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQY NSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELT KNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSPGK

[0427] 232 EAETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQGCWLDDET CYDRTDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTSGGGDKTHTCPPCPAPEL LGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQY NSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELT KNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSPGK

[0428] 233 GRAETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQGCWLDDF NCYDRTDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTSGGGDKTHTCPPCPAPE LLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQ YNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDEL TKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQ GNVFSCSVMHEALHNHYTQKSLSLSPGK

[0429] 234 GRSETQECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQGCWLDDF NCYDRTDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTSGGGDKTHTCPPCPAPE LLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQ YNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDEL TKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQ GNVFSCSVMHEALHNHYTQKSLSLSPGK

[0430] 235 EAETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIELVKKGCWLDDFN CYDRQECVATKDSPEVYFCCCEGNMCNEKFSYFPEMEVTQPTSGGGDKTHTCPPCPAPEL LGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQY NSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELT KNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSPGK

[0431]

[0432] PATENT

[0433] ATTORNEY DOCKET NO.: 51184-064WO2

[0434] SEQ ID NO: Amino Acid Sequence

[0435] 236 EAETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIELVKKGCWLDDFN CYDRQECVATKENPQVYFCCCEGNMCNEKFSYFPEMEVTQPTSGGGDKTHTCPPCPAPEL LGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQY NSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELT KNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSPGK

[0436] 237 AETRECIYYNANWELERTNQSGLERCEGEQDKRRHCFATWKNISGSIEIVKQGCWLDDFNC YDRTDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTSGGGDKTHTCPPCPAPELL GGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQY NSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELT KNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSPGK

[0437] 238 AETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQGCWLDDETC YDRTDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTSGGGDKTHTCPPCPAPELL GGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQY NSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELT KNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSPGK

[0438] 239 RAETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQGCWLDDFN CYDRTDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTSGGGDKTHTCPPCPAPEL LGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQY NSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELT KNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSPGK

[0439] 240 RSETQECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQGCWLDDFN CYDRTDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTSGGGDKTHTCPPCPAPEL LGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQY NSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELT KNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSPGK

[0440] 241 AETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIELVKKGCWLDDFNC YDRQECVATKDSPEVYFCCCEGNMCNEKFSYFPEMEVTQPTSGGGDKTHTCPPCPAPELL GGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQY NSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELT KNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSPGK

[0441]

[0442] PATENT

[0443] ATTORNEY DOCKET NO.: 51184-064WO2

[0444] SEQ ID NO: Amino Acid Sequence

[0445] 242 AETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIELVKKGCWLDDFNC YDRQECVATKENPQVYFCCCEGNMCNEKFSYFPEMEVTQPTSGGGDKTHTCPPCPAPELL GGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQY NSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELT KNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSPGK

[0446] 243 ETRECIYYNANWELERTNQSGLERCEGEQDKRRHCFATWKNISGSIEIVKQGCWLDDFNCY DRTDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTSGGGDKTHTCPPCPAPELLG GPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNS TYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKN QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNV FSCSVMHEALHNHYTQKSLSLSPGK

[0447] 244 ETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQGCWLDDETCY DRTDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTSGGGDKTHTCPPCPAPELLG GPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNS TYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKN QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNV FSCSVMHEALHNHYTQKSLSLSPGK

[0448] 245 AETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQGCWLDDFNC YDRTDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTSGGGDKTHTCPPCPAPELL GGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQY NSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELT KNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSPGK

[0449] 246 SETQECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQGCWLDDFNC YDRTDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTSGGGDKTHTCPPCPAPELL GGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQY NSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELT KNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSPGK

[0450] 247 ETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIELVKKGCWLDDFNCY DRQECVATKDSPEVYFCCCEGNMCNEKFSYFPEMEVTQPTSGGGDKTHTCPPCPAPELLG GPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNS TYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKN QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNV FSCSVMHEALHNHYTQKSLSLSPGK

[0451]

[0452] PATENT

[0453] ATTORNEY DOCKET NO.: 51184-064WO2

[0454] SEQ ID NO: Amino Acid Sequence

[0455] 248 ETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIELVKKGCWLDDFNCY DRQECVATKENPQVYFCCCEGNMCNEKFSYFPEMEVTQPTSGGGDKTHTCPPCPAPELLG GPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNS TYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKN QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNV FSCSVMHEALHNHYTQKSLSLSPGK

[0456] 249 TRECIYYNANWELERTNQSGLERCEGEQDKRRHCFATWKNISGSIEIVKQGCWLDDFNCYD RTDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTSGGGDKTHTCPPCPAPELLGG PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNST YRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKN QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNV FSCSVMHEALHNHYTQKSLSLSPGK

[0457] 250 TRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQGCWLDDETCYD RTDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTSGGGDKTHTCPPCPAPELLGG PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNST YRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKN QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNV FSCSVMHEALHNHYTQKSLSLSPGK

[0458] 251 QECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQGCWLDDFNCYDR TDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTSGGGDKTHTCPPCPAPELLGGP SVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQ VSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVF SCSVMHEALHNHYTQKSLSLSPGK

[0459] 252 ETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQGCWLDDFNCY DRTDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTSGGGDKTHTCPPCPAPELLG GPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNS TYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKN QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNV FSCSVMHEALHNHYTQKSLSLSPGK

[0460] 253 ETQECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQGCWLDDFNCY DRTDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTSGGGDKTHTCPPCPAPELLG GPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNS TYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKN QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNV FSCSVMHEALHNHYTQKSLSLSPGK

[0461]

[0462] PATENT

[0463] ATTORNEY DOCKET NO.: 51184-064WO2

[0464] SEQ ID NO: Amino Acid Sequence

[0465] 254 TRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIELVKKGCWLDDFNCYD RQECVATKDSPEVYFCCCEGNMCNEKFSYFPEMEVTQPTSGGGDKTHTCPPCPAPELLGG PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNST YRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKN QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNV FSCSVMHEALHNHYTQKSLSLSPGK

[0466] 255 TRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIELVKKGCWLDDFNCYD RQECVATKENPQVYFCCCEGNMCNEKFSYFPEMEVTQPTSGGGDKTHTCPPCPAPELLGG PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNST YRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKN QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNV FSCSVMHEALHNHYTQKSLSLSPGK

[0467] 256 RECIYYNANWELERTNQSGLERCEGEQDKRRHCFATWKNISGSIEIVKQGCWLDDFNCYDR TDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTSGGGDKTHTCPPCPAPELLGGP SVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQ VSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVF SCSVMHEALHNHYTQKSLSLSPGK

[0468] 257 RECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQGCWLDDETCYDR TDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTSGGGDKTHTCPPCPAPELLGGP SVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQ VSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVF SCSVMHEALHNHYTQKSLSLSPGK

[0469] 258 TRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQGCWLDDFNCYD RTDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTSGGGDKTHTCPPCPAPELLGG PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNST YRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKN QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNV FSCSVMHEALHNHYTQKSLSLSPGK

[0470] 259 TQECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQGCWLDDFNCYD RTDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTSGGGDKTHTCPPCPAPELLGG PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNST YRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKN QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNV FSCSVMHEALHNHYTQKSLSLSPGK

[0471]

[0472] PATENT

[0473] ATTORNEY DOCKET NO.: 51184-064WO2

[0474] SEQ ID NO: Amino Acid Sequence

[0475] 260 RECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIELVKKGCWLDDFNCYD RQECVATKDSPEVYFCCCEGNMCNEKFSYFPEMEVTQPTSGGGDKTHTCPPCPAPELLGG PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNST YRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKN QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNV FSCSVMHEALHNHYTQKSLSLSPGK

[0476] 261 RECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIELVKKGCWLDDFNCYD RQECVATKENPQVYFCCCEGNMCNEKFSYFPEMEVTQPTSGGGDKTHTCPPCPAPELLGG PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNST YRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKN QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNV FSCSVMHEALHNHYTQKSLSLSPGK

[0477] 262 RECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQGCWLDDFNCYDR TDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTSGGGDKTHTCPPCPAPELLGGP SVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQ VSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVF SCSVMHEALHNHYTQKSLSLSPGK

[0478] 263 GRGEAETRECIYYNANWELERTNQSGLERCEGEQRKRLHCYASWRNSSGTIEIVKQGCWLD DFNCYDRTDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTSGGGDKTHTCPPCPA PELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPRE EQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSR DELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW QQGNVFSCSVMHEALHNHYTQKSLSLSPGK

[0479]

[0480] Furthermore, in some embodiments, a polypeptide described herein (e.g., an ActRII chimera-Fc fusion protein) has a serum half-life of at least 7 days in humans. The polypeptide may bind to activin A with a KD of 10 pM or higher. In some embodiments, the polypeptide binds to activin A, activin B, and / or myostatin and exhibits reduced (e.g., weak) binding to BMP9 (e.g., compared to wild-type extracellular ActRIIB). In some embodiments, the polypeptide that has reduced or weak binding to BMP9 has the sequence TEEN (SEQ ID NO: 265) or TKEN (SEQ ID NO: 266) at positions X3, X4, X5, and Xe. In some embodiments, the polypeptide that has reduced or weak binding to BMP9 has the sequence KKDS (SEQ ID NO: 267) or TKDS (SEQ ID NO: 268) at positions X3, X4, X5, and Xe. In some embodiments, the polypeptide does not substantially bind to human BMP9.

[0481] In some embodiments, the polypeptide including an extracellular ActRII chimera may bind to human activin A with a KD of about 800 pM or less (e.g., a KD of about 800, 700, 600, 500, 400, 300, 200, 100, 90, 80, 70, 60, 50, 40, 30, 20, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 pM or less, e.g., a KD of between about 800 pM and about 30 pM). In some embodiments, the polypeptide including an extracellular ActRII chimera may bind to human activin A with a KD of about 500 pM or less (e.g., a KD of about 500, 400, 300, 200, 100, 90, 80, 70, 60, 50, 40, 30, 20, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 pM or less, e.g., a KD of between about 500 pM and about 30 pM). In some embodiments, the polypeptide including anPATENT

[0482] ATTORNEY DOCKET NO.: 51184-064WO2

[0483] extracellular ActRII chimera may bind to human activin A with a KD of about 100 pM or less (e.g., a KD of about 100, 90, 80, 70, 60, 50, 40, 30, 20, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 pM or less, e.g., a KD of between about 100 pM and about 30 pM). In some embodiments, the polypeptide including an extracellular ActRII chimera may bind to human activin A with a KD of about 50 pM or less (e.g., a KD of about 50, 40, 30, 20, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 pM or less, e.g., a KD of between about 50 pM and about 30 pM). In some embodiments, the polypeptide including an extracellular ActRII chimera may bind to human activin A with a KD of about 50 pM.

[0484] In some embodiments, the polypeptide including an extracellular ActRII chimera has an IC50 of about 200 ng / mL or less in a cellular assay that measures inhibition of activin A signaling (e.g., an IC50 of about 200, 100, 90, 80, 70, 60, 50, 40, 30, 20, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 ng / mL or less, e.g., an IC50 of between about 200 ng / mL and about 1 ng / mL). In some embodiments, the polypeptide including an extracellular ActRII chimera has an IC50 of about 175 ng / mL or less in a cellular assay that measures inhibition of activin A signaling (e.g., an IC50 of about 175, 100, 90, 80, 70, 60, 50, 40, 30, 20, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 ng / mL or less, e.g., an IC50 of between about 175 ng / mL and about 1 ng / mL). In some embodiments, the polypeptide including an extracellular ActRII chimera has an IC50 of about 125 ng / mL or less in a cellular assay that measures inhibition of activin A signaling (e.g., an IC50 of about 125, 100, 90, 80, 70, 60, 50, 40, 30, 20, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 ng / mL or less, e.g., an IC50 of between about 125 ng / mL and about 1 ng / mL). In some embodiments, the polypeptide including an extracellular ActRII chimera has an IC50 of about 5000 pM or less in a cellular assay that measures inhibition of activin A signaling (e.g., an IC50 of about 5000, 4000, 3000, 2000, 1000, 900, 800, 700, 600, 500, 400, 300, 200, or 100 pM or less, e.g., an IC50 of between about 5000 pM and about 200 pM). In some embodiments, the polypeptide including an extracellular ActRII chimera has an IC50 of about 4000 pM or less in a cellular assay that measures inhibition of activin A signaling (e.g., an IC50 of about 4000, 3000, 2000, 1000, 900, 800, 700, 600, 500, 400, 300, 200, or 100 pM or less, e.g., an IC50 of between about 4000 pM and about 200 pM). In some embodiments, the polypeptide including an extracellular ActRII chimera has an IC50 of about 3000 pM or less in a cellular assay that measures inhibition of activin A signaling (e.g., an IC50 of about 3000, 2000, 1000, 900, 800, 700, 600, 500, 400, 300, 200, or 100 pM or less, e.g., an IC50 of between about 3000 pM and about 200 pM). Cellular assays that measure inhibition of activin A signaling are known in the art (see, e.g., International Patent Application Publication No. WO2021189019, which is incorporated herein by reference in its entirety). For example, the cellular assay may be a luciferase reporter assay in which activin A ligand is incubated with cells expressing a Smad binding element (SBE)-Luciferase reporter (BPS Bioscience), which activates the downstream signaling that results in luciferase expression. When activin A ligand is pre-incubated with a polypeptide including an extracellular ActRII chimera before being added to the cells, there is a loss of luciferase signal corresponding to the extent of activin A ligand inhibition. By testing a series of polypeptide concentrations ranging from no inhibition to complete inhibition of activin A signaling, the IC50 value may be calculated.

[0485] In some embodiments, the polypeptide may bind to human activin B with a KD of 800 pM or less (e.g., a KD of about 800, 700, 600, 500, 400, 300, 200, 100, 90, 80, 70, 60, 50, 40, 30, 20, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 pM or less, e.g., a KD of between about 800 pM and about 5 pM).

[0486] In some embodiments, the polypeptide including an extracellular ActRII chimera has an IC50 of about 200 ng / mL or less in a cellular assay that measures inhibition of activin B signaling (e.g., an IC50 ofPATENT

[0487] ATTORNEY DOCKET NO.: 51184-064WO2

[0488] about 200, 100, 90, 80, 70, 60, 50, 40, 30, 20, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 ng / mL or less, e.g., an IC50 of between about 200 ng / mL and about 1 ng / mL). In some embodiments, the polypeptide including an extracellular ActRII chimera has an IC50 of about 5000 pM or less in a cellular assay that measures inhibition of activin B signaling (e.g., an IC50 of about 5000, 4000, 3000, 2000, 1000, 900, 800, 700, 600, 500, 400, 300, 200, or 100 pM or less, e.g., an IC50 of between about 5000 pM and about 200 pM).

[0489] Cellular assays that measure inhibition of activin B signaling are known in the art (see, e.g., International Patent Application Publication No. WO2021189019, which is incorporated herein by reference in its entirety). For example, the cellular assay may be a luciferase reporter assay in which activin B ligand is incubated with cells expressing an SBE-Luciferase reporter (BPS Bioscience), which activates the downstream signaling that results in luciferase expression. When activin B ligand is pre-incubated with a polypeptide including an extracellular ActRII chimera before being added to the cells, there is a loss of luciferase signal corresponding to the extent of activin B ligand inhibition. By testing a series of polypeptide concentrations ranging from no inhibition to complete inhibition of activin B signaling, the IC50 value may be calculated.

[0490] The polypeptide may also bind to growth and differentiation factor 11 (GDF-11) with a KD of approximately 0.5 pM or higher (e.g., a KD of about 0.5, 1 , 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, or 200 pM or higher).

[0491] ActRIIB variants

[0492] In some embodiments, the ActRII variant for use according to the methods described herein is an extracellular ActRIIB variant constructed by introducing amino acid residues of ActRIIA into ActRIIB, or by introducing novel amino acid substitutions into ActRIIB, with the goal of reducing BMP9 binding to prevent or reduce disruption of endogenous BMP9 signaling. The amino acid substitutions may also impart beneficial physiological and pharmacokinetic properties of ActRIIA, such as longer half-life as an Fc fusion protein. The preferred ActRIIB variants also exhibit similar or improved binding to activins and / or myostatin compared to wild-type ActRIIB, which allows them to compete with endogenous activin receptors for ligand binding and reduce or inhibit endogenous activin receptor signaling. In some embodiments, amino acid substitutions may be introduced into an extracellular ActRIIB variant to reduce or remove the binding affinity of the variant to BMP9.

[0493] Polypeptides described herein include an extracellular ActRIIB variant having at least one amino acid substitution relative to the wild-type extracellular ActRIIB having the sequence of SEQ ID NO: 45. Possible amino acid substitutions at 28 different positions may be introduced to an extracellular ActRIIB variant (Table 5). An extracellular ActRIIB variant may have one or more (e.g., 1 -28, 1 -25, 1 -23, 1 -21 , 1 -19, 1-17, 1-15, 1-13, 1-11 , 1-9, 1-7, 1-5, 1-3, or 1-2; e.g., 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, 25, 26, 27, or 28) amino acid substitutions relative the sequence of a wildtype extracellular ActRIIB (SEQ ID NO: 45). In some embodiments, an extracellular ActRIIB variant (e.g., an extracellular ActRIIB variant having a sequence of SEQ ID NO: 269) may include amino acid substitutions at all of the 28 positions as listed in Table 5. In some embodiments, an extracellular ActRIIB variant may include amino acid substitutions at a number of positions, e.g., at 3, 4, 5, 6, 7, 8, 9, 10, 12, 15, 16, 18, 20, 22, 24, 26, or 27 out of the 28 positions, as listed in Table 5. In some embodiments, thePATENT

[0494] ATTORNEY DOCKET NO.: 51184-064WO2

[0495] substitutions are substitutions of an amino acid from ActRIIA into the same position in ActRIIB. In some embodiments, the substitutions are novel changes (e.g., substitutions of amino acids that are not in the corresponding position of ActRIIA, e.g., S48T, 151 L, Q69D, or E70T).

[0496] Amino acid substitutions can worsen or improve the activity and / or binding affinity of the ActRIIB variants of the invention (e.g., an extracellular ActRIIB variant having the sequence of any one of SEQ ID NOs: 269-283 (e.g., SEQ ID NOs: 270-283)). In some embodiments, the amino acid substitutions worsen the binding affinity of the ActRIIB variants to BMP9 (e.g., the variants have reduced binding to BMP9 relative to wild-type extracellular ActRIIB or have lower binding to BMP9 than to other ActRIIB ligands (e.g., activin A or B, myostatin, or GDF-11)). In some embodiments, the ActRIIB variants have reduced, weak, or no substantial binding to BMP9. In some embodiments, the amino acid substitutions improve the binding affinity of ActRIIB to myostatin, activin A or B, and / or GDF-11 (e.g., the variants have improved binding affinity relative to wild-type extracellular ActRIIB or bind more strongly to myostatin, activin A or B, or GDF-11 than to BMP9). In some embodiments, the amino acid substitutions reduce the binding affinity of ActRIIB to myostatin, activin A or B, and / or GDF-11 (e.g., the variants have decreased binding affinity relative to wild-type extracellular ActRIIB or bind more weakly to myostatin, activin A or B, or GDF-11 than to BMP9). In some embodiments, the amino acid substitutions do not substantially change extracellular ActRIIB function (e.g., the ActRIIB variants are functionally equivalent to the wild-type extracellular ActRIIB). In some embodiments, the amino acid substitutions confer an ActRIIA property or activity on the ActRIIB variant (e.g., the ActRIIB variant has a longer half-life as an Fc fusion protein than WT extracellular ActRIIB-Fc). Preferably, the ActRIIB variants have one or more, two or more, or three or more of the above properties (e.g., reduced BMP9 binding and improved binding to activin A or B, myostatin, and / or GDF-11 , or reduced BMP9 binding and functional equivalence to wild-type ActRIIB).

[0497] The ActRIIB variants (e.g., an extracellular ActRIIB variant having the sequence of any one of SEQ ID NOs: 269-283 (e.g., SEQ ID NOs: 270-283)) preferably have one or more amino acid substitutions that reduce BMP9 binding. In some embodiments, the amino acid substitution that reduces BMP9 binding is E75K (e.g., X24 is K in SEQ ID NO: 269). In some embodiments, the amino acid substitutions that reduce BMP9 binding are Q69T and E70D (e.g., X21 is T and X22 is D in SEQ ID NO: 269). In some embodiments, the amino acid substitutions that reduce BMP9 binding are Q69D and E70T (e.g., X21 is D and X22 is T in SEQ ID NO: 269). In some embodiments, the amino acid substitutions that reduce BMP9 binding are T74K, E75K, E76D, N77S, and Q79E (e.g., X23, X24, X25, X26, and X28 are K, K, D, S, and E, respectively, in SEQ ID NO: 269). In some embodiments, the ActRIIB variants have more than one of the aforementioned amino acid substitutions that reduce BMP9 binding (e.g., substitution E75K and substitutions Q69D and E70T, or substitution E75K and substitutions Q69T and E70D). In some embodiments, the ActRIIB variants have one or more amino acid substitutions that reduce BMP9 binding, and one or more additional amino acid substitutions. The additional amino acid substitutions may confer other beneficial properties, such as altered binding to activins or myostatin or improved activity. For example, amino acid substitutions T74K, E75K, E76D, N77S, and Q79E lead to a reduction in ActRIIB variant activity (e.g., compared to wild-type extracellular ActRIIB), but including additional substitutions S25T and S47I; E31 Y, E33D, and Q34K; or Y41 F, R45K, and K56Q improves the effect of the ActRIIB variant. The additional amino acid substitutions may include one or more of substitutionsPATENT

[0498] ATTORNEY DOCKET NO.: 51184-064WO2

[0499] I11L, Y12F, L19K, E20D, S25T, L27V, R29P, E31Y, E33D, Q34K, L38R, Y41F, R45K, S47I, S48T, T50S, 151 L, L53I, K56Q and F63I, T74K, E76D, N77S, Q79E, or F89M.

[0500] In some embodiments, a polypeptide described herein includes an extracellular ActRIIB variant having the sequence of SEQ ID NO: 269.

[0501] Table 5. Amino acid substitutions in an extracellular ActRIIB variant having

[0502] a sequence of SEQ ID NO: 269 GRGEAETRECX1X2YNANWEX3X4RTNQX5GX6EX7CX8GX9X10DKRX11HCX12ASWX13NX14X15GX16X17E X18VKX19GCWLDDX20NCYDRX21X22CVAX23X24X25X26PX27VYFCCCEGNX28CNERFTHLPEAGGPEVT YEPPPTAPT

[0503] (SEQ ID NO: 269)

[0504] Xi I or L X15 S orT x2F orY X16 S orT X3L or K X17 I or L X4 D or E X18 I or L x5T or S X19 K or Q x6L or V X20 F or I x7P or R X21 Q, T, or D Xs Y or E X22 E, D, or T x9D or E X23 K orT X10 K or Q X24 K or E X11 R or L X25 D or E X12 Y or F X26 S or N X13 R or K X27 E or Q X14 S or I X28 F or M

[0505]

[0506] In some embodiments, a polypeptide for use in a method described herein includes an extracellular ActRIIB variant having a sequence of any one of SEQ ID NOs: 270-283 (Table 6).

[0507] Table 6. Extracellular ActRIIB variants having the sequences of SEQ ID NOs: 270-283 SEQ ID NO: Amino Acid Sequence

[0508] 270 GRGEAETRECIFYNANWEKDRTNQSGLEPCYGDQDKRRHCFASWKNSSGTIELVK QGCWLDDINCYDRQECVAKKDSPEVYFCCCEGNFCNERFTHLPEAGGPEVTYEP PPTAPT

[0509]

[0510] PATENT

[0511] ATTORNEY DOCKET NO.: 51184-064WO2

[0512] SEQ ID NO: Amino Acid Sequence

[0513] 271 GRGEAETRECIYYNANWELDRTNQSGLERCEGEQDKRLHCYASWRNSSGTIELVK KGCWLDDINCYDRQECVATKENPQVYFCCCEGNFCNERFTHLPEAGGPEVTYEPP PTAPT

[0514] 272 GRGEAETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIELVK KGCWLDDFNCYDRQECVAKKDSPEVYFCCCEGNFCNERFTHLPEAGGPEVTYEP PPTAPT

[0515] 273 GRGEAETRECIYYNANWELERTNQTGLERCEGEQDKRLHCYASWRNISGTIELVK KGCWLDDFNCYDRQECVAKKDSPEVYFCCCEGNFCNERFTHLPEAGGPEVTYEP PPTAPT

[0516] 274 GRGEAETRECIYYNANWELERTNQTGLERCEGEQDKRLHCYASWRNITGTIELVKK GCWLDDFNCYDRQECVAKKDSPEVYFCCCEGNFCNERFTHLPEAGGPEVTYEPP PTAPT

[0517] 275 GRGEAETRECIYYNANWELERTNQSGLEPCEGEQDKRLHCYASWRNSSGTIELVK KGCWLDDFNCYDRQECVAKKDSPEVYFCCCEGNFCNERFTHLPEAGGPEVTYEP PPTAPT

[0518] 276 GRGEAETRECIYYNANWELERTNQSGLERCYGDKDKRLHCYASWRNSSGTIELVK KGCWLDDFNCYDRQECVAKKDSPEVYFCCCEGNFCNERFTHLPEAGGPEVTYEP PPTAPT

[0519] 277 GRGEAETRECIYYNANWELERTNQSGLERCEGEQDKRLHCFASWKNSSGTIELVK QGCWLDDFNCYDRQECVAKKDSPEVYFCCCEGNFCNERFTHLPEAGGPEVTYEP PPTAPT

[0520] 278 GRGEAETRECIFYNANWEKDRTNQSGLERCEGEQDKRLHCYASWRNSSGTIELVK KGCWLDDFNCYDRQECVAKKDSPEVYFCCCEGNFCNERFTHLPEAGGPEVTYEP PPTAPT

[0521] 279 GRGEAETRECIYYNANWELERTNQSGLERCYGDQDKRRHCYASWRNSSGTIELV KKGCWLDDFNCYDRQECVAKKDSPEVYFCCCEGNFCNERFTHLPEAGGPEVTYE PPPTAPT

[0522] 280 GRGEAETRECLYYNANWELERTNQSGVERCEGEKDKRLHCYASWRNSSGSLEIV KKGCWLDDFNCYDRTDCVATEENPQVYFCCCEGNMCNERFTHLPEAGGPEVTYE PPPTAPT

[0523] 281 GRGEAETRECLYYNANWELERTNQSGVERCEGEKDKRLHCYASWRNSSGSLEIV KKGCWLDDFNCYDRDTCVATEENPQVYFCCCEGNMCNERFTHLPEAGGPEVTYE PPPTAPT

[0524] 282 GRGEAETRECLYYNANWELERTNQSGVERCEGEKDKRLHCYASWRNSSGSLEIV KKGCWLDDFNCYDRTDCVATKENPQVYFCCCEGNMCNERFTHLPEAGGPEVTYE PPPTAPT

[0525]

[0526] PATENT

[0527] ATTORNEY DOCKET NO.: 51184-064WO2

[0528] SEQ ID NO: Amino Acid Sequence

[0529] 283 GRGEAETREOLYYNANWELERTNQSGVEROEGEKDKRLHOYASWRNSSGSLEIV KKGCWLDDFNCYDRDTCVATKENPQVYFCCCEGNMCNERFTHLPEAGGPEVTYE PPPTAPT

[0530]

[0531] In some embodiments, the extracellular ActRIIB variant has an N-terminal truncation of 1-7 amino acids (e.g., 1, 2, 3, 4, 5, 6, or 7 amino acids). The N-terminal truncation can involve the removal of 1-7 amino acids from the N-terminus of any of the ActRIIB variants shown in Tables 5 and 6. The N-terminal truncation can remove amino acids up to two amino acids before the first cysteine (e.g., the two amino acids before the first cysteine (RE) are retained in the N-terminally truncated ActRIIB variants).

[0532] In some embodiments, a polypeptide including an extracellular ActRIIB variant may further include an Fc domain monomer, which may be fused to the N- or C-terminus (e.g., C-terminus) of the extracellular ActRIIB variant by way of a linker or other covalent bonds. A polypeptide including an extracellular ActRIIB variant fused to an Fc domain monomer may form a dimer (e.g., homodimer or heterodimer) through the interaction between two Fc domain monomers, which combine to form an Fc domain in the dimer.

[0533] Furthermore, in some embodiments, a polypeptide including an ActRIIB variant described herein (e.g., an ActRIIB variant-Fc fusion protein) has a serum half-life of at least 7 days in humans. The polypeptide including an extracellular ActRIIB variant may bind to activin A with a KD of 10 pM or higher. In some embodiments, the polypeptide including an extracellular ActRIIB variant does not bind to BMP9 or activin A. In some embodiments, the polypeptide including an extracellular ActRIIB variant binds to activin A, activin B, and / or myostatin and exhibits reduced (e.g., weak) binding to BMP9. In some embodiments, the polypeptide including an extracellular ActRIIB variant does not substantially bind to human BMP9.

[0534] In some embodiments, the polypeptide including an extracellular ActRIIB variant may bind to human activin A with a KD of about 800 pM or less (e.g., a KD of about 800, 700, 600, 500, 400, 300, 200, 100, 90, 80, 70, 60, 50, 40, 30, 20, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 pM or less, e.g., a KD of between about 800 pM and about 30 pM). In some embodiments, the polypeptide including an extracellular ActRIIB variant may bind to human activin A with a KD of about 500 pM or less (e.g., a KD of about 500, 400, 300, 200, 100, 90, 80, 70, 60, 50, 40, 30, 20, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 pM or less, e.g., a KD of between about 500 pM and about 30 pM). In some embodiments, the polypeptide including an extracellular ActRIIB variant may bind to human activin A with a KD of about 100 pM or less (e.g., a KD of about 100, 90, 80, 70, 60, 50, 40, 30, 20, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 pM or less, e.g., a KD of between about 100 pM and about 30 pM). In some embodiments, the polypeptide including an extracellular ActRIIB variant may bind to human activin A with a KD of about 50 pM or less (e.g., a KD of about 50, 40, 30, 20, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 pM or less, e.g., a KD of between about 50 pM and about 30 pM).

[0535] In some embodiments, the polypeptide including an extracellular ActRIIB variant has an IC50 of about 200 ng / mL or less in a cellular assay that measures inhibition of activin A signaling (e.g., an IC50 of about 200, 100, 90, 80, 70, 60, 50, 40, 30, 20, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 ng / mL or less, e.g., an IC50 of between about 200 ng / mL and about 1 ng / mL). In some embodiments, the polypeptide including anPATENT

[0536] ATTORNEY DOCKET NO.: 51184-064WO2

[0537] extracellular ActRIIB variant has an IC50 of about 100 ng / mL or less in a cellular assay that measures inhibition of activin A signaling (e.g., an IC50 of about 100, 90, 80, 70, 60, 50, 40, 30, 20, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 ng / mL or less, e.g., an IC50 of between about 100 ng / mL and about 1 ng / mL). In some embodiments, the polypeptide including an extracellular ActRIIB variant has an IC50 of about 5000 pM or less in a cellular assay that measures inhibition of activin A signaling (e.g., an IC50 of about 5000, 4000, 3000, 2000, 1000, 900, 800, 700, 600, 500, 400, 300, 200, or 100 pM or less, e.g., an IC50 of between about 5000 pM and about 200 pM). In some embodiments, the polypeptide including an extracellular ActRIIB variant has an IC50 of about 3000 pM or less in a cellular assay that measures inhibition of activin A signaling (e.g., an IC50 of about 3000, 2000, 1000, 900, 800, 700, 600, 500, 400, 300, 200, or 100 pM or less, e.g., an IC50 of between about 3000 pM and about 200 pM). Cellular assays that measure inhibition of activin A signaling are known in the art (see, e.g., International Patent Application Publication No. WO2021189019, which is incorporated herein by reference in its entirety). For example, the cellular assay may be a luciferase reporter assay in which activin A ligand is incubated with cells expressing an SBE-Luciferase reporter (BPS Bioscience), which activates the downstream signaling that results in luciferase expression. When activin A ligand is pre-incubated with a polypeptide including an extracellular ActRIIB variant before being added to the cells, there is a loss of luciferase signal corresponding to the extent of activin A ligand inhibition. By testing a series of polypeptide concentrations ranging from no inhibition to complete inhibition of activin A signaling, the IC50 value may be calculated.

[0538] In some embodiments, the polypeptide including an extracellular ActRIIB variant may bind to human activin B with a KD of 800 pM or less (e.g., a KD of about 800, 700, 600, 500, 400, 300, 200, 100, 90, 80, 70, 60, 50, 40, 30, 20, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 pM or less, e.g., a KD of between about 800 pM and about 200 pM).

[0539] In some embodiments, the polypeptide including an extracellular ActRIIB variant has an IC50 of about 200 ng / mL or less in a cellular assay that measures inhibition of activin B signaling (e.g., an IC50 of about 200, 100, 90, 80, 70, 60, 50, 40, 30, 20, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 ng / mL or less, e.g., an IC50 of between about 200 ng / mL and about 1 ng / mL). In some embodiments, the polypeptide including an extracellular ActRIIB variant has an IC50 of about 5000 pM or less in a cellular assay that measures inhibition of activin B signaling (e.g., an IC50 of about 5000, 4000, 3000, 2000, 1000, 900, 800, 700, 600, 500, 400, 300, 200, or 100 pM or less, e.g., an IC50 of between about 5000 pM and about 200 pM). Cellular assays that measure inhibition of activin B signaling are known in the art (see, e.g., International Patent Application Publication No. WO2021189019, which is incorporated herein by reference in its entirety). For example, the cellular assay may be a luciferase reporter assay in which activin B ligand is incubated with cells expressing an SBE-Luciferase reporter (BPS Bioscience), which activates the downstream signaling that results in luciferase expression. When activin B ligand is pre-incubated with a polypeptide including an extracellular ActRIIB variant before being added to the cells, there is a loss of luciferase signal corresponding to the extent of activin B ligand inhibition. By testing a series of polypeptide concentrations ranging from no inhibition to complete inhibition of activin B signaling, the IC50 value may be calculated.

[0540] The polypeptide including an extracellular ActRIIB variant may also bind to growth and differentiation factor 11 (GDF-11) with a KD of approximately 0.5 pM or higher (e.g., a KD of about 0.5, 1 ,PATENT

[0541] ATTORNEY DOCKET NO.: 51184-064WO2

[0542] 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, or 200 pM or higher).

[0543] Fc domains

[0544] In some embodiments, a polypeptide described herein may include an extracellular ActRII variant (e.g., an extracellular ActRII chimera or an extracellular ActRIIB variant) fused to an Fc domain monomer of an immunoglobulin or a fragment of an Fc domain to increase the serum half-life of the polypeptide. A polypeptide including an extracellular ActRII variant fused to an Fc domain monomer may form a dimer (e.g., homodimer or heterodimer) through the interaction between two Fc domain monomers, which form an Fc domain in the dimer. As conventionally known in the art, an Fc domain is the protein structure that is found at the C-terminus of an immunoglobulin. An Fc domain includes two Fc domain monomers that are dimerized by the interaction between the CH3 antibody constant domains. A wild-type Fc domain forms the minimum structure that binds to an Fc receptor, e.g., FcyRI, FcyRlla, FcyRllb, FcyRllla, FcyRlllb, FcyRIV. In some embodiments, an Fc domain may be mutated to lack effector functions, typical of a “dead” Fc domain. For example, an Fc domain may include specific amino acid substitutions that are known to minimize the interaction between the Fc domain and an Fey receptor. In some embodiments, the Fc domain is from an IgG 1 antibody and includes one or both of amino acid substitutions L234A and L235A. In some embodiments, the Fc domain is from an IgG 1 antibody and includes amino acid substitutions L234A and L235A. In some embodiments, an Fc domain is from an lgG1 antibody and includes one or more of amino acid substitutions M252Y, S254T, and T256E. In some embodiments, the Fc domain is from an lgG1 antibody and includes amino acid substitutions M252Y, S254T, and T256E. In some embodiments, the Fc domain is from an lgG1 antibody and includes one or more of amino acid substitutions L234A, L235A, M252Y, S254T, and T256E. In some embodiments, an Fc domain is from an IgG 1 antibody and includes amino acid substitutions L234A, L235A, M252Y, S254T, and T256E. In some embodiments, the Fc domain is from an lgG1 antibody and includes one or more of amino acid substitutions L234A, L235A, and G237A. In some embodiments, the Fc domain is from an lgG1 antibody and includes amino acid substitutions L234A, L235A, and G237A. In some embodiments, the Fc domain is from an lgG1 antibody and includes one or more of amino acid substitutions D265A, K322A, and N434A. In some embodiments, an Fc domain is from an IgG 1 antibody and includes amino acid substitutions D265A, K322A, and N434A. The aforementioned amino acid positions are defined according to Kabat (Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD. (1991)). The Kabat numbering of amino acid residues may be determined for a given antibody by alignment at regions of homology of the sequence of the antibody with a “standard” Kabat numbered sequence. Furthermore, in some embodiments, an Fc domain does not induce any immune system-related response. For example, the Fc domain in a dimer of a polypeptide including an extracellular ActRII variant fused to an Fc domain monomer may be modified to reduce the interaction or binding between the Fc domain and an Fey receptor. The sequence of an Fc domain monomer that may be fused to an extracellular ActRII variant (e.g., an extracellular ActRII chimera or an extracellular ActRIIB variant) is shown below (SEQ ID NO: 48):PATENT

[0545] ATTORNEY DOCKET NO.: 51184-064WO2

[0546] THTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHN AKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPVPIEKTISKAKGQPREPQVYTL PPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGPFFLYSKLTVDKS RWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

[0547] The sequence of a wild-type Fc domain that may be fused to an extracellular ActRII variant (e.g., an extracellular ActRII chimera or an extracellular ActRIIB variant) is shown below in SEQ ID NO: 100:

[0548] DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEV HNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQV YTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVD KSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

[0549] In some embodiments, the Fc domain monomer fused to an extracellular ActRII variant lacks a terminal lysine. An exemplary sequence for a wild-type Fc domain lacking a terminal lysine is provided below (SEQ ID NO: 264):

[0550] DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEV HNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQV YTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVD KSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG

[0551] In some embodiments, the Fc domain monomer fused to an extracellular ActRII variant (e.g., an extracellular ActRII chimera or an extracellular ActRIIB variant) includes amino acid substitutions L14A, L15A, M32Y, S34T, and T36E relative to the sequence of SEQ ID NO: 100. An exemplary sequence of an Fc domain including amino acid substitutions L14A, L15A, M32Y, S34T, and T36E relative to the sequence of SEQ ID NO: 100 is shown below (SEQ ID NO: 285):

[0552] DKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLYITREPEVTCVVVDVSHEDPEVKFNWYVDGVEV HNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQV YTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVD KSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG

[0553] In some embodiments, an Fc domain is from an lgG1 antibody and includes amino acid substitutions L12A, L13A, and G15A, relative to the sequence of SEQ ID NO: 48. In some embodiments, an Fc domain is from an lgG1 antibody and includes amino acid substitutions D43A, K100A, and N212A, relative to the sequence of SEQ ID NO: 48. In some embodiments, the terminal lysine is absent from the Fc domain monomer having the sequence of SEQ ID NO: 48 or SEQ ID NO: 100. In some embodiments, an extracellular ActRII variant described herein (e.g., an extracellular ActRII chimera having the sequence of any one of SEQ ID NOs: 1 -43 (e.g., SEQ ID NOs: 22-43) or an extracellular ActRIIB variant having the sequence of any one of SEQ ID NOs: 269-283 (e.g., SEQ ID NOs: 270-283)) may be fused to the N- orPATENT

[0554] ATTORNEY DOCKET NO.: 51184-064WO2

[0555] C-terminus of an Fc domain monomer (e.g., SEQ ID NO: 48, SEQ ID NO: 100, SEQ ID NO: 264, or SEQ ID NO: 285) through conventional genetic or chemical means, e.g., chemical conjugation. If desired, a linker (e.g., a spacer) can be inserted between the extracellular ActRII variant and the Fc domain monomer. The Fc domain monomer can be fused to the N- or C-terminus (e.g., C-terminus) of the extracellular ActRII variant. The Fc domain monomer can be of immunoglobulin antibody isotype IgG, IgE, IgM, IgA, or IgD. Additionally, the Fc domain monomer can be an IgG subtype (e.g., IgG 1 , lgG2a, lgG2b, lgG3, or lgG4) . In some embodiments, the Fc domain monomer is an IgG 1 Fc domain monomer (e.g., a human lgG1 Fc domain monomer).

[0556] In some embodiments, the Fc domain contains one or more amino acid substitutions that reduce or inhibit Fc domain dimerization. In some embodiments, the Fc domain contains a hinge domain. The Fc domain can be of immunoglobulin antibody isotype IgG, IgE, IgM, IgA, or IgD. Additionally, the Fc domain can be an IgG subtype (e.g., IgG 1 , lgG2a, lgG2b, lgG3, or lgG4) . The Fc domain can also be a non-naturally occurring Fc domain, e.g., a recombinant Fc domain.

[0557] Methods of engineering Fc domains that have reduced dimerization are known in the art. In some embodiments, one or more amino acids with large sidechains (e.g., tyrosine or tryptophan) may be introduced to the CH3-CH3 dimer interface to hinder dimer formation due to steric clash. In other embodiments, one or more amino acids with small sidechains (e.g., alanine, valine, or threonine) may be introduced to the CH3-CH3 dimer interface to remove favorable interactions. Methods of introducing amino acids with large or small sidechains in the CH3 domain are described in, e.g., Ying et al. (J Biol Chem. 287:19399-19408, 2012), U.S. Patent Publication No. 2006 / 0074225, U.S. Patent Nos. 8,216,805 and 5,731 ,168, Ridgway et al. (Protein Eng. 9:617-612, 1996), Atwell et al. (J Mol Biol. 270:26-35, 1997), and Merchant et al. (Nat Biotechnol. 16:677-681 , 1998), all of which are incorporated herein by reference in their entireties.

[0558] In yet other embodiments, one or more amino acid residues in the CH3 domain that make up the CH3-CH3 interface between two Fc domains are replaced with positively charged amino acid residues (e.g., lysine, arginine, or histidine) or negatively charged amino acid residues (e.g., aspartic acid or glutamic acid) such that the interaction becomes electrostatically unfavorable depending on the specific charged amino acids introduced. Methods of introducing charged amino acids in the CH3 domain to disfavor or prevent dimer formation are described in, e.g., Ying et al. (J Biol Chem. 287:19399-19408, 2012), U.S. Patent Publication Nos. 2006 / 0074225, 2012 / 0244578, and 2014 / 0024111, all of which are incorporated herein by reference in their entireties.

[0559] In some embodiments of the invention, an Fc domain includes one or more of the following amino acid substitutions: T366W, T366Y, T394W, F405W, Y349T, Y349E, Y349V, L351T, L351H, L351N, L352K, P353S, S354D, D356K, D356R, D356S, E357K, E357R, E357Q, S364A, T366E, L368T, L368Y, L368E, K370E, K370D, K370Q, K392E, K392D, T394N, P395N, P396T, V397T, V397Q, L398T, D399K, D399R, D399N, F405T, F405H, F405R, Y407T, Y407H, Y407I, K409E, K409D, K409T, and K409I, relative to the sequence of human IgG 1. In some embodiments, the terminal lysine is absent from the Fc domain amino acid sequence. In one particular embodiment, an Fc domain includes the amino acid substitution T366W, relative to the sequence of human lgG1.PATENT

[0560] ATTORNEY DOCKET NO.: 51184-064WO2

[0561] Linkers

[0562] A polypeptide described herein may include an extracellular ActRII variant (e.g., an extracellular ActRII chimera having the sequence of any one of SEQ ID NOs: 1-43 (e.g., SEQ ID NOs: 22-43) or an extracellular ActRIIB variant having the sequence of any one of SEQ ID NOs: 269-283 (e.g., SEQ ID NOs: 270-283)) fused to an Fc domain monomer by way of a linker, which can increase stability of the polypeptide. In the present invention, a linker between an Fc domain monomer (e.g., the sequence of SEQ ID NO: 48, SEQ ID NO: 100, SEQ ID NO: 264, or SEQ ID NO: 285) and an extracellular ActRII variant (e.g., an extracellular ActRII chimera having the sequence of any one of SEQ ID NOs: 1-43 (e.g., SEQ ID NOs: 22-43) or an extracellular ActRIIB variant having the sequence of any one of SEQ ID NOs: 269-283 (e.g., SEQ ID NOs: 270-283)) can be an amino acid spacer including 1-200 amino acids.

[0563] Suitable peptide spacers are known in the art, and include, for example, peptide linkers containing flexible amino acid residues such as glycine, alanine, and serine. In some embodiments, a spacer can contain motifs, e.g., multiple or repeating motifs, of GA, GS, GG, GGA, GGS, GGG, GGGA (SEQ ID NO: 49), GGGS (SEQ ID NO: 50), GGGG (SEQ ID NO: 51), GGGGA (SEQ ID NO: 52), GGGGS (SEQ ID NO: 53), GGGGG (SEQ ID NO: 54), GGAG (SEQ ID NO: 55), GGSG (SEQ ID NO: 56), AGGG (SEQ ID NO: 57), or SGGG (SEQ ID NO: 58). In some embodiments, a spacer can contain 2 to 12 amino acids including motifs of GA or GS, e.g., GA, GS, GAGA (SEQ ID NO: 59), GSGS (SEQ ID NO: 60), GAGAGA (SEQ ID NO: 61), GSGSGS (SEQ ID NO: 62), GAGAGAGA (SEQ ID NO: 63), GSGSGSGS (SEQ ID NO: 64), GAGAGAGAGA (SEQ ID NO: 65), GSGSGSGSGS (SEQ ID NO: 66), GAGAGAGAGAGA (SEQ ID NO: 67), and GSGSGSGSGSGS (SEQ ID NO: 68). In some embodiments, a spacer can contain 3 to 12 amino acids including motifs of GGA or GGS, e.g., GGA, GGS, GGAGGA (SEQ ID NO: 69), GGSGGS (SEQ ID NO: 70), GGAGGAGGA (SEQ ID NO: 71), GGSGGSGGS (SEQ ID NO: 72), GGAGGAGGAGGA (SEQ ID NO: 73), and GGSGGSGGSGGS (SEQ ID NO: 74). In yet some embodiments, a spacer can contain 4 to 12 amino acids including motifs of GGAG (SEQ ID NO: 55), GGSG (SEQ ID NO: 56), e.g., GGAG (SEQ ID NO: 55), GGSG (SEQ ID NO: 56), GGAGGGAG (SEQ ID NO: 75), GGSGGGSG (SEQ ID NO: 76), GGAGGGAGGGAG (SEQ ID NO: 77), and GGSGGGSGGGSG (SEQ ID NO: 78). In some embodiments, a spacer can contain motifs of GGGGA (SEQ ID NO: 52) or GGGGS (SEQ ID NO: 53), e.g., GGGGAGGGGAGGGGA (SEQ ID NO: 79) and GGGGSGGGGSGGGGS (SEQ ID NO: 80). In some embodiments of the invention, an amino acid spacer between an Fc domain monomer and an extracellular ActRII variant (e.g., an extracellular ActRII chimera having the sequence of any one of SEQ ID NOs: 1-43 (e.g., SEQ ID NOs: 22-43) or an extracellular ActRIIB variant having the sequence of any one of SEQ ID NOs: 269-283 (e.g., SEQ ID NOs: 270-283)) may be GGG, GGGA (SEQ ID NO: 49), GGGG (SEQ ID NO: 51), GGGAG (SEQ ID NO: 81), GGGAGG (SEQ ID NO: 82), or GGGAGGG (SEQ ID NO: 83).

[0564] In some embodiments, a spacer can also contain amino acids other than glycine, alanine, and serine, e.g., AAAL (SEQ ID NO: 84), AAAK (SEQ ID NO: 85), AAAR (SEQ ID NO: 86), EGKSSGSGSESKST (SEQ ID NO: 87), GSAGSAAGSGEF (SEQ ID NO: 88), AEAAAKEAAAKA (SEQ ID NO: 89), KESGSVSSEQLAQFRSLD (SEQ ID NO: 90), GENLYFQSGG (SEQ ID NO: 91), SACYCELS (SEQ ID NO: 92), RSIAT (SEQ ID NO: 93), RPACKIPNDLKQKVMNH (SEQ ID NO: 94), GGSAGGSGSGSSGGSSGASGTGTAGGTGSGSGTGSG (SEQ ID NO: 95), AAANSSIDLISVPVDSR (SEQ ID NO: 96), or GGSGGGSEGGGSEGGGSEGGGSEGGGSEGGGSGGGS (SEQ ID NO: 97). InPATENT

[0565] ATTORNEY DOCKET NO.: 51184-064WO2

[0566] some embodiments, a spacer can contain motifs, e.g., multiple or repeating motifs, of EAAAK (SEQ ID NO: 98). In some embodiments, a spacer can contain motifs, e.g., multiple or repeating motifs, of prolinerich sequences such as (XP)n, in which X may be any amino acid (e.g., A, K, or E) and n is from 1-5, and PAPAP (SEQ ID NO: 99).

[0567] The length of the peptide spacer and the amino acids used can be adjusted depending on the two proteins involved and the degree of flexibility desired in the final protein fusion polypeptide. The length of the spacer can be adjusted to ensure proper protein folding and avoid aggregate formation.

[0568] In some embodiments, the linker between an Fc domain monomer (e.g., the sequence of SEQ ID NO: 48, SEQ ID NO: 100, SEQ ID NO: 264, or SEQ ID NO: 285) and an extracellular ActRII variant described herein (e.g., or an extracellular ActRII chimera having the sequence of any one of SEQ ID NOs: 1 -43 (e.g., SEQ ID NOs: 22-43) or an extracellular ActRIIB variant having the sequence of any one of SEQ ID NOs: 269-283 (e.g., SEQ ID NOs: 270-283)) is an amino acid spacer having the sequence GGG. For example, a polypeptide of the invention can contain an extracellular ActRII chimera (e.g., any one of SEQ ID NOs: 22-43) fused to an Fc domain monomer (e.g., SEQ ID NO: 100) by a GGG linker. An exemplary polypeptide containing an ActRII chimera of SEQ ID NO: 41 , a GGG linker, and an Fc domain monomer (SEQ ID NO: 100) is provided below (SEQ ID NO: 216):

[0569] GAILGRSETQECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIEIVKQ GCWLDDFNCYDRTDCVEKKDSPQVYFCCCEGNMCNEKFSYFPEMEVTQPTSGGGDK THTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDG VEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK GQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVL DSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

[0570] In another example, a polypeptide for use in the methods described herein can contain an extracellular ActRIIB variant (e.g., any one of SEQ ID NOs: 270-283) fused to an Fc domain monomer (e.g., the sequence of SEQ ID NO: 48, SEQ ID NO: 100, SEQ ID NO: 264, or SEQ ID NO: 285) by a GGG linker. An exemplary polypeptide containing an ActRIIB variant of SEQ ID NO: 283, a GGG linker, and an Fc domain monomer (SEQ ID NO: 100) is provided below (SEQ ID NO: 284):

[0571] GRGEAETRECLYYNANWELERTNQSGVERCEGEKDKRLHCYASWRNSSGSLEIVKKGC WLDDFNCYDRDTCVATKENPQVYFCCCEGNMCNERFTHLPEAGGPEVTYEPPPTAPTG GGDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWY VDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISK AKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVL DSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

[0572] The C-terminal Lys339 of the polypeptide of SEQ ID NO: 216 (the C-terminal Lys in the Fc region of SEQ ID NO: 216) and the C-terminal Lys345 of the polypeptide of SEQ ID NO: 284 (the C-terminal Lys in the Fc region of SEQ ID NO: 284) may or may not be present, without affecting the structure or stability of the polypeptide. The disclosure specifically contemplates SEQ ID NO: 216 that does not include the C-terminal Lys corresponding to Lys339 and SEQ ID NO: 284 that does not include the C-terminal LysPATENT

[0573] ATTORNEY DOCKET NO.: 51184-064WO2

[0574] corresponding to Lys345. The polypeptide of SEQ ID NO: 216 may be expressed including a C-terminal Lys339 which then may be proteolytically cleaved upon expression of the polypeptide, and the polypeptide of SEQ ID NO: 284 may be expressed including a C-terminal Lys345 which then may be proteolytically cleaved upon expression of the polypeptide (e.g., the polypeptides of SEQ ID NO: 216 and SEQ ID NO: 284 are expressed using nucleic acid constructs encoding the polypeptide including a C-terminal lysine residue). The polypeptides of SEQ ID NO: 216 and SEQ ID NO: 284 may also be expressed without including the C-terminal Lys339 and the C-terminal Lys345, respectively.

[0575] Vectors, host cells, and protein production

[0576] The polypeptides described herein can be produced from a host cell. A host cell refers to a vehicle that includes the necessary cellular components, e.g., organelles, needed to express the polypeptides and fusion polypeptides described herein from their corresponding nucleic acids. The nucleic acids may be included in nucleic acid vectors that can be introduced into the host cell by conventional techniques known in the art (e.g., transformation, transfection, electroporation, calcium phosphate precipitation, direct microinjection, infection, or the like). The choice of nucleic acid vectors depends in part on the host cells to be used. Generally, preferred host cells are of either eukaryotic (e.g., mammalian) or prokaryotic (e.g., bacterial) origin.

[0577] Nucleic acid vector construction and host cells

[0578] A nucleic acid sequence encoding the amino acid sequence of a polypeptide described herein may be prepared by a variety of methods known in the art. These methods include, but are not limited to, oligonucleotide-mediated (or site-directed) mutagenesis, PCR mutagenesis, ligation, and overlap extension PCR. A nucleic acid molecule encoding a polypeptide described herein may be obtained using standard techniques, e.g., gene synthesis. Alternatively, a nucleic acid molecule encoding a wild-type extracellular ActRIIA or ActRIIB may be mutated to include specific amino acid substitutions using standard techniques in the art, e.g., QUIKCHANGE™ mutagenesis. Nucleic acid molecules can be synthesized using a nucleotide synthesizer or PCR techniques.

[0579] A nucleic acid sequence encoding a polypeptide described herein may be inserted into a vector capable of replicating and expressing the nucleic acid molecule in prokaryotic or eukaryotic host cells. Many vectors are available in the art and can be used for the purpose of the invention. Each vector may include various components that may be adjusted and optimized for compatibility with the particular host cell. For example, the vector components may include, but are not limited to, an origin of replication, a selection marker gene, a promoter, a ribosome binding site, a signal sequence, the nucleic acid sequence encoding protein of interest, and a transcription termination sequence.

[0580] In some embodiments, mammalian cells may be used as host cells for the invention. Examples of mammalian cell types include, but are not limited to, human embryonic kidney (HEK) (e.g., HEK293, HEK 293F), Chinese hamster ovary (CHO), HeLa, COS, PC3, Vero, MC3T3, NSO, Sp2 / 0, VERY, BHK, MDCK, W138, BT483, Hs578T, HTB2, BT20, T47D, NSO (a murine myeloma cell line that does not endogenously produce any immunoglobulin chains), CRL7O3O, and HsS78Bst cells. In some embodiments, E. co / / ' cells may also be used as host cells for the invention. Examples of E. co / / strains include, but are not limited to, E. coli294 (ATCC®31 ,446), E. coli h 1776 (ATCC®31 ,537, E. coli BL21 (DE3) (ATCC® BAA- 1025), and E.PATENT

[0581] ATTORNEY DOCKET NO.: 51184-064WO2

[0582] coll RV308 (ATCC®31 ,608). Different host cells have characteristic and specific mechanisms for the posttranslational processing and modification of protein products (e.g., glycosylation). Appropriate cell lines or host systems may be chosen to ensure the correct modification and processing of the polypeptide expressed. The above-described expression vectors may be introduced into appropriate host cells using conventional techniques in the art, e.g., transformation, transfection, electroporation, calcium phosphate precipitation, and direct microinjection. Once the vectors are introduced into host cells for protein production, host cells are cultured in conventional nutrient media modified as appropriate for inducing promoters, selecting transformants, or amplifying the genes encoding the desired sequences. Methods for expression of therapeutic proteins are known in the art, see, for example, Paulina Baibas, Argelia Lorence (eds.) Recombinant Gene Expression: Reviews and Protocols (Methods in Molecular Biology), Humana Press; 2nd ed. 2004 and Vladimir Voynov and Justin A. Caravella (eds.) Therapeutic Proteins: Methods and Protocols (Methods in Molecular Biology) Humana Press; 2nd ed. 2012.

[0583] Protein production, recovery, and purification

[0584] Host cells used to produce the polypeptides described herein may be grown in media known in the art and suitable for culturing of the selected host cells. Examples of suitable media for mammalian host cells include Minimal Essential Medium (MEM), Dulbecco’s Modified Eagle’s Medium (DMEM), Expi293™ Expression Medium, DMEM with supplemented fetal bovine serum (FBS), and RPMI-1640. Examples of suitable media for bacterial host cells include Luria broth (LB) plus necessary supplements, such as a selection agent, e.g., ampicillin. Host cells are cultured at suitable temperatures, such as from about 20 °C to about 39 °C, e.g., from 25 °C to about 37 °C, preferably 37 °C, and CO2 levels, such as 5 to 10%. The pH of the medium is generally from about 6.8 to 7.4, e.g., 7.0, depending mainly on the host organism. If an inducible promoter is used in the expression vector of the invention, protein expression is induced under conditions suitable for the activation of the promoter.

[0585] In some embodiments, depending on the expression vector and the host cells used, the expressed protein may be secreted from the host cells (e.g., mammalian host cells) into the cell culture media. Protein recovery may involve filtering the cell culture media to remove cell debris. The proteins may be further purified. A polypeptide described herein may be purified by any method known in the art of protein purification, for example, by chromatography (e.g., ion exchange, affinity, and size-exclusion column chromatography), centrifugation, differential solubility, or by any other standard technique for the purification of proteins. For example, the protein can be isolated and purified by appropriately selecting and combining affinity columns such as Protein A column (e.g., POROS® Protein A chromatography) with chromatography columns (e.g., POROS® HS-50 cation exchange chromatography), filtration, ultra filtration, salting-out and dialysis procedures.

[0586] In other embodiments, host cells may be disrupted, e.g., by osmotic shock, sonication, or lysis, to recover the expressed protein. Once the cells are disrupted, cell debris may be removed by centrifugation or filtration. In some instances, a polypeptide can be conjugated to marker sequences, such as a peptide to facilitate purification. An example of a marker amino acid sequence is a hexa-histidine peptide (His-tag), which binds to nickel-functionalized agarose affinity column with micromolar affinity. Other peptide tags useful for purification include, but are not limited to, the hemagglutinin “HA” tag, which corresponds to an epitope derived from influenza hemagglutinin protein (Wilson et al., Cell 37:767, 1984).PATENT

[0587] ATTORNEY DOCKET NO.: 51184-064WO2

[0588] Alternatively, the polypeptides described herein can be produced by the cells of a subject (e.g., a human), e.g., in the context of gene therapy, by administering a vector (such as a viral vector (e.g., a retroviral vector, adenoviral vector, poxviral vector (e.g., vaccinia viral vector, such as Modified Vaccinia Ankara (MVA)), adeno-associated viral vector, and alphaviral vector)) containing a nucleic acid molecule encoding the polypeptide described herein. The vector, once inside a cell of the subject (e.g., by transformation, transfection, electroporation, calcium phosphate precipitation, direct microinjection, infection, etc.) will promote expression of the polypeptide, which is then secreted from the cell. If treatment of a disease or disorder is the desired outcome, no further action may be required. If collection of the protein is desired, blood may be collected from the subject and the protein purified from the blood by methods known in the art.

[0589] Pharmaceutical compositions and preparations

[0590] The invention features pharmaceutical compositions that include the polypeptides described herein (e.g., a polypeptide including an extracellular ActRII chimera (e.g., an extracellular ActRII chimera having the sequence of any one of SEQ ID NOs: 1-43 (e.g., SEQ ID NOs: 22-43) or an extracellular ActRIIB variant having the sequence of any one of SEQ ID NOs: 269-283 (e.g., SEQ ID NOs: 270-283)). In some embodiments, a pharmaceutical composition of the invention includes a polypeptide including an extracellular ActRII variant (e.g., an extracellular ActRII chimera having the sequence of any one of SEQ ID NOs: 1 -43 (e.g., SEQ ID NOs: 22-43) or an extracellular ActRIIB variant having the sequence of any one of SEQ ID NOs: 269-283 (e.g., SEQ ID NOs: 270-283)) fused to an Fc domain monomer as the therapeutic protein. In some embodiments, a pharmaceutical composition including a polypeptide described herein may be used in combination with other agents (e.g., therapeutic biologies and / or small molecules) or compositions in a therapy. In addition to a therapeutically effective amount of the polypeptide, the pharmaceutical composition may include one or more pharmaceutically acceptable carriers or excipients, which can be formulated by methods known to those skilled in the art. In some embodiments, a pharmaceutical composition of the invention includes a nucleic acid molecule (DNA or RNA, e.g., mRNA) encoding a polypeptide of the invention, or a vector containing such a nucleic acid molecule.

[0591] Acceptable carriers and excipients in the pharmaceutical compositions are nontoxic to recipients at the dosages and concentrations employed. Acceptable carriers and excipients may include buffers such as phosphate, citrate, HEPES, and TAE, antioxidants such as ascorbic acid and methionine, preservatives such as hexamethonium chloride, octadecyldimethylbenzyl ammonium chloride, resorcinol, and benzalkonium chloride, proteins such as human serum albumin, gelatin, dextran, and immunoglobulins, hydrophilic polymers such as polyvinylpyrrolidone, amino acids such as glycine, glutamine, histidine, arginine, and lysine, and carbohydrates such as glucose, mannose, sucrose, and sorbitol. Pharmaceutical compositions of the invention can be administered parenterally in the form of an injectable formulation. Pharmaceutical compositions for injection can be formulated using a sterile solution or any pharmaceutically acceptable liquid as a vehicle. Pharmaceutically acceptable vehicles include, but are not limited to, sterile water, physiological saline, and cell culture media (e.g., Dulbecco’s Modified Eagle Medium (DMEM), a-Modified Eagles Medium (a-MEM), F-12 medium). FormulationPATENT

[0592] ATTORNEY DOCKET NO.: 51184-064WO2

[0593] methods are known in the art, see e.g., Banga (ed.) Therapeutic Peptides and Proteins: Formulation, Processing and Delivery Systems (3rd ed.) Taylor & Francis Group, CRC Press (2015).

[0594] The pharmaceutical compositions may be prepared in microcapsules, such as hydroxylmethylcellulose or gelatin-microcapsule and poly-(methylmethacrylate) microcapsule. The pharmaceutical compositions may also be prepared in other drug delivery systems such as liposomes, albumin microspheres, microemulsions, nanoparticles, and nanocapsules. Such techniques are described in Remington: The Science and Practice of Pharmacy 22ndedition (2012). The pharmaceutical compositions to be used for in vivo administration must be sterile. This is readily accomplished by filtration through sterile filtration membranes.

[0595] The pharmaceutical compositions may also be prepared as a sustained-release formulation. Suitable examples of sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing the polypeptides of the invention. Examples of sustained release matrices include polyesters, hydrogels, polylactides, copolymers of L-glutamic acid and y ethyl-L-glutamate, non-degradable ethylene-vinyl acetate, degradable lactic acid-glycolic acid copolymers such as LUPRON DEPOT™, and poly-D-(-)-3-hydroxybutyric acid. Some sustained-release formulations enable release of molecules over a few months, e.g., one to six months, while other formulations release pharmaceutical compositions of the invention for shorter time periods, e.g., days to weeks.

[0596] The pharmaceutical composition may be formed in a unit dose form as needed. The amount of active component, e.g., a polypeptide of the invention, included in the pharmaceutical preparations is such that a suitable dose within the designated range is provided (e.g., a dose within the range of 0.01 -100 mg / kg of body weight).

[0597] The pharmaceutical composition for gene therapy can be in an acceptable diluent or can include a slow-release matrix in which the gene delivery vehicle is imbedded. If hydrodynamic injection is used as the delivery method, the pharmaceutical composition containing a nucleic acid molecule encoding a polypeptide described herein or a vector (e.g., a viral vector) containing the nucleic acid molecule is delivered rapidly in a large fluid volume intravenously. Vectors that may be used as in vivo gene delivery vehicle include, but are not limited to, retroviral vectors, adenoviral vectors, poxviral vectors (e.g., vaccinia viral vectors, such as Modified Vaccinia Ankara), adeno-associated viral vectors, and alphaviral vectors.

[0598] Routes, dosage, and administration

[0599] Pharmaceutical compositions that include the polypeptides described herein as the therapeutic proteins may be formulated for, e.g., intravenous administration, parenteral administration, subcutaneous administration, intramuscular administration, intra-arterial administration, intrathecal administration, or intraperitoneal administration. The pharmaceutical composition may also be formulated for, or administered via, oral, nasal, spray, aerosol, rectal, or vaginal administration. For injectable formulations, various effective pharmaceutical carriers are known in the art. See, e.g., ASHP Handbook on Injectable Drugs, Toissel, 18th ed. (2014).

[0600] In some embodiments, a pharmaceutical composition that includes a nucleic acid molecule encoding a polypeptide described herein or a vector containing such nucleic acid molecule may be administered by way of gene delivery. Methods of gene delivery are well-known to one of skill in the art. Vectors that may be used for in vivo gene delivery and expression include, but are not limited to, retroviralPATENT

[0601] ATTORNEY DOCKET NO.: 51184-064WO2

[0602] vectors, adenoviral vectors, poxviral vectors (e.g., vaccinia viral vectors, such as Modified Vaccinia Ankara (MVA)), adeno-associated viral vectors, and alphaviral vectors. In some embodiments, mRNA molecules encoding polypeptides described herein may be administered directly to a subject.

[0603] In some embodiments of the present invention, nucleic acid molecules encoding a polypeptide described herein or vectors containing such nucleic acid molecules may be administered using a hydrodynamic injection platform. In the hydrodynamic injection method, a nucleic acid molecule encoding a polypeptide described herein is put under the control of a strong promoter in an engineered plasmid (e.g., a viral plasmid). The plasmid is often delivered rapidly in a large fluid volume intravenously.

[0604] Hydrodynamic injection uses controlled hydrodynamic pressure in veins to enhance cell permeability such that the elevated pressure from the rapid injection of the large fluid volume results in fluid and plasmid extravasation from the vein. The expression of the nucleic acid molecule is driven primarily by the liver. In mice, hydrodynamic injection is often performed by injection of the plasmid into the tail vein. In certain embodiments, mRNA molecules encoding a polypeptide described herein may be administered using hydrodynamic injection.

[0605] The dosage of the pharmaceutical compositions depends on factors including the route of administration, the disease to be treated, and physical characteristics, e.g., age, weight, general health, of the subject. A pharmaceutical composition may include a dosage of a polypeptide described herein ranging from 0.01 to 500 mg / kg (e.g., 0.01 , 0.1 , 0.2, 0.3, 0.325, 0.35, 0.375, 0.4, 0.5, 0.75, 1 , 1.25, 1.5, 1.75, 2, 2.25, 2.5, 2.75, 3, 3.25, 3.5, 3.75, 4, 4.25, 4.5, 4.75, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 100, 150, 200, 250, 300, 350, 400, 450, or 500 mg / kg) and, in a more specific embodiment, about 0.1 to about 30 mg / kg and, in a more specific embodiment, about 0.3 to about 30 mg / kg. The dosage may be adapted by the physician in accordance with conventional factors such as the extent of the disease and different parameters of the subject.

[0606] The pharmaceutical compositions are administered in a manner compatible with the dosage formulation and in such amount as is therapeutically effective to result in an improvement or remediation of the symptoms. The pharmaceutical compositions are administered in a variety of dosage forms, e.g., intravenous dosage forms, subcutaneous dosage forms, and oral dosage forms (e.g., ingestible solutions, drug release capsules). Generally, therapeutic proteins are dosed at 0.1-100 mg / kg, e.g., 0.5-50 mg / kg. Pharmaceutical compositions that include a polypeptide of the invention may be administered to a subject in need thereof, for example, one or more times (e.g., 1-10 times or more) daily, weekly, biweekly, every four weeks, monthly, every eight weeks, bimonthly, every 12 weeks, quarterly, every sixteen weeks biannually, annually, or as medically necessary. In some embodiments, pharmaceutical compositions that include a polypeptide described herein may be administered to a subject in need thereof weekly, biweekly, every four weeks, monthly, every eight weeks, bimonthly, every twelve weeks, quarterly, or every sixteen weeks. Dosages may be provided in either a single or multiple dosage regimens. The timing between administrations may increase as the medical condition improves or decrease as the health of the patient declines.

[0607] Methods of treatment

[0608] The ActRII variants described herein have improved properties compared to endogenous ActRIIA and ActRIIB. For example, the ActRIIB variants generated by introducing residues from ActRIIA intoPATENT

[0609] ATTORNEY DOCKET NO.: 51184-064WO2

[0610] ActRIIB may retain the beneficial properties of ActRIIB, such high binding affinity to activins A and B, and gain some of the beneficial properties of ActRIIA, such as reduced binding affinity to BMP9 and longer serum half-life as an Fc fusion protein. In addition, the ActRII chimeras generated by combining extracellular portions of ActRIIA and ActRIIB may possess beneficial properties of both ActRIIB (e.g., strong binding affinity to activins A and B) and ActRIIA (e.g., reduced binding affinity to BMP9 and / or longer serum half-life as an Fc fusion protein (e.g., compared to ActRIIB-Fc)). These ActRIIB variant and ActRII chimera properties make for a useful therapeutic that can compete with endogenous activin receptors for ligand binding. As the ActRIIB variants and ActRII chimeras contain the extracellular portion of the receptor, they will be soluble and able to bind to and sequester ligands (e.g., activins A and B, myostatin, GDF11) without activating intracellular signaling pathways.

[0611] Autosomal dominant polycystic kidney disease (ADPKD)

[0612] The polypeptides described herein (e.g., a polypeptide including an extracellular ActRII variant (e.g., an extracellular ActRII chimera having the sequence of any one of SEQ ID NOs: 1-43 (e.g., SEQ ID NOs: 22-43) or an extracellular ActRIIB variant having the sequence of any one of SEQ ID NOs: 269-283 (e.g., SEQ ID NOs: 270-283))) can be used to treat a subject having ADPKD. In some embodiments, the subject has a mutation in the gene encoding polycystin 1 (PKD1) or polycystin 2 (PKD2). In some embodiments, the subject is male. In some embodiments, the subject is female. In some embodiments, the subject is an adult (e.g., 18 years of age or older, such as 20, 30, 40, 50, 60, or 70 years of age or older). In some embodiments, the subject is a pediatric subject (e.g., younger than 18 years of age, such as 15 years of age, 12 years of age, 10 years of age, or younger). In some embodiments, the subject is identified as having ADPKD prior to treatment with an ActRII variant described herein. In some embodiments, the method includes a step of identifying the subject as having ADPKD prior to treatment with an ActRII variant described herein. The subject may be identified as having ADPKD based on one or more of genetic testing (e.g., for a mutation in PKD1 or PKD2), family history, urinalysis (for detecting hematuria and proteinuria), blood tests (e.g., to evaluate GFR), hematologic studies (for assessing renal insufficiency), and renal ultrasonography (for detecting the presence of cysts in the kidneys). A subject that may be treated as described herein may have mild renal impairment (e.g., a GFR from 60 to 89 mL / min / 1.73 m2), moderate renal impairment, (e.g., a GFR from 30 to 59 mL / min / 1.73 m2), or severe renal impairment (e.g., a GFR from 15 to 29 mL / min / 1.73 m2) at the time of treatment initiation. The subject may have an elevated level of proteinuria (e.g., greater than or equal to 200 mg protein per day (24 h urine protein)), an elevated protein-to-creatinine ratio (PCR) (e.g., greater than or equal to 300 mg / g creatinine), and / or an elevated albumin-to- creatinine ratio (ACR) (e.g., greater than or equal to 200 mg / g creatinine). The subject may also have elevated levels of certain proteins in serum or urine, such as N-acetyl-p-D-glucosaminidase (NAG), neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1), interleukin-18 (IL-18), connective tissue growth factor (CTGF), monocyte chemoattractant protein 1 (MCP1), collagen IV (Col IV) fragments, collagen III (Col III) fragments, or podocyte proteins (e.g., markers of podocyte injury, such as nephrin and podocin), and / or elevated levels of certain proteins in blood, such as cystatin C, p-trace protein (BTP), or beta-2-microglobulin (B2M). In some embodiments, the subject has elevated blood urea nitrogen or elevated creatinine in blood.PATENT

[0613] ATTORNEY DOCKET NO.: 51184-064WO2

[0614] The methods described herein may also include a step of assessing GFR or eGFR, kidney fibrosis, kidney inflammation, PCR, ACR, UACR (urinary albumin-creatinine-ratio), hematuria, proteinuria, albuminuria, the level of certain proteins in the urine, serum, or blood (e.g., the proteins described hereinabove), blood urea nitrogen, or creatinine in blood prior to treatment with or administration of the compositions described herein. The estimated GFR may be calculated based on serum creatinine values, e.g., using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation, the Cockcroft-Gault formula, or the Modification of Diet in Renal Disease (MDRD) formula, which are all known in the art. These assessments can also be performed after treatment with or administration of the compositions described herein (e.g., after the administration of one or more doses of a composition described herein, or one month, two months, three months, four months, six months, one year or longer after treatment initiation with a composition described herein.

[0615] The compositions described herein are administered in an amount sufficient to treat ADPKD, improve kidney function, improve GFR or eGFR, reduce kidney fibrosis, or reduce kidney inflammation (i.e., nephritis, such as interstitial nephritis or glomerulonephritis). In some embodiments, the methods described herein reduce kidney cyst volume, hepatic cyst volume, or pancreatic cyst volume. In some embodiments, the methods described herein slow or inhibit progression of cardiovascular disease, such as hypertension, an aneurysm, mitral valve prolapse, aortic dissection, atrial fibrillation, left ventricular hypertrophy, aortic calcification, soft tissue calcification, cardiomyopathy, vasculitis, or left-sided heart failure. In some embodiments, the methods described herein slow or inhibit progression of bone disease, such as osteoporosis, bone pain, bone fracture, soft tissue calcification, osteopenia, osteopetrosis, bone cancer or cancer metastasis-related bone loss (e.g., multiple myeloma, osteosarcoma, breast cancer, prostate cancer, lung cancer, or kidney cancer), Paget’s disease, renal osteodystrophy, treatment-related bone loss, osteogenesis imperfecta, neuromuscular disease-related bone loss, burn-induced bone loss, anorexia-related bone loss, diet-related bone loss, bone loss associated with the treatment of obesity, low gravity-related bone loss, or immobility-related bone loss. In some embodiments, the methods described herein slow or inhibit progression of diverticular disease. In some embodiments, the methods described herein prevent urinary tract infections or decrease the frequency or severity of urinary tract infections. In some embodiments, the methods described herein reduce kidney weight. In some embodiments, the methods described herein reduce expression of a SMAD2 / 3 target gene, such as Col1a1 , Fn1 (EDA), or PAH . In some embodiments, the methods described herein slow or inhibit the progression of kidney fibrosis, delay the development of kidney fibrosis, slow or inhibit the progression of kidney inflammation, slow or inhibit a decline in kidney function, delay or prevent the onset of end stage renal disease, delay or prevent the need for dialysis, delay or prevent the need for continuous renal replacement therapy, or delay or prevent the need for a kidney transplant. Kidney function may be assessed by measuring GFR and improving kidney function or slowing or inhibiting a decline in kidney function may result in improving GFR or slowing or stopping a progressive decline in GFR. Kidney function may also be assessed by determining PCR, ACR, or UACR, and improving kidney function or slowing or inhibiting a decline in kidney function may result in improving (i.e., reducing) the PCR, ACR or UACR or slowing or stopping a progressive increase in PCR, ACR or UACR. Kidney function may also be assessed by measuring proteins present in the urine, serum, or blood. For example, kidney function may be assessed by measuring NAG, NGAL, KIM-1 , IL-18, CTGF, MCP1 , Col IV fragments, Col III fragment levels, nephrin,PATENT

[0616] ATTORNEY DOCKET NO.: 51184-064WO2

[0617] and / or podocin in the urine or serum of a subject, or measuring cystatin C, BTP, or B2M in the blood of a subject, and an improvement in kidney function may lead to reduced levels of one or more of these proteins in urine, serum, or blood. The proteins may be quantified, for example, by enzyme-linked immunosorbent assay (ELISA), or radioimmunoassay (RIA) using commercially available kits. Kidney function may also be assessed by measuring blood urea nitrogen, creatinine in the blood, creatinine clearance, or proteinuria, and an improvement in kidney function may be indicated by reduced blood urea nitrogen, reduced creatinine in the blood, improved creatinine clearance, or reduced proteinuria. In some embodiments, the method treats, prevents, delays the onset of, slows the progression of, or reduces the risk of hematuria, proteinuria, albuminuria, or a decline in GFR. In some embodiments, the methods described herein improve life expectancy for a subject with ADPKD. These outcomes can be assessed by comparing measurements obtained after treatment to measurements taken prior to treatment or by comparing measurements obtained after treatment to measurements from subjects with ADPKD who were not treated with a composition described herein. These effects may occur, for example, within 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 15 weeks, 20 weeks, 25 weeks, or more, following administration of the compositions described herein. The patient may be evaluated 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, or more following administration of the composition depending on the dose and route of administration used for treatment. Depending on the outcome of the evaluation, the patient may receive additional treatments.

[0618] In any of the methods described herein, a polypeptide including an extracellular ActRII chimera (e.g., an extracellular ActRII chimera having the sequence of any one of SEQ ID NOs: 1-43 (e.g., SEQ ID NOs: 22-43)) that further includes a C-terminal extension of one to six amino acids (e.g., 1 , 2, 3, 4, 5, 6 or more amino acids from extracellular ActRIIA or ActRII B) may be used as the therapeutic protein. In any of the methods described herein, a dimer (e.g., homodimer or heterodimer) formed by the interaction of two Fc domain monomers that are each fused to a polypeptide including an extracellular ActRII variant (e.g., an extracellular ActRII chimera having the sequence of any one of SEQ ID NOs: 1 -43 (e.g., SEQ ID NOs: 22-43) or an extracellular ActRIIB variant having the sequence of any one of SEQ ID NOs: 269-283 (e.g., SEQ ID NOs: 270-283)) may be used as the therapeutic protein. In any of the methods described herein, an extracellular ActRII variant (e.g., an extracellular ActRII chimera having the sequence of any one of SEQ ID NOs: 1 -43 (e.g., SEQ ID NOs: 22-43) or an extracellular ActRIIB variant having the sequence of any one of SEQ ID NOs: 269-283 (e.g., SEQ ID NOs: 270-283)) fused to an Fc domain monomer may be used as the therapeutic protein. Nucleic acids encoding the polypeptides described herein, or vectors containing said nucleic acids can also be administered according to any of the methods described herein. In any of the methods described herein, the polypeptide, nucleic acid, or vector can be administered as part of a pharmaceutical composition.

[0619] Compositions that can be administered to a subject according to the methods described herein are provided in Table 7 and Table 8, below.

[0620] Lupus nephritis

[0621] The polypeptides described herein (e.g., a polypeptide including an extracellular ActRII variant (e.g., an extracellular ActRII chimera having the sequence of any one of SEQ ID NOs: 1-43 (e.g., SEQ ID NOs: 22-43) or an extracellular ActRIIB variant having the sequence of any one of SEQ ID NOs: 269-283PATENT

[0622] ATTORNEY DOCKET NO.: 51184-064WO2

[0623] (e.g., SEQ ID NOs: 270-283))) can be used to treat a subject having lupus nephritis. In some embodiments, the subject is male. In some embodiments, the subject is female. In some embodiments, the subject is an adult (e.g., 18 years of age or older, such as 20, 30, 40, 50, 60, or 70 years of age or older). In some embodiments, the subject is a pediatric subject (e.g., younger than 18 years of age, such as 15 years of age, 12 years of age, 10 years of age, or younger). In some embodiments, the subject is identified as having lupus nephritis prior to treatment with an ActRII variant described herein. In some embodiments, the method includes a step of identifying the subject as having lupus nephritis prior to treatment with an ActRII variant described herein. The subject may be identified as having lupus nephritis based on one or more of urinalysis (for detecting hematuria and proteinuria), blood tests (e.g., to evaluate GFR), and kidney biopsy.

[0624] A subject that may be treated as described herein may have mild renal impairment (e.g., a GFR from 60 to 89 mL / min / 1.73 m2), moderate renal impairment, (e.g., a GFR from 30 to 59 mL / min / 1.73 m2), or severe renal impairment (e.g., a GFR from 15 to 29 mL / min / 1.73 m2) at the time of treatment initiation. The subject may have an elevated level of proteinuria (e.g., greater than or equal to 200 mg protein per day (24 h urine protein)), an elevated PCR (e.g., greater than or equal to 300 mg / g creatinine), and / or an elevated ACR (e.g., greater than or equal to 200 mg / g creatinine). The subject may also have elevated levels of certain proteins in serum or urine, such as NAG, NGAL, KIM-1 , IL-18, CTGF, MCP1 , Col IV fragments, Col III fragments, or podocyte proteins (e.g., markers of podocyte injury, such as nephrin and podocin), and / or elevated levels of certain proteins in blood, such as cystatin C, BTP, or B2M. In some embodiments, the subject has elevated blood urea nitrogen or elevated creatinine in blood.

[0625] The methods described herein may also include a step of assessing GFR or eGFR, kidney fibrosis, kidney inflammation, PCR, ACR, UACR, hematuria, proteinuria, albuminuria, the level of certain proteins in the urine, serum, or blood (e.g., the proteins described hereinabove), blood urea nitrogen, or creatinine in blood prior to treatment with or administration of the compositions described herein. The estimated GFR may be calculated based on serum creatinine values, e.g., using the CKD-EPI equation, the Cockcroft-Gault formula, or the MDRD formula, which are all known in the art. These assessments can also be performed after treatment with or administration of the compositions described herein (e.g., after the administration of one or more doses of a composition described herein, or one month, two months, three months, four months, six months, one year or longer after treatment initiation with a composition described herein.

[0626] The compositions described herein are administered in an amount sufficient to treat lupus nephritis, improve kidney function, improve GFR or eGFR, reduce kidney fibrosis, or reduce kidney inflammation (i.e., nephritis, such as interstitial nephritis or glomerulonephritis). In some embodiments, the methods described herein slow or inhibit progression of cardiovascular disease, such as hypertension or left ventricular hypertrophy. In some embodiments, the methods described herein slow or inhibit progression of bone disease, such as osteoporosis, bone pain, bone fracture, soft tissue calcification, osteopenia, osteopetrosis, bone cancer or cancer metastasis-related bone loss (e.g., multiple myeloma, osteosarcoma, breast cancer, prostate cancer, lung cancer, or kidney cancer), Paget’s disease, renal osteodystrophy, treatment-related bone loss, osteogenesis imperfecta, neuromuscular disease-related bone loss, burn-induced bone loss, anorexia-related bone loss, diet-related bone loss, bone loss associated with the treatment of obesity, low gravity-related bone loss, or immobility-related bone loss. InPATENT

[0627] ATTORNEY DOCKET NO.: 51184-064WO2

[0628] some embodiments, the methods described herein slow or inhibit the progression of kidney fibrosis, delay the development of kidney fibrosis, slow or inhibit the progression of kidney inflammation, slow or inhibit a decline in kidney function, delay or prevent the onset of end stage renal disease, delay or prevent the need for dialysis, delay or prevent the need for continuous renal replacement therapy, or delay or prevent the need for a kidney transplant. Kidney function may be assessed by measuring GFR and improving kidney function or slowing or inhibiting a decline in kidney function may result in improving GFR or slowing or stopping a progressive decline in GFR. Kidney function may also be assessed by determining PCR, ACR, or UACR, and improving kidney function or slowing or inhibiting a decline in kidney function may result in improving (i.e., reducing) the PCR, ACR or UACR or slowing or stopping a progressive increase in PCR, ACR or UACR. Kidney function may also be assessed by measuring proteins present in the urine, serum, or blood. For example, kidney function may be assessed by measuring NAG, NGAL, KIM-1 , IL-18, CTGF, MCP1 , Col IV fragments, Col III fragment levels, nephrin, and / or podocin in the urine or serum of a subject, or measuring cystatin C, BTP, or B2M in the blood of a subject, and an improvement in kidney function may lead to reduced levels of one or more of these proteins in urine, serum, or blood. The proteins may be quantified, for example, by ELISA, or RIA using commercially available kits. Kidney function may also be assessed by measuring blood urea nitrogen, creatinine in the blood, creatinine clearance, or proteinuria, and an improvement in kidney function may be indicated by reduced blood urea nitrogen, reduced creatinine in the blood, improved creatinine clearance, or reduced proteinuria. In some embodiments, the method treats, prevents, delays the onset of, slows the progression of, or reduces the risk of hematuria, proteinuria, albuminuria, or a decline in GFR. In some embodiments, the methods described herein improve life expectancy for a subject with lupus nephritis. These outcomes can be assessed by comparing measurements obtained after treatment to measurements taken prior to treatment or by comparing measurements obtained after treatment to measurements from subjects with lupus nephritis who were not treated with a composition described herein. These effects may occur, for example, within 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 15 weeks, 20 weeks, 25 weeks, or more, following administration of the compositions described herein. The patient may be evaluated 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, or more following administration of the composition depending on the dose and route of administration used for treatment. Depending on the outcome of the evaluation, the patient may receive additional treatments.

[0629] In any of the methods described herein, a polypeptide including an extracellular ActRII chimera (e.g., an extracellular ActRII chimera having the sequence of any one of SEQ ID NOs: 1-43 (e.g., SEQ ID NOs: 22-43)) that further includes a C-terminal extension of one to six amino acids (e.g., 1 , 2, 3, 4, 5, 6 or more amino acids from extracellular ActRIIA or ActRII B) may be used as the therapeutic protein. In any of the methods described herein, a dimer (e.g., homodimer or heterodimer) formed by the interaction of two Fc domain monomers that are each fused to a polypeptide including an extracellular ActRII variant (e.g., an extracellular ActRII chimera having the sequence of any one of SEQ ID NOs: 1 -43 (e.g., SEQ ID NOs: 22-43) or an extracellular ActRIIB variant having the sequence of any one of SEQ ID NOs: 269-283 (e.g., SEQ ID NOs: 270-283)) may be used as the therapeutic protein. In any of the methods described herein, an extracellular ActRII variant (e.g., an extracellular ActRII chimera having the sequence of any one of SEQ ID NOs: 1 -43 (e.g., SEQ ID NOs: 22-43) or an extracellular ActRIIB variant having the sequence ofPATENT

[0630] ATTORNEY DOCKET NO.: 51184-064WO2

[0631] any one of SEQ ID NOs: 269-283 (e.g., SEQ ID NOs: 270-283)) fused to an Fc domain monomer may be used as the therapeutic protein. Nucleic acids encoding the polypeptides described herein, or vectors containing said nucleic acids can also be administered according to any of the methods described herein. In any of the methods described herein, the polypeptide, nucleic acid, or vector can be administered as part of a pharmaceutical composition.

[0632] Compositions that can be administered to a subject according to the methods described herein are provided in Table 7 and Table 8, below.

[0633] ANCA-associated vasculitis

[0634] The polypeptides described herein (e.g., a polypeptide including an extracellular ActRII variant (e.g., an extracellular ActRII chimera having the sequence of any one of SEQ ID NOs: 1-43 (e.g., SEQ ID NOs: 22-43) or an extracellular ActRIIB variant having the sequence of any one of SEQ ID NOs: 269-283 (e.g., SEQ ID NOs: 270-283))) can be used to treat a subject having ANCA-associated vasculitis. In some embodiments, the subject is male. In some embodiments, the subject is female. In some embodiments, the subject is an adult (e.g., 18 years of age or older, such as 20, 30, 40, 50, 60, or 70 years of age or older). In some embodiments, the subject is a pediatric subject (e.g., younger than 18 years of age, such as 15 years of age, 12 years of age, 10 years of age, or younger). In some embodiments, the subject is identified as having ANCA-associated vasculitis prior to treatment with an ActRII variant described herein. In some embodiments, the method includes a step of identifying the subject as having ANCA-associated vasculitis prior to treatment with an ActRII variant described herein. The subject may be identified as having ANCA-associated vasculitis based on one or more of blood tests (e.g., to evaluate GFR), and kidney biopsy.

[0635] A subject that may be treated as described herein may have mild renal impairment (e.g., a GFR from 60 to 89 mL / min / 1.73 m2), moderate renal impairment, (e.g., a GFR from 30 to 59 mL / min / 1.73 m2), or severe renal impairment (e.g., a GFR from 15 to 29 mL / min / 1.73 m2) at the time of treatment initiation. The subject may have an elevated level of proteinuria (e.g., greater than or equal to 200 mg protein per day (24 h urine protein)), an elevated PCR (e.g., greater than or equal to 300 mg / g creatinine), and / or an elevated ACR (e.g., greater than or equal to 200 mg / g creatinine). The subject may also have elevated levels of certain proteins in serum or urine, such as NAG, NGAL, KIM-1 , IL-18, CTGF, MCP1 , Col IV fragments, Col III fragments, or podocyte proteins (e.g., markers of podocyte injury, such as nephrin and podocin), and / or elevated levels of certain proteins in blood, such as cystatin C, BTP, or B2M. In some embodiments, the subject has elevated blood urea nitrogen or elevated creatinine in blood.

[0636] The methods described herein may also include a step of assessing GFR or eGFR, kidney fibrosis, kidney inflammation, PCR, ACR, UACR, hematuria, proteinuria, albuminuria, the level of certain proteins in the urine, serum, or blood (e.g., the proteins described hereinabove), blood urea nitrogen, or creatinine in blood prior to treatment with or administration of the compositions described herein. The estimated GFR may be calculated based on serum creatinine values, e.g., using the CKD-EPI equation, the Cockcroft-Gault formula, or the MDRD formula, which are all known in the art. These assessments can also be performed after treatment with or administration of the compositions described herein (e.g., after the administration of one or more doses of a composition described herein, or one month, twoPATENT

[0637] ATTORNEY DOCKET NO.: 51184-064WO2

[0638] months, three months, four months, six months, one year or longer after treatment initiation with a composition described herein.

[0639] The compositions described herein are administered in an amount sufficient to treat ANCA-associated vasculitis, improve kidney function, improve GFR or eGFR, reduce kidney fibrosis, or reduce kidney inflammation (i.e., nephritis, such as interstitial nephritis or glomerulonephritis). In some embodiments, the methods described herein slow or inhibit progression of cardiovascular disease, such as hypertension or left ventricular hypertrophy. In some embodiments, the methods described herein slow or inhibit progression of bone disease, such as osteoporosis, bone pain, bone fracture, soft tissue calcification, osteopenia, osteopetrosis, bone cancer or cancer metastasis-related bone loss (e.g., multiple myeloma, osteosarcoma, breast cancer, prostate cancer, lung cancer, or kidney cancer), Paget’s disease, renal osteodystrophy, treatment-related bone loss, osteogenesis imperfecta, neuromuscular disease-related bone loss, burn-induced bone loss, anorexia-related bone loss, diet-related bone loss, bone loss associated with the treatment of obesity, low gravity-related bone loss, or immobility-related bone loss. In some embodiments, the methods described herein slow or inhibit the progression of kidney fibrosis, delay the development of kidney fibrosis, slow or inhibit the progression of kidney inflammation, slow or inhibit a decline in kidney function, delay or prevent the onset of end stage renal disease, delay or prevent the need for dialysis, delay or prevent the need for continuous renal replacement therapy, or delay or prevent the need for a kidney transplant. Kidney function may be assessed by measuring GFR and improving kidney function or slowing or inhibiting a decline in kidney function may result in improving GFR or slowing or stopping a progressive decline in GFR. Kidney function may also be assessed by determining PCR, ACR, or UACR, and improving kidney function or slowing or inhibiting a decline in kidney function may result in improving (i.e., reducing) the PCR, ACR or UACR or slowing or stopping a progressive increase in PCR, ACR or UACR. Kidney function may also be assessed by measuring proteins present in the urine, serum, or blood. For example, kidney function may be assessed by measuring NAG, NGAL, KIM-1 , IL-18, CTGF, MCP1 , Col IV fragments, Col III fragment levels, nephrin, and / or podocin in the urine or serum of a subject, or measuring cystatin C, BTP, or B2M in the blood of a subject, and an improvement in kidney function may lead to reduced levels of one or more of these proteins in urine, serum, or blood. The proteins may be quantified, for example, by ELISA, or RIA using commercially available kits. Kidney function may also be assessed by measuring blood urea nitrogen, creatinine in the blood, creatinine clearance, or proteinuria, and an improvement in kidney function may be indicated by reduced blood urea nitrogen, reduced creatinine in the blood, improved creatinine clearance, or reduced proteinuria. In some embodiments, the method treats, prevents, delays the onset of, slows the progression of, or reduces the risk of hematuria, proteinuria, albuminuria, or a decline in GFR. In some embodiments, the methods described herein improve life expectancy for a subject with ANCA-associated vasculitis. These outcomes can be assessed by comparing measurements obtained after treatment to measurements taken prior to treatment or by comparing measurements obtained after treatment to measurements from subjects with ANCA-associated vasculitis who were not treated with a composition described herein. These effects may occur, for example, within 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 15 weeks, 20 weeks, 25 weeks, or more, following administration of the compositions described herein. The patient may be evaluated 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, or more following administration of thePATENT

[0640] ATTORNEY DOCKET NO.: 51184-064WO2

[0641] composition depending on the dose and route of administration used for treatment. Depending on the outcome of the evaluation, the patient may receive additional treatments.

[0642] In any of the methods described herein, a polypeptide including an extracellular ActRII chimera (e.g., an extracellular ActRII chimera having the sequence of any one of SEQ ID NOs: 1-43 (e.g., SEQ ID NOs: 22-43)) that further includes a C-terminal extension of one to six amino acids (e.g., 1 , 2, 3, 4, 5, 6 or more amino acids from extracellular ActRIIA or ActRIIB) may be used as the therapeutic protein. In any of the methods described herein, a dimer (e.g., homodimer or heterodimer) formed by the interaction of two Fc domain monomers that are each fused to a polypeptide including an extracellular ActRII variant (e.g., an extracellular ActRII chimera having the sequence of any one of SEQ ID NOs: 1 -43 (e.g., SEQ ID NOs: 22-43) or an extracellular ActRIIB variant having the sequence of any one of SEQ ID NOs: 269-283 (e.g., SEQ ID NOs: 270-283)) may be used as the therapeutic protein. In any of the methods described herein, an extracellular ActRII variant (e.g., an extracellular ActRII chimera having the sequence of any one of SEQ ID NOs: 1 -43 (e.g., SEQ ID NOs: 22-43) or an extracellular ActRIIB variant having the sequence of any one of SEQ ID NOs: 269-283 (e.g., SEQ ID NOs: 270-283)) fused to an Fc domain monomer may be used as the therapeutic protein. Nucleic acids encoding the polypeptides described herein, or vectors containing said nucleic acids can also be administered according to any of the methods described herein. In any of the methods described herein, the polypeptide, nucleic acid, or vector can be administered as part of a pharmaceutical composition.

[0643] Compositions that can be administered to a subject according to the methods described herein are provided in Table 7 and Table 8, below.

[0644] IgA nephropathy

[0645] The polypeptides described herein (e.g., a polypeptide including an extracellular ActRII variant (e.g., an extracellular ActRII chimera having the sequence of any one of SEQ ID NOs: 1-43 (e.g., SEQ ID NOs: 22-43) or an extracellular ActRIIB variant having the sequence of any one of SEQ ID NOs: 269-283 (e.g., SEQ ID NOs: 270-283))) can be used to treat a subject having IgA nephropathy. In some embodiments, the subject is male. In some embodiments, the subject is female. In some embodiments, the subject is an adult (e.g., 18 years of age or older, such as 20, 30, 40, 50, 60, or 70 years of age or older). In some embodiments, the subject is a pediatric subject (e.g., younger than 18 years of age, such as 15 years of age, 12 years of age, 10 years of age, or younger). In some embodiments, the subject is identified as having IgA nephropathy prior to treatment with an ActRII variant described herein. In some embodiments, the method includes a step of identifying the subject as having IgA nephropathy prior to treatment with an ActRII variant described herein. The subject may be identified as having IgA nephropathy based on one or more of blood tests (e.g., to evaluate creatinine or cystatin C), urinalysis (e.g., to check for blood or protein in the urine), and kidney biopsy.

[0646] A subject that may be treated as described herein may have mild renal impairment (e.g., a GFR from 60 to 89 mL / min / 1.73 m2), moderate renal impairment, (e.g., a GFR from 30 to 59 mL / min / 1.73 m2), or severe renal impairment (e.g., a GFR from 15 to 29 mL / min / 1.73 m2) at the time of treatment initiation. The subject may have an elevated level of proteinuria (e.g., greater than or equal to 200 mg protein per day (24 h urine protein)), an elevated PCR (e.g., greater than or equal to 300 mg / g creatinine), and / or an elevated ACR (e.g., greater than or equal to 200 mg / g creatinine). The subject may also have elevatedPATENT

[0647] ATTORNEY DOCKET NO.: 51184-064WO2

[0648] levels of certain proteins in serum or urine, such as NAG, NGAL, KIM-1 , IL-18, CTGF, MCP1 , Col IV fragments, Col III fragments, or podocyte proteins (e.g., markers of podocyte injury, such as nephrin and podocin), and / or elevated levels of certain proteins in blood, such as cystatin C, BTP, or B2M. In some embodiments, the subject has elevated blood urea nitrogen or elevated creatinine in blood.

[0649] The methods described herein may also include a step of assessing GFR or eGFR, kidney fibrosis, kidney inflammation, PCR, ACR, UACR, hematuria, proteinuria, albuminuria, the level of certain proteins in the urine, serum, or blood (e.g., the proteins described hereinabove), blood urea nitrogen, or creatinine in blood prior to treatment with or administration of the compositions described herein. The estimated GFR may be calculated based on serum creatinine values, e.g., using the CKD-EPI equation, the Cockcroft-Gault formula, or the MDRD formula, which are all known in the art. These assessments can also be performed after treatment with or administration of the compositions described herein (e.g., after the administration of one or more doses of a composition described herein, or one month, two months, three months, four months, six months, one year or longer after treatment initiation with a composition described herein.

[0650] The compositions described herein are administered in an amount sufficient to treat IgA nephropathy, improve kidney function, improve GFR or eGFR, reduce kidney fibrosis, or reduce kidney inflammation (i.e., nephritis, such as interstitial nephritis or glomerulonephritis). In some embodiments, the methods described herein slow or inhibit progression of cardiovascular disease, such as hypertension or left ventricular hypertrophy. In some embodiments, the methods described herein slow or inhibit progression of bone disease, such as osteoporosis, bone pain, bone fracture, soft tissue calcification, osteopenia, osteopetrosis, bone cancer or cancer metastasis-related bone loss (e.g., multiple myeloma, osteosarcoma, breast cancer, prostate cancer, lung cancer, or kidney cancer), Paget’s disease, renal osteodystrophy, treatment-related bone loss, osteogenesis imperfecta, neuromuscular disease-related bone loss, burn-induced bone loss, anorexia-related bone loss, diet-related bone loss, bone loss associated with the treatment of obesity, low gravity-related bone loss, or immobility-related bone loss. In some embodiments, the methods described herein slow or inhibit the progression of kidney fibrosis, delay the development of kidney fibrosis, slow or inhibit the progression of kidney inflammation, slow or inhibit a decline in kidney function, delay or prevent the onset of end stage renal disease, delay or prevent the need for dialysis, delay or prevent the need for continuous renal replacement therapy, or delay or prevent the need for a kidney transplant. Kidney function may be assessed by measuring GFR and improving kidney function or slowing or inhibiting a decline in kidney function may result in improving GFR or slowing or stopping a progressive decline in GFR. Kidney function may also be assessed by determining PCR, ACR, or UACR, and improving kidney function or slowing or inhibiting a decline in kidney function may result in improving (i.e., reducing) the PCR, ACR or UACR or slowing or stopping a progressive increase in PCR, ACR or UACR. Kidney function may also be assessed by measuring proteins present in the urine, serum, or blood. For example, kidney function may be assessed by measuring NAG, NGAL, KIM-1 , IL-18, CTGF, MCP1 , Col IV fragments, Col III fragment levels, nephrin, and / or podocin in the urine or serum of a subject, or measuring cystatin C, BTP, or B2M in the blood of a subject, and an improvement in kidney function may lead to reduced levels of one or more of these proteins in urine, serum, or blood. The proteins may be quantified, for example, by ELISA, or RIA using commercially available kits. Kidney function may also be assessed by measuring blood urea nitrogen, creatinine in thePATENT

[0651] ATTORNEY DOCKET NO.: 51184-064WO2

[0652] blood, creatinine clearance, or proteinuria, and an improvement in kidney function may be indicated by reduced blood urea nitrogen, reduced creatinine in the blood, improved creatinine clearance, or reduced proteinuria. In some embodiments, the method treats, prevents, delays the onset of, slows the progression of, or reduces the risk of hematuria, proteinuria, albuminuria, or a decline in GFR. In some embodiments, the methods described herein improve life expectancy for a subject with IgA nephropathy. These outcomes can be assessed by comparing measurements obtained after treatment to measurements taken prior to treatment or by comparing measurements obtained after treatment to measurements from subjects with IgA nephropathy who were not treated with a composition described herein. These effects may occur, for example, within 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 15 weeks, 20 weeks, 25 weeks, or more, following administration of the compositions described herein. The patient may be evaluated 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, or more following administration of the composition depending on the dose and route of administration used for treatment. Depending on the outcome of the evaluation, the patient may receive additional treatments.

[0653] In any of the methods described herein, a polypeptide including an extracellular ActRII chimera (e.g., an extracellular ActRII chimera having the sequence of any one of SEQ ID NOs: 1-43 (e.g., SEQ ID NOs: 22-43)) that further includes a C-terminal extension of one to six amino acids (e.g., 1 , 2, 3, 4, 5, 6 or more amino acids from extracellular ActRIIA or ActRII B) may be used as the therapeutic protein. In any of the methods described herein, a dimer (e.g., homodimer or heterodimer) formed by the interaction of two Fc domain monomers that are each fused to a polypeptide including an extracellular ActRII variant (e.g., an extracellular ActRII chimera having the sequence of any one of SEQ ID NOs: 1 -43 (e.g., SEQ ID NOs: 22-43) or an extracellular ActRIIB variant having the sequence of any one of SEQ ID NOs: 269-283 (e.g., SEQ ID NOs: 270-283)) may be used as the therapeutic protein. In any of the methods described herein, an extracellular ActRII variant (e.g., an extracellular ActRII chimera having the sequence of any one of SEQ ID NOs: 1 -43 (e.g., SEQ ID NOs: 22-43) or an extracellular ActRIIB variant having the sequence of any one of SEQ ID NOs: 269-283 (e.g., SEQ ID NOs: 270-283)) fused to an Fc domain monomer may be used as the therapeutic protein. Nucleic acids encoding the polypeptides described herein, or vectors containing said nucleic acids can also be administered according to any of the methods described herein. In any of the methods described herein, the polypeptide, nucleic acid, or vector can be administered as part of a pharmaceutical composition.

[0654] Compositions that can be administered to a subject according to the methods described herein are provided in Table 7 and Table 8, below.

[0655] Table 7

[0656] Row Composition

[0657] 1 A polypeptide comprising an extracellular activin receptor type II (ActRII) chimera, the chimera having a sequence of any one of GAILGRAETRECIYYNANWELERTNQSGLERCEGEQX1KRRHCFATWKNISGSIEIVKQGCWLDDX2X3CYD RTDCVX4X5X6X7X8PX9VYFCCCEGNMCNEKFSYFPEMEVTQPTS (SEQ ID NO: 1), GAILGRAETRECIYYNANWELERTNQSGLERCEGEQX1KRLHCFATWKNISGSIEIVKQGCWLDDX2X3CYDR TDCVX4X5X6X7X8PX9VYFCCCEGNMCNEKFSYFPEMEVTQPTS (SEQ ID NO: 2),

[0658]

[0659] PATENT

[0660] ATTORNEY DOCKET NO.: 51184-064WO2

[0661] Row Composition GAILGRAETRECIYYNANWELERTNQSGLERCEGEQX1KRLHCYASWKNISGSIEIVKQGCWLDDX2X3CYD RTDCVX4X5X6X7X8PX9VYFCCCEGNMCNEKFSYFPEMEVTQPTS (SEQ ID NO: 3), GAILGRAETRECIYYNANWELERTNQSGLERCEGEQX1KRLHCYASWRNSSGSIEIVKQGCWLDDX2X3CYD RTDCVX4X5X6X7X8PX9VYFCCCEGNMCNEKFSYFPEMEVTQPTS (SEQ ID NO: 4), GAILGRAETRECIYYNANWELERTNQSGLERCEGEQX1KRLHCYASWRNSSGTIEIVKQGCWLDDX2X3CYD RTDCVX4X5X6X7X8PX9VYFCCCEGNMCNEKFSYFPEMEVTQPTS (SEQ ID NO: 5), GAILGRAETRECIYYNANWELERTNQSGLERCEGEQX1KRLHCYASWRNSSGTIELVKKGCWLDDX2X3CYD RTDCVX4X5X6X7X8PX9VYFCCCEGNMCNEKFSYFPEMEVTQPTS (SEQ ID NO: 6), GAILGRAETRECIYYNANWELERTNQSGLERCEGEQX1KRLHCYASWRNSSGTIELVKKGCWLDDX2X3CYD RQECVX4X5X6X7X8PX9VYFCCCEGNMCNEKFSYFPEMEVTQPTS (SEQ ID NO: 7), GRGEAETRECIYYNANWELERTNQSGLERCEGEQX1KRRHCFATWKNISGSIEIVKQGCWLDD X2X3CYDRTDCVX4X5X6X7X8PX9VYFCCCEGNMCNEKFSYFPEMEVTQPTS (SEQ ID NO: 8), GRGEAETRECIYYNANWELERTNQSGLERCEGEQX1KRLHCFATWKNISGSIEIVKQGCWLDD X2X3CYDRTDCVX4X5X6X7X8PX9VYFCCCEGNMCNEKFSYFPEMEVTQPTS (SEQ ID NO: 9), GRGEAETRECIYYNANWELERTNQSGLERCEGEQX1KRLHCYASWKNISGSIEIVKQGCWLDD X2X3CYDRTDCVX4X5X6X7X8PX9VYFCCCEGNMCNEKFSYFPEMEVTQPTS (SEQ ID NO: 10), GRGEAETRECIYYNANWELERTNQSGLERCEGEQX1KRLHCYASWRNSSGSIEIVKQGCWLDDX2X3CYDR TDCVX4X5X6X7X8PX9VYFCCCEGNMCNEKFSYFPEMEVTQPTS (SEQ ID NO: 11), GRGEAETRECIYYNANWELERTNQSGLERCEGEQX1KRLHCYASWRNSSGTIEIVKQGCWLDDX2X3CYDR TDCVX4X5X6X7X8PX9VYFCCCEGNMCNEKFSYFPEMEVTQPTS (SEQ ID NO: 12), GRGEAETRECIYYNANWELERTNQSGLERCEGEQX1KRLHCYASWRNSSGTIELVKKGCWLDDX2X3CYDR TDCVX4X5X6X7X8PX9VYFCCCEGNMCNEKFSYFPEMEVTQPTS (SEQ ID NO: 13), GRGEAETRECIYYNANWELERTNQSGLERCEGEQX1KRLHCYASWRNSSGTIELVKKGCWLDDX2X3CYDR QECVX4X5X6X7X8PX9VYFCCCEGNMCNEKFSYFPEMEVTQPTS (SEQ ID NO: 14), GAILGRSETQECIYYNANWELERTNQSGLERCEGEQX1KRRHCFATWKNISGSIEIVKQGCWLDDX2X3CYD RTDCVX4X5X6X7X8PX9VYFCCCEGNMCNEKFSYFPEMEVTQPTS (SEQ ID NO: 15), GAILGRSETQECIYYNANWELERTNQSGLERCEGEQX1KRLHCFATWKNISGSIEIVKQGCWLDDX2X3CYDR TDCVX4X5X6X7X8PX9VYFCCCEGNMCNEKFSYFPEMEVTQPTS (SEQ ID NO: 16), GAILGRSETQECIYYNANWELERTNQSGLERCEGEQX1KRLHCYASWKNISGSIEIVKQGCWLDDX2X3CYD RTDCVX4X5X6X7X8PX9VYFCCCEGNMCNEKFSYFPEMEVTQPTS (SEQ ID NO: 17), GAILGRSETQECIYYNANWELERTNQSGLERCEGEQX1KRLHCYASWRNSSGSIEIVKQGCWLDDX2X3CYD RTDCVX4X5X6X7X8PX9VYFCCCEGNMCNEKFSYFPEMEVTQPTS (SEQ ID NO: 18), GAILGRSETQECIYYNANWELERTNQSGLERCEGEQX1KRLHCYASWRNSSGTIEIVKQGCWLDDX2X3CYD RTDCVX4X5X6X7X8PX9VYFCCCEGNMCNEKFSYFPEMEVTQPTS (SEQ ID NO: 19), GAILGRSETQECIYYNANWELERTNQSGLERCEGEQX1KRLHCYASWRNSSGTIELVKKGCWLDDX2X3CYD RTDCVX4X5X6X7X8PX9VYFCCCEGNMCNEKFSYFPEMEVTQPTS (SEQ ID NO: 20), and GAILGRSETQECIYYNANWELERTNQSGLERCEGEQX1KRLHCYASWRNSSGTIELVKKGCWLDDX2X3CYD RQECVX4X5X6X7X8PX9VYFCCCEGNMCNEKFSYFPEMEVTQPTS (SEQ ID NO: 21),

[0662] wherein Xi is D or R, X2 is I, F, E, D, Y, S, N, Q, or T, X3 is N or T, X4 is A or E, X5 is T or K, Xs is E or K, X7 is E or D, Xs is N or S, and Xg is Q, E, K, R, D, or N, optionally wherein the chimera is truncated from the N- terminus by deletion of 1 , 2, 3, 4, 5, 6, 7, 8, or 9 amino acids, wherein the chimera retains the two amino acids before the first cysteine.

[0663]

[0664] PATENT

[0665] ATTORNEY DOCKET NO.: 51184-064WO2

[0666] Row Composition

[0667] 2 The polypeptide of row 1 , wherein the chimera has the sequence of GAILGRAETRECIYYNANWELERTNQSGLERCEGEQX1KRRHCFATWKNISGSIEIVKQGCWLDDX2X3CYD RTDCVX4X5X6X7X8PX9VYFCCCEGNMCNEKFSYFPEMEVTQPTS (SEQ ID NO: 1).

[0668] 3 The polypeptide of row 1 , wherein the chimera has the sequence of GAILGRAETRECIYYNANWELERTNQSGLERCEGEQX1KRLHCFATWKNISGSIEIVKQGCWLDDX2X3CYDR TDCVX4X5X6X7X8PX9VYFCCCEGNMCNEKFSYFPEMEVTQPTS (SEQ ID NO: 2).

[0669] 4 The polypeptide of row 1 , wherein the chimera has the sequence of GAILGRAETRECIYYNANWELERTNQSGLERCEGEQX1KRLHCYASWKNISGSIEIVKQGCWLDDX2X3CYD RTDCVX4X5X6X7X8PX9VYFCCCEGNMCNEKFSYFPEMEVTQPTS (SEQ ID NO: 3).

[0670] 5 The polypeptide of row 1 , wherein the chimera has the sequence of GAILGRAETRECIYYNANWELERTNQSGLERCEGEQX1KRLHCYASWRNSSGSIEIVKQGCWLDDX2X3CYD RTDCVX4X5X6X7X8PX9VYFCCCEGNMCNEKFSYFPEMEVTQPTS (SEQ ID NO: 4).

[0671] 6 The polypeptide of row 1 , wherein the chimera has the sequence of GAILGRAETRECIYYNANWELERTNQSGLERCEGEQX1KRLHCYASWRNSSGTIEIVKQGCWLDDX2X3CYD RTDCVX4X5X6X7X8PX9VYFCCCEGNMCNEKFSYFPEMEVTQPTS (SEQ ID NO: 5).

[0672] 7 The polypeptide of row 1 , wherein the chimera has the sequence of GAILGRAETRECIYYNANWELERTNQSGLERCEGEQX1KRLHCYASWRNSSGTIELVKKGCWLDDX2X3CYD RTDCVX4X5X6X7X8PX9VYFCCCEGNMCNEKFSYFPEMEVTQPTS (SEQ ID NO: 6).

[0673] 8 The polypeptide of row 1 , wherein the chimera has the sequence of GAILGRAETRECIYYNANWELERTNQSGLERCEGEQX1KRLHCYASWRNSSGTIELVKKGCWLDDX2X3CYD RQECVX4X5X6X7X8PX9VYFCCCEGNMCNEKFSYFPEMEVTQPTS (SEQ ID NO: 7).

[0674] 9 The polypeptide of row 1 , wherein the chimera has the sequence of GRGEAETRECIYYNANWELERTNQSGLERCEGEQX1KRRHCFATWKNISGSIEIVKQGCWLDDX2X3CYDRT DCVX4X5X6X7X8PX9VYFCCCEGNMCNEKFSYFPEMEVTQPTS (SEQ ID NO: 8).

[0675] 10 The polypeptide of row 1 , wherein the chimera has the sequence of GRGEAETRECIYYNANWELERTNQSGLERCEGEQX1KRLHCFATWKNISGSIEIVKQGCWLDDX2X3CYDRT DCVX4X5X6X7X8PX9VYFCCCEGNMCNEKFSYFPEMEVTQPTS (SEQ ID NO: 9).

[0676] 11 The polypeptide of row 1 , wherein the chimera has the sequence of GRGEAETRECIYYNANWELERTNQSGLERCEGEQX1KRLHCYASWKNISGSIEIVKQGCWLDDX2X3CYDRT DCVX4X5X6X7X8PX9VYFCCCEGNMCNEKFSYFPEMEVTQPTS (SEQ ID NO: 10).

[0677] 12 The polypeptide of row 1 , wherein the chimera has the sequence of GRGEAETRECIYYNANWELERTNQSGLERCEGEQX1KRLHCYASWRNSSGSIEIVKQGCWLDDX2X3CYDR TDCVX4X5X6X7X8PX9VYFCCCEGNMCNEKFSYFPEMEVTQPTS (SEQ ID NO: 11).

[0678] 13 The polypeptide of row 1 , wherein the chimera has the sequence of GRGEAETRECIYYNANWELERTNQSGLERCEGEQX1KRLHCYASWRNSSGTIEIVKQGCWLDDX2X3CYDR TDCVX4X5X6X7X8PX9VYFCCCEGNMCNEKFSYFPEMEVTQPTS (SEQ ID NO: 12).

[0679] 14 The polypeptide of row 1 , wherein the chimera has the sequence of GRGEAETRECIYYNANWELERTNQSGLERCEGEQX1KRLHCYASWRNSSGTIELVKKGCWLDDX2X3CYDR TDCVX4X5X6X7X8PX9VYFCCCEGNMCNEKFSYFPEMEVTQPTS (SEQ ID NO: 13).

[0680] 15 The polypeptide of row 1 , wherein the chimera has the sequence of GRGEAETRECIYYNANWELERTNQSGLERCEGEQX1KRLHCYASWRNSSGTIELVKKGCWLDDX2X3CYDR QECVX4X5X6X7X8PX9VYFCCCEGNMCNEKFSYFPEMEVTQPTS (SEQ ID NO: 14).

[0681]

[0682] PATENT

[0683] ATTORNEY DOCKET NO.: 51184-064WO2

[0684] Row Composition

[0685] 16 The polypeptide of row 1 , wherein the chimera has the sequence of GAILGRSETQECIYYNANWELERTNQSGLERCEGEQX1KRRHCFATWKNISGSIEIVKQGCWLDDX2X3CYD RTDCVX4X5X6X7X8PX9VYFCCCEGNMCNEKFSYFPEMEVTQPTS (SEQ ID NO: 15).

[0686] 17 The polypeptide of row 1 , wherein the chimera has the sequence of GAILGRSETQECIYYNANWELERTNQSGLERCEGEQX1KRLHCFATWKNISGSIEIVKQGCWLDDX2X3CYDR TDCVX4X5X6X7X8PX9VYFCCCEGNMCNEKFSYFPEMEVTQPTS (SEQ ID NO: 16).

[0687] 18 The polypeptide of row 1 , wherein the chimera has the sequence of GAILGRSETQECIYYNANWELERTNQSGLERCEGEQX1KRLHCYASWKNISGSIEIVKQGCWLDDX2X3CYD RTDCVX4X5X6X7X8PX9VYFCCCEGNMCNEKFSYFPEMEVTQPTS (SEQ ID NO: 17).

[0688] 19 The polypeptide of row 1 , wherein the chimera has the sequence of GAILGRSETQECIYYNANWELERTNQSGLERCEGEQX1KRLHCYASWRNSSGSIEIVKQGCWLDDX2X3CYD RTDCVX4X5X6X7X8PX9VYFCCCEGNMCNEKFSYFPEMEVTQPTS (SEQ ID NO: 18).

[0689] 20 The polypeptide of row 1 , wherein the chimera has the sequence of GAILGRSETQECIYYNANWELERTNQSGLERCEGEQX1KRLHCYASWRNSSGTIEIVKQGCWLDDX2X3CYD RTDCVX4X5X6X7X8PX9VYFCCCEGNMCNEKFSYFPEMEVTQPTS (SEQ ID NO: 19).

[0690] 21 The polypeptide of row 1 , wherein the chimera has the sequence of GAILGRSETQECIYYNANWELERTNQSGLERCEGEQX1KRLHCYASWRNSSGTIELVKKGCWLDDX2X3CYD RTDCVX4X5X6X7X8PX9VYFCCCEGNMCNEKFSYFPEMEVTQPTS (SEQ ID NO: 20).

[0691] 22 The polypeptide of row 1 , wherein the chimera has the sequence of GAILGRSETQECIYYNANWELERTNQSGLERCEGEQX1KRLHCYASWRNSSGTIELVKKGCWLDDX2X3CYD RQECVX4X5X6X7X8PX9VYFCCCEGNMCNEKFSYFPEMEVTQPTS (SEQ ID NO: 21).

[0692] 23 The polypeptide of any one of rows 1-22, wherein Xi is D.

[0693] 24 The polypeptide of any one of rows 1-22, wherein Xi is R.

[0694] 25 The polypeptide of any one of rows 1-24, wherein X2 is I.

[0695] 26 The polypeptide of any one of rows 1 -24, wherein X2 is F.

[0696] 27 The polypeptide of any one of rows 1-24, wherein X2 is E.

[0697] 28 The polypeptide of any one of rows 1-24, wherein X2 is D.

[0698] 29 The polypeptide of any one of rows 1 -24, wherein X2 is Y.

[0699] 30 The polypeptide of any one of rows 1-24, wherein X2 is S.

[0700] 31 The polypeptide of any one of rows 1-24, wherein X2 is N.

[0701] 32 The polypeptide of any one of rows 1 -24, wherein X2 is Q.

[0702] 33 The polypeptide of any one of rows 1 -24, wherein X2 is T.

[0703] 34 The polypeptide of any one of rows 1-33, wherein X3 is N.

[0704] 35 The polypeptide of any one of rows 1 -33, wherein X3 is T.

[0705] 36 The polypeptide of any one of rows 1 -35, wherein X4 is A.

[0706] 37 The polypeptide of any one of rows 1-35, wherein X4 is E.

[0707] 38 The polypeptide of any one of rows 1 -37, wherein X5 is T.

[0708] 39 The polypeptide of any one of rows 1 -37, wherein X5 is K.

[0709] 40 The polypeptide of any one of rows 1-39, wherein Xs is E.

[0710] 41 The polypeptide of any one of rows 1 -39, wherein Xs is K.

[0711] 42 The polypeptide of any one of rows 1 -41 , wherein X7 is E.

[0712] 43 The polypeptide of any one of rows 1 -41 , wherein X7 is D.

[0713] 44 The polypeptide of any one of rows 1-43, wherein Xs is N.

[0714]

[0715] PATENT

[0716] ATTORNEY DOCKET NO.: 51184-064WO2

[0717] Row Composition

[0718] 45 The polypeptide of any one of rows 1-43, wherein Xs is S.

[0719] 46 The polypeptide of any one of rows 1 -45, wherein Xg is Q.

[0720] 47 The polypeptide of any one of rows 1-45, wherein Xg is E.

[0721] 48 The polypeptide of any one of rows 1 -45, wherein Xg is K.

[0722] 49 The polypeptide of any one of rows 1-45, wherein Xg is R.

[0723] 50 The polypeptide of any one of rows 1-45, wherein Xg is D.

[0724] 51 The polypeptide of any one of rows 1-45, wherein Xg is N.

[0725] 52 The polypeptide of any one of rows 1 -51 , wherein Xs is T, Xs is E, X? is E, and Xs is N.

[0726] 53 The polypeptide of any one of rows 1 -51 , wherein Xs is T, Xs is K, X? is E, and Xs is N.

[0727] 54 The polypeptide of any one of rows 1 -53, wherein X2 is E and Xs is T.

[0728] 55 The polypeptide of any one of rows 1 -53, wherein X2 is I or F and Xs is N.

[0729] 56 The polypeptide of row 55, wherein X2 is I.

[0730] 57 The polypeptide of row 55, wherein X2 is F.

[0731] 58 The polypeptide of row 1 , wherein the chimera has the sequence of any one of SEQ ID NOs: 22-43. 59 The polypeptide of row 58, wherein the chimera has the sequence of SEQ ID NO: 22.

[0732] 60 The polypeptide of row 58, wherein the chimera has the sequence of SEQ ID NO: 23.

[0733] 61 The polypeptide of row 58, wherein the chimera has the sequence of SEQ ID NO: 24.

[0734] 62 The polypeptide of row 58, wherein the chimera has the sequence of SEQ ID NO: 25.

[0735] 63 The polypeptide of row 58, wherein the chimera has the sequence of SEQ ID NO: 40.

[0736] 64 The polypeptide of row 58, wherein the chimera has the sequence of SEQ ID NO: 41.

[0737] 65 The polypeptide of row 58, wherein the chimera has the sequence of SEQ ID NO: 28.

[0738] 66 The polypeptide of row 58, wherein the chimera has the sequence of SEQ ID NO: 42.

[0739] 67 The polypeptide of row 58, wherein the chimera has the sequence of SEQ ID NO: 43.

[0740] 68 The polypeptide of row 58, wherein the chimera has the sequence of SEQ ID NO: 37.

[0741] 69 The polypeptide of any one of rows 1-68, wherein the chimera is truncated from the N-terminus by deletion of one amino acid.

[0742] 70 The polypeptide of any one of rows 1-68, wherein the chimera is truncated from the N-terminus by deletion of two amino acids.

[0743] 71 The polypeptide of any one of rows 1-68, wherein the chimera is truncated from the N-terminus by deletion of three amino acids.

[0744] 72 The polypeptide of any one of rows 1-68, wherein the chimera is truncated from the N-terminus by deletion of four amino acids.

[0745] 73 The polypeptide of any one of rows 1-68, wherein the chimera is truncated from the N-terminus by deletion of five amino acids.

[0746] 74 The polypeptide of any one of rows 1-68, wherein the chimera is truncated from the N-terminus by deletion of six amino acids.

[0747] 75 The polypeptide of any one of rows 1-68, wherein the chimera is truncated from the N-terminus by deletion of seven amino acids.

[0748] 76 The polypeptide of any one of rows 1-68, wherein the chimera is truncated from the N-terminus by deletion of eight amino acids.

[0749] 77 The polypeptide of any one of rows 1-68, wherein the chimera is truncated from the N-terminus by deletion of nine amino acids.

[0750]

[0751] PATENT

[0752] ATTORNEY DOCKET NO.: 51184-064WO2

[0753] Row Composition

[0754] 78 The polypeptide of any one of rows 1 and 69-77, wherein the chimera has the sequence of any one of SEQ ID NOs: 111-183.

[0755] 79 The polypeptide of row 78, wherein the chimera has the sequence of SEQ ID NO 111.

[0756] 80 The polypeptide of row 78, wherein the chimera has the sequence of SEQ ID NO 116.

[0757] 81 The polypeptide of row 78, wherein the chimera has the sequence of SEQ ID NO 117.

[0758] 82 The polypeptide of row 78, wherein the chimera has the sequence of SEQ ID NO 118.

[0759] 83 The polypeptide of row 78, wherein the chimera has the sequence of SEQ ID NO 119.

[0760] 84 The polypeptide of row 78, wherein the chimera has the sequence of SEQ ID NO 120.

[0761] 85 The polypeptide of row 78, wherein the chimera has the sequence of SEQ ID NO 121.

[0762] 86 The polypeptide of row 78, wherein the chimera has the sequence of SEQ ID NO 122.

[0763] 87 The polypeptide of row 78, wherein the chimera has the sequence of SEQ ID NO 126.

[0764] 88 The polypeptide of row 78, wherein the chimera has the sequence of SEQ ID NO 130.

[0765] 89 The polypeptide of row 78, wherein the chimera has the sequence of SEQ ID NO 142.

[0766] 90 The polypeptide of row 78, wherein the chimera has the sequence of SEQ ID NO 143.

[0767] 91 The polypeptide of row 78, wherein the chimera has the sequence of SEQ ID NO 146.

[0768] 92 The polypeptide of row 78, wherein the chimera has the sequence of SEQ ID NO 147.

[0769] 93 The polypeptide of row 78, wherein the chimera has the sequence of SEQ ID NO 149.

[0770] 94 The polypeptide of row 78, wherein the chimera has the sequence of SEQ ID NO 150.

[0771] 95 The polypeptide of row 78, wherein the chimera has the sequence of SEQ ID NO 151.

[0772] 96 The polypeptide of row 78, wherein the chimera has the sequence of SEQ ID NO 152.

[0773] 97 The polypeptide of row 78, wherein the chimera has the sequence of SEQ ID NO 153.

[0774] 98 The polypeptide of row 78, wherein the chimera has the sequence of SEQ ID NO 154.

[0775] 99 The polypeptide of row 78, wherein the chimera has the sequence of SEQ ID NO 155.

[0776] 100 The polypeptide of row 78, wherein the chimera has the sequence of SEQ ID NO 156.

[0777] 101 The polypeptide of row 78, wherein the chimera has the sequence of SEQ ID NO 158.

[0778] 102 The polypeptide of row 78, wherein the chimera has the sequence of SEQ ID NO 159.

[0779] 103 The polypeptide of row 78, wherein the chimera has the sequence of SEQ ID NO 161.

[0780] 104 The polypeptide of row 78, wherein the chimera has the sequence of SEQ ID NO 162.

[0781] 105 The polypeptide of row 78, wherein the chimera has the sequence of SEQ ID NO 163.

[0782] 106 The polypeptide of row 78, wherein the chimera has the sequence of SEQ ID NO 164.

[0783] 107 The polypeptide of row 78, wherein the chimera has the sequence of SEQ ID NO 167.

[0784] 108 The polypeptide of row 78, wherein the chimera has the sequence of SEQ ID NO 171.

[0785] 109 The polypeptide of row 78, wherein the chimera has the sequence of SEQ ID NO 172.

[0786] 110 The polypeptide of row 78, wherein the chimera has the sequence of SEQ ID NO 173.

[0787] 111 The polypeptide of row 78, wherein the chimera has the sequence of SEQ ID NO 176.

[0788] 112 The polypeptide of row 78, wherein the chimera has the sequence of SEQ ID NO 177.

[0789] 113 The polypeptide of row 78, wherein the chimera has the sequence of SEQ ID NO 179.

[0790] 114 The polypeptide of row 78, wherein the chimera has the sequence of SEQ ID NO 183.

[0791] 115 The polypeptide of any one of rows 1-114, wherein the polypeptide (e.g., the chimera) further includes a C- terminal extension of one or more amino acids (e.g., 1 , 2, 3, 4, 5, 6, or more amino acids from wild-type extracellular ActRIIA or Act Rl IB) .

[0792] 116 The polypeptide of row 115, wherein the C-terminal extension is NP.

[0793] 117 The polypeptide of row 115, wherein the C-terminal extension is NPVTPK (SEQ ID NO: 104).

[0794]

[0795] PATENT

[0796] ATTORNEY DOCKET NO.: 51184-064WO2

[0797] Row Composition

[0798] 118 The polypeptide of any one of rows 1-117, wherein the polypeptide further includes an Fc domain monomer fused to the C-terminus of the polypeptide (e.g., the C-terminus of the chimera) by way of a linker.

[0799] 119 The polypeptide of row 118, wherein the Fc domain monomer is an IgG 1 Fc domain monomer.

[0800] 120 The polypeptide of row 119, wherein the IgG 1 Fc domain monomer is a human IgG 1 Fc domain monomer.

[0801] 121 The polypeptide of row 118, wherein the Fc domain monomer has the sequence of SEQ ID NO: 48, SEQ ID NO: 100, SEQ ID NO: 264, or SEQ ID NO: 285.

[0802] 122 The polypeptide of row 121 , wherein the Fc domain monomer has the sequence of SEQ ID NO: 100 or SEQ ID NO: 264.

[0803] 123 The polypeptide of row 121 , wherein the Fc domain monomer has the sequence of SEQ ID NO: 100. 124 The polypeptide of row 121 , wherein the Fc domain monomer has the sequence of SEQ ID NO: 264. 125 The polypeptide of row 121 , wherein the Fc domain monomer has the sequence of SEQ ID NO: 285. 126 The polypeptide of any one of rows 118-125, wherein the polypeptide has the sequence of any one of SEQ ID NOs: 107-110 and SEQ ID NOs: 184-263.

[0804] 127 The polypeptide of row 126, wherein the polypeptide has the sequence of SEQ ID NO 107.

[0805] 128 The polypeptide of row 126, wherein the polypeptide has the sequence of SEQ ID NO 108.

[0806] 129 The polypeptide of row 126, wherein the polypeptide has the sequence of SEQ ID NO 109.

[0807] 130 The polypeptide of row 126, wherein the polypeptide has the sequence of SEQ ID NO 110.

[0808] 131 The polypeptide of row 126, wherein the polypeptide has the sequence of SEQ ID NO 184.

[0809] 132 The polypeptide of row 126, wherein the polypeptide has the sequence of SEQ ID NO 189.

[0810] 133 The polypeptide of row 126, wherein the polypeptide has the sequence of SEQ ID NO 190.

[0811] 134 The polypeptide of row 126, wherein the polypeptide has the sequence of SEQ ID NO 191.

[0812] 135 The polypeptide of row 126, wherein the polypeptide has the sequence of SEQ ID NO 192.

[0813] 136 The polypeptide of row 126, wherein the polypeptide has the sequence of SEQ ID NO 193.

[0814] 137 The polypeptide of row 126, wherein the polypeptide has the sequence of SEQ ID NO 194.

[0815] 138 The polypeptide of row 126, wherein the polypeptide has the sequence of SEQ ID NO 195.

[0816] 139 The polypeptide of row 126, wherein the polypeptide has the sequence of SEQ ID NO 199.

[0817] 140 The polypeptide of row 126, wherein the polypeptide has the sequence of SEQ ID NO 200.

[0818] 141 The polypeptide of row 126, wherein the polypeptide has the sequence of SEQ ID NO 213.

[0819] 142 The polypeptide of row 126, wherein the polypeptide has the sequence of SEQ ID NO 214.

[0820] 143 The polypeptide of row 126, wherein the polypeptide has the sequence of SEQ ID NO 215.

[0821] 144 The polypeptide of row 126, wherein the polypeptide has the sequence of SEQ ID NO 216.

[0822] 145 The polypeptide of row 126, wherein the polypeptide has the sequence of SEQ ID NO 217.

[0823] 146 The polypeptide of row 126, wherein the polypeptide has the sequence of SEQ ID NO 218.

[0824] 147 The polypeptide of row 126, wherein the polypeptide has the sequence of SEQ ID NO 221.

[0825] 148 The polypeptide of row 126, wherein the polypeptide has the sequence of SEQ ID NO 222.

[0826] 149 The polypeptide of row 126, wherein the polypeptide has the sequence of SEQ ID NO 225.

[0827] 150 The polypeptide of row 126, wherein the polypeptide has the sequence of SEQ ID NO 226.

[0828] 151 The polypeptide of row 126, wherein the polypeptide has the sequence of SEQ ID NO 228.

[0829] 152 The polypeptide of row 126, wherein the polypeptide has the sequence of SEQ ID NO 229.

[0830] 153 The polypeptide of row 126, wherein the polypeptide has the sequence of SEQ ID NO 230.

[0831] 154 The polypeptide of row 126, wherein the polypeptide has the sequence of SEQ ID NO 231.

[0832] 155 The polypeptide of row 126, wherein the polypeptide has the sequence of SEQ ID NO 232.

[0833] 156 The polypeptide of row 126, wherein the polypeptide has the sequence of SEQ ID NO 233.

[0834]

[0835] PATENT

[0836] ATTORNEY DOCKET NO.: 51184-064WO2

[0837] Row Composition

[0838] 157 The polypeptide of row 126, wherein the polypeptide has the sequence of SEQ ID NO: 234.

[0839] 158 The polypeptide of row 126, wherein the polypeptide has the sequence of SEQ ID NO: 235.

[0840] 159 The polypeptide of row 126, wherein the polypeptide has the sequence of SEQ ID NO: 236.

[0841] 160 The polypeptide of row 126, wherein the polypeptide has the sequence of SEQ ID NO: 237.

[0842] 161 The polypeptide of row 126, wherein the polypeptide has the sequence of SEQ ID NO: 238.

[0843] 162 The polypeptide of row 126, wherein the polypeptide has the sequence of SEQ ID NO: 240.

[0844] 163 The polypeptide of row 126, wherein the polypeptide has the sequence of SEQ ID NO: 243.

[0845] 164 The polypeptide of row 126, wherein the polypeptide has the sequence of SEQ ID NO: 246.

[0846] 165 The polypeptide of row 126, wherein the polypeptide has the sequence of SEQ ID NO: 248.

[0847] 166 The polypeptide of row 126, wherein the polypeptide has the sequence of SEQ ID NO: 251.

[0848] 167 The polypeptide of row 126, wherein the polypeptide has the sequence of SEQ ID NO: 253.

[0849] 168 The polypeptide of row 126, wherein the polypeptide has the sequence of SEQ ID NO: 257.

[0850] 169 The polypeptide of row 126, wherein the polypeptide has the sequence of SEQ ID NO: 259.

[0851] 170 The polypeptide of row 126, wherein the polypeptide has the sequence of SEQ ID NO: 263.

[0852] 171 The polypeptide of any one of rows 118-170, wherein the polypeptide forms a dimer.

[0853] 172 The polypeptide of row 171, wherein the polypeptide forms a homodimer.

[0854] 173 The polypeptide of any one of rows 118-172, wherein the linker is an amino acid spacer.

[0855] 174 The polypeptide of row 173, wherein the amino acid spacer is GGG, GGGA (SEQ ID NO: 49), GGGG (SEQ ID NO: 51), GGGAG (SEQ ID NO: 81), GGGAGG (SEQ ID NO: 82), or GGGAGGG (SEQ ID NO: 83). 175 The polypeptide of row 173, wherein the amino acid spacer is GGS, GGGS (SEQ ID NO: 50), GGGGS (SEQ ID NO: 53), GGSG (SEQ ID NO: 56), or SGGG (SEQ ID NO: 58).

[0856] 176 The polypeptide of row 173, wherein the amino acid spacer is GA, GS, GG, GGA, GGS, GGGS (SEQ ID NO: 50), GGGGA (SEQ ID NO: 52), GGGGS (SEQ ID NO: 53), GGGGG (SEQ ID NO: 54), GGAG (SEQ ID NO: 55), GGSG (SEQ ID NO: 56), AGGG (SEQ ID NO: 57), SGGG (SEQ ID NO: 58), GAGA (SEQ ID NO: 59), GSGS (SEQ ID NO: 60), GAGAGA (SEQ ID NO: 61), GSGSGS (SEQ ID NO: 62), GAGAGAGA (SEQ ID NO: 63), GSGSGSGS (SEQ ID NO: 64), GAGAGAGAGA (SEQ ID NO: 65), GSGSGSGSGS (SEQ ID NO: 66), GAGAGAGAGAGA (SEQ ID NO: 67), GSGSGSGSGSGS (SEQ ID NO: 68), GGAGGA (SEQ ID NO: 69), GGSGGS (SEQ ID NO: 70), GGAGGAGGA (SEQ ID NO: 71), GGSGGSGGS (SEQ ID NO: 72), GGAGGAGGAGGA (SEQ ID NO: 73), GGSGGSGGSGGS (SEQ ID NO: 74), GGAGGGAG (SEQ ID NO: 75), GGSGGGSG (SEQ ID NO: 76), GGAGGGAGGGAG (SEQ ID NO: 77), GGSGGGSGGGSG (SEQ ID NO: 78), GGGGAGGGGAGGGGA (SEQ ID NO: 79), GGGGSGGGGSGGGGS (SEQ ID NO: 80), AAAL (SEQ ID NO: 84), AAAK (SEQ ID NO: 85), AAAR (SEQ ID NO: 86), EGKSSGSGSESKST (SEQ ID NO: 87), GSAGSAAGSGEF (SEQ ID NO: 88), AEAAAKEAAAKA (SEQ ID NO: 89), KESGSVSSEQLAQFRSLD (SEQ ID NO: 90), GENLYFQSGG (SEQ ID NO: 91), SACYCELS (SEQ ID NO: 92), RSIAT (SEQ ID NO: 93), RPACKIPNDLKQKVMNH (SEQ ID NO: 94), GGSAGGSGSGSSGGSSGASGTGTAGGTGSGSGTGSG (SEQ ID NO: 95), AAANSSIDLISVPVDSR (SEQ ID NO: 96), GGSGGGSEGGGSEGGGSEGGGSEGGGSEGGGSGGGS (SEQ ID NO: 97), EAAAK (SEQ ID NO: 98), or PAPAP (SEQ ID NO: 99).

[0857] 177 The polypeptide of any one of rows 1-176, wherein the polypeptide (e.g., an ActRII chimera-Fc fusion protein) has a serum half-life of at least seven days.

[0858] 178 The polypeptide of any one of rows 1-177, wherein the polypeptide has increased binding to one or more ActRII ligands (e.g., activin A, activin B, myostatin, and / or GDF-11) compared to wild-type ActRIIA and / or wild-type ActRIIB (e.g., wild-type extracellular ActRIIA and / or ActRIIB).

[0859]

[0860] PATENT

[0861] ATTORNEY DOCKET NO.: 51184-064WO2

[0862] Row Composition

[0863] 179 The polypeptide of any one of rows 1-178, wherein the polypeptide has decreased binding to bone morphogenetic protein 9 (BMP9, e.g., human BMP9) compared to wild-type ActRIIB (e.g., wild-type extracellular ActRIIB).

[0864] 180 The polypeptide of any one of rows 1-179, wherein the polypeptide binds to activin A, activin B, and / or myostatin and has reduced or weak binding to human BMP9 (e.g., compared to wild-type extracellular ActRIIB).

[0865] 181 The polypeptide of any one of rows 1-180, wherein the polypeptide does not substantially bind to human BMP9.

[0866] 182 The polypeptide of any one of rows 1-181, wherein the polypeptide binds to human activin A with a KD of 800 pM or less.

[0867] 183 The polypeptide of any one of rows 1 -182, wherein the polypeptide binds to human activin A with a KD of 100 pM or less.

[0868] 184 The polypeptide of any one of rows 1 -183, wherein the polypeptide binds to human activin A with a KD of 50 pM or less.

[0869] 185 The polypeptide of any one of rows 1-184, wherein the polypeptide has an IC50 of 200 ng / mL or less in a cellular assay that measures inhibition of activin A signaling.

[0870] 186 The polypeptide of any one of rows 1-185, wherein the polypeptide has an IC50 of 150 ng / mL or less in a cellular assay that measures inhibition of activin A signaling.

[0871] 187 The polypeptide of any one of rows 1-186, wherein the polypeptide binds to human activin B with a KD of 800 pM or less.

[0872] 188 The polypeptide of any one of rows 1-187, wherein the polypeptide binds to human activin B with a KD of 50 pM or less.

[0873] 189 The polypeptide of any one of rows 1-188, wherein the polypeptide has an IC50 of about 200 ng / mL or less in a cellular assay that measures inhibition of activin B signaling.

[0874] 190 The polypeptide of any one of rows 1-189, wherein the polypeptide has an IC50 of about 50 ng / mL or less in a cellular assay that measures inhibition of activin B signaling.

[0875] 191 The polypeptide of any one of rows 1-190, wherein the polypeptide binds to human GDF-11 with a KD of 0.5 pM or higher.

[0876] 192 A nucleic acid molecule encoding the polypeptide of any one of rows 1-191.

[0877] 193 A vector comprising the nucleic acid molecule of row 192.

[0878] 194 A host cell that expresses the polypeptide of any one of rows 1-191, wherein the host cell comprises the nucleic acid molecule of row 192 or the vector of row 193, wherein the nucleic acid molecule or vector is expressed in the host cell.

[0879] 195 A pharmaceutical composition comprising the polypeptide of any one of rows 1 -191 , the nucleic acid molecule of row 192, or the vector of row 193 and one or more pharmaceutically acceptable carriers or excipients.

[0880] 196 The pharmaceutical composition of row 195, wherein the polypeptide, nucleic acid molecule, or vector is in a therapeutically effective amount.

[0881] 197 A construct comprising two identical polypeptides (e.g., a homodimer), each comprising an extracellular Act R 11 chimera of any one of rows 1-117 (e.g., an Act R 11 chimera having a sequence of any one of SEQ ID NOs: 1 -43 and 111-183) fused (e.g., linked using an amino acid spacer) to the N- or C-terminus of an Fc domain monomer (e.g., the sequence of SEQ ID NO: 48, SEQ ID NO: 100, SEQ ID NO: 264, or SEQ ID NO: 285). The two Fc domain monomers in the two polypeptides interact to form an Fc domain in the construct.

[0882]

[0883] PATENT

[0884] ATTORNEY DOCKET NO.: 51184-064WO2

[0885] Row Composition

[0886] 198 A construct comprising two different polypeptides (e.g., a heterodimer), each comprising an extracellular Act R 11 chimera of any one of rows 1-117 (e.g., an Act R 11 chimera having a sequence of any one of SEQ ID NOs: 1 -43 and 111-183) fused (e.g., linked using an amino acid spacer) to the N- or C-terminus of an Fc domain monomer (e.g., the sequence of SEQ ID NO: 48, SEQ ID NO: 100, SEQ ID NO: 264, or SEQ ID NO: 285). The two Fc domain monomers in the two polypeptides interact to form an Fc domain in the construct.

[0887]

[0888] Table 8

[0889] Row Composition

[0890] 1 A polypeptide comprising an extracellular activin receptor type IIB (ActRIIB) variant, the variant having one or more amino acid substitutions relative to the sequence of GRGEAETRECIYYNANWELERTNQSGLERCEGEQDKRLHCYASWRNSSGTIELVKKGCWLDDFNCYD RQECVATEENPQVYFCCCEGNFCNERFTHLPEAGGPEVTYEPPPTAPT (SEQ ID NO: 45), wherein the variant comprises one or more amino acid substitutions that impart reduced BMP9 binding relative to wild type extracellular ActRIIB and one or more additional amino acid substitutions, wherein the substitutions that reduce BMP9 binding comprise one or more of:

[0891] a) amino acid substitution E75K;

[0892] b) amino acid substitutions Q69T and E70D; or

[0893] c) amino acid substitutions Q69D and E70T,

[0894] optionally wherein the variant is truncated from the N-terminus by deletion of 1 , 2, 3, 4, 5, 6, or 7 amino acids.

[0895] 2 The polypeptide of row 1 , wherein the variant comprises one or more amino acid substitutions selected from the group consisting of 111L, Y12F, L19K, E20D, S25T, L27V, R29P, E31Y, E33D, Q34K, L38R, Y41 F, R45K, S47I, S48T, T50S, 151 L, L53I, K56Q, F63I, T74K, E76D, N77S, Q79E, and F89M.

[0896] 3 The polypeptide of row 1 or 2, wherein the variant comprises amino acid substitutions E75K, E20D, and F63I.

[0897] 4 The polypeptide of row 1 or 2, wherein the variant comprises amino acid substitution E75K.

[0898] 5 The polypeptide of row 4, wherein the variant comprises amino acid substitutions T74K, E76D, N77S, and Q79E.

[0899] 6 The polypeptide of row 5, wherein the variant further comprises one or more additional amino acid substitutions.

[0900] 7 The polypeptide of row 6, wherein the variant comprises amino acid substitutions Y41 F, R45K, and K56Q.

[0901] 8 The polypeptide of row 7, wherein the variant further comprises amino acid substitutions Y12F, L19K, E20D, R29P, E31Y, E33D, L38R, and F63I.

[0902] 9 The polypeptide of row 6, wherein the variant comprises amino acid substitutions S25T and S47I.

[0903] 10 The polypeptide of row 9, wherein the variant comprises amino acid substitution S48T.

[0904] 11 The polypeptide of row 6, wherein the variant comprises amino acid substitution R29P.

[0905] 12 The polypeptide of row 6, wherein the variant comprises amino acid substitutions E31 Y, E33D, and Q34K.

[0906] 13 The polypeptide of row 6, wherein the variant comprises amino acid substitutions Y12F, L19K, and E20D.

[0907]

[0908] PATENT

[0909] ATTORNEY DOCKET NO.: 51184-064WO2

[0910] Row Composition

[0911] 14 The polypeptide of row 6, wherein the variant comprises amino acid substitutions E31 Y, E33D, and L38R.

[0912] 15 The polypeptide of row 1 or 2, wherein the variant comprises amino acid substitutions Q69T and E70D.

[0913] 16 The polypeptide of any one of rows 1 , 2, and 15, wherein the variant comprises amino acid substitutions Q69T and E70D and additional amino acid substitutions 111 L, L27V, Q34K, T50S, 151 L, L53I, and F89M.

[0914] 17 The polypeptide of row 1 or 2, wherein the variant comprises amino acid substitutions Q69D and E70T.

[0915] 18 The polypeptide of any one of rows 1 , 2, and 17, wherein the variant comprises amino acid substitutions Q69D and E70T and additional amino acid substitutions 111 L, L27V, Q34K, T50S, 151 L, L53I, and F89M.

[0916] 19 The polypeptide of any one of rows 15-18, wherein the variant comprises amino acid substitution E75K.

[0917] 20 A polypeptide comprising an ActRIIB variant, the variant having a sequence of GRGEAETRECX1X2YNANWEX3X4RTNQX5GX6EX7CX8GX9X10DKRX11HCX12ASWX13NX14X15GX16X17E X18VKX19GCWLDDX20NCYDRX21X22CVAX23X24X25X26PX27VYFCCCEGNX28CNERFTHLPEAGGPEVTY EPPPTAPT (SEQ ID NO: 269), wherein Xi is I or L; X2is F or Y; X3is L or K; X4is D or E; X5is T or S; Xs is L or V; X7 is P or R; Xs is Y or E; Xg is D or E; X10 is K or Q; Xu is R or L; X12 is Y or F; X13 is R or K; X14 is S or I; X15 is S or T; Xis is S or T; X17 is I or L; Xis is I or L; X19 is K or Q; X20 is F or I; X21 is Q, T, or D; X22 is E, D, or T; X23 is K or T; X24 is K or E; X25 is D or E; X26 is S or N; X27 is E or Q; and X28 is F or M, and wherein X24 is E and / or either X21 is T and X22 is D or X21 is D and X22 is T, and wherein the variant has at least one amino acid substitution relative to a wild-type extracellular ActRIIB having the sequence of SEQ ID NO: 45, optionally wherein the variant is truncated from the N-terminus by deletion of 1 , 2, 3, 4, 5, 6, or 7 amino acids.

[0918] 21 The polypeptide of row 20, wherein Xi is I.

[0919] 22 The polypeptide of row 20, wherein Xi is L.

[0920] 23 The polypeptide of any one of rows 20-22, wherein X2 is F.

[0921] 24 The polypeptide of any one of rows 20-22, wherein X2 is Y.

[0922] 25 The polypeptide of any one of rows 20-24, wherein X3 is L.

[0923] 26 The polypeptide of any one of rows 20-24, wherein X3 is K.

[0924] 27 The polypeptide of any one of rows 20-26, wherein X4 is D.

[0925] 28 The polypeptide of any one of rows 20-26, wherein X4 is E.

[0926] 29 The polypeptide of any one of rows 20-28, wherein X5 is T.

[0927] 30 The polypeptide of any one of rows 20-28, wherein X5 is S.

[0928] 31 The polypeptide of any one of rows 20-30, wherein Xs is L.

[0929] 32 The polypeptide of any one of rows 20-30, wherein Xs is V.

[0930] 33 The polypeptide of any one of rows 20-32, wherein X7 is P.

[0931] 34 The polypeptide of any one of rows 20-32, wherein X7 is R.

[0932] 35 The polypeptide of any one of rows 20-34, wherein Xs is Y.

[0933] 36 The polypeptide of any one of rows 20-34, wherein Xs is E.

[0934] 37 The polypeptide of any one of rows 20-36, wherein Xg is D.

[0935] 38 The polypeptide of any one of rows 20-36, wherein Xg is E.

[0936] 39 The polypeptide of any one of rows 20-38, wherein X10 is K.

[0937] 40 The polypeptide of any one of rows 20-38, wherein X10 is Q.

[0938] 41 The polypeptide of any one of rows 20-40, wherein Xu is R.

[0939] 42 The polypeptide of any one of rows 20-40, wherein Xu is L.

[0940] 43 The polypeptide of any one of rows 20-42, wherein X12 is Y.

[0941]

[0942] PATENT

[0943] ATTORNEY DOCKET NO.: 51184-064WO2

[0944] Row Composition

[0945] 44 The polypeptide of any one of rows 20-42, wherein X12 is F.

[0946] 45 The polypeptide of any one of rows 20-44, wherein X13 is R.

[0947] 46 The polypeptide of any one of rows 20-44, wherein X13 is K.

[0948] 47 The polypeptide of any one of rows 20-46, wherein Xu is S.

[0949] 48 The polypeptide of any one of rows 20-46, wherein Xu is I.

[0950] 49 The polypeptide of any one of rows 20-48, wherein X15 is S.

[0951] 50 The polypeptide of any one of rows 20-48, wherein X15 is T.

[0952] 51 The polypeptide of any one of rows 20-50, wherein Xu is S.

[0953] 52 The polypeptide of any one of rows 20-50, wherein Xu is T.

[0954] 53 The polypeptide of any one of rows 20-52, wherein X17 is I.

[0955] 54 The polypeptide of any one of rows 20-52, wherein X17 is L.

[0956] 55 The polypeptide of any one of rows 20-54, wherein Xu is I.

[0957] 56 The polypeptide of any one of rows 20-54, wherein Xu is L.

[0958] 57 The polypeptide of any one of rows 20-56, wherein X19 is K.

[0959] 58 The polypeptide of any one of rows 20-56, wherein X19 is Q.

[0960] 59 The polypeptide of any one of rows 20-58, wherein X20 is F.

[0961] 60 The polypeptide of any one of rows 20-58, wherein X20 is I.

[0962] 61 The polypeptide of any one of rows 20-60, wherein X21 is Q.

[0963] 62 The polypeptide of any one of rows 20-60, wherein X21 is T.

[0964] 63 The polypeptide of any one of rows 20-60, wherein X21 is D.

[0965] 64 The polypeptide of any one of rows 20-61 , wherein X22 is E.

[0966] 65 The polypeptide of any one of rows 20-60 and 62, wherein X22 is D.

[0967] 66 The polypeptide of any one of rows 20-60 and 63, wherein X22 is T.

[0968] 67 The polypeptide of any one of rows 20-66, wherein X23 is K.

[0969] 68 The polypeptide of any one of rows 20-66, wherein X23 is T.

[0970] 69 The polypeptide of any one of rows 20-68, wherein X24 is K.

[0971] 70 The polypeptide of any one of rows 20-60, 62, 63, and 65-68, wherein X24 is E.

[0972] 71 The polypeptide of any one of rows 20-70, wherein X25 is D.

[0973] 72 The polypeptide of any one of rows 20-70, wherein X25 is E.

[0974] 73 The polypeptide of any one of rows 20-72, wherein X26 is S.

[0975] 74 The polypeptide of any one of rows 20-72, wherein X26 is N.

[0976] 75 The polypeptide of any one of rows 20-74, wherein X27 is E.

[0977] 76 The polypeptide of any one of rows 20-74, wherein X27 is Q.

[0978] 77 The polypeptide of any one of rows 20-76, wherein X28 is F.

[0979] 78 The polypeptide of any one of rows 20-76, wherein X28 is M.

[0980] 79 The polypeptide of any one of rows 20-78, wherein X23 is T, X24 is K, X25 is E, and X26 is N.

[0981] 80 The polypeptide of any one of rows 20-78, wherein X23 is T, X24 is E, X25 is E, and X26 is N.

[0982] 81 The polypeptide of any one of rows 20-78, wherein X23 is K, X24 is K, X25 is D, and X26 is S.

[0983] 82 The polypeptide of any one of rows 1-81 , wherein the variant has the sequence of any one of SEQ ID NOs: 270-283.

[0984] 83 The polypeptide of row 82, wherein the variant has the sequence of SEQ ID NO: 271 .

[0985] 84 The polypeptide of row 82, wherein the variant has the sequence of SEQ ID NO: 277.

[0986]

[0987] PATENT

[0988] ATTORNEY DOCKET NO.: 51184-064WO2

[0989] Row Composition

[0990] 85 The polypeptide of row 82, wherein the variant has the sequence of SEQ ID NO: 280.

[0991] 86 The polypeptide of row 82, wherein the variant has the sequence of SEQ ID NO: 281.

[0992] 87 The polypeptide of row 82, wherein the variant has the sequence of SEQ ID NO: 282.

[0993] 88 The polypeptide of row 82, wherein the variant has the sequence of SEQ ID NO: 283.

[0994] 89 The polypeptide of any one of rows 1-88, wherein the amino acid at position X24 is replaced with the amino acid K.

[0995] 90 The polypeptide of any one of rows 1-88, wherein the amino acid at position X24 is replaced with the amino acid E.

[0996] 91 The polypeptide of any one of rows 1-90, wherein the variant is truncated from the N-terminus by deletion of one amino acid.

[0997] 92 The polypeptide of any one of rows 1-90, wherein the variant is truncated from the N-terminus by deletion of two amino acids.

[0998] 93 The polypeptide of any one of rows 1-90, wherein the variant is truncated from the N-terminus by deletion of three amino acids.

[0999] 94 The polypeptide of any one of rows 1-90, wherein the variant is truncated from the N-terminus by deletion of four amino acids.

[1000] 95 The polypeptide of any one of rows 1-90, wherein the variant is truncated from the N-terminus by deletion of five amino acids.

[1001] 96 The polypeptide of any one of rows 1-90, wherein the variant is truncated from the N-terminus by deletion of six amino acids.

[1002] 97 The polypeptide of any one of rows 1-90, wherein the variant is truncated from the N-terminus by deletion of seven amino acids.

[1003] 98 The polypeptide of any one of rows 1 -97, further comprising an Fc domain monomer fused to the C- terminus of the polypeptide (e.g., the C-terminus of the ActRIIB variant) by way of a linker.

[1004] 99 The polypeptide of row 98, wherein the Fc domain monomer is an IgG 1 Fc domain monomer.

[1005] 100 The polypeptide of row 99, wherein the IgG 1 Fc domain monomer is a human IgG 1 Fc domain monomer.

[1006] 101 The polypeptide of row 98, wherein the Fc domain monomer comprises the sequence of SEQ ID NO: 48, SEQ ID NO: 100, SEQ ID NO: 264, or SEQ ID NO: 285.

[1007] 102 The polypeptide of row 101 , wherein the Fc domain monomer comprises the sequence of SEQ ID NO:

[1008] 100 or SEQ ID NO: 264.

[1009] 103 The polypeptide of row 101 , wherein the Fc domain monomer comprises the sequence of SEQ ID NO:

[1010] 100.

[1011] 104 The polypeptide of row 101 , wherein the Fc domain monomer comprises the sequence of SEQ ID NO:

[1012] 264.

[1013] 105 The polypeptide of row 101 , wherein the Fc domain monomer comprises the sequence of SEQ ID NO:

[1014] 285.

[1015] 106 The polypeptide of any one of rows 98-105, wherein the polypeptide forms a dimer.

[1016] 107 The polypeptide of row 106, wherein the polypeptide forms a homodimer.

[1017] 108 The polypeptide of any one of rows 98-107, wherein the linker is an amino acid spacer.

[1018] 109 The polypeptide of row 108, wherein the amino acid spacer is GGG, GGGA (SEQ ID NO: 49), GGGG (SEQ ID NO: 51), GGGAG (SEQ ID NO: 81), GGGAGG (SEQ ID NO: 82), or GGGAGGG (SEQ ID NO: 83).

[1019]

[1020] PATENT

[1021] ATTORNEY DOCKET NO.: 51184-064WO2

[1022] Row Composition

[1023] 110 The polypeptide of row 109, wherein the amino acid spacer is GGG.

[1024] 111 The polypeptide of row 103 or 110, wherein the polypeptide has the sequence of SEQ ID NO: 284. 112 The polypeptide of row 108, wherein the amino acid spacer is GA, GS, GG, GGA, GGS, GGG, GGGS (SEQ ID NO: 50), GGGGA (SEQ ID NO: 52), GGGGS (SEQ ID NO: 53), GGGGG (SEQ ID NO: 54), GGAG (SEQ ID NO: 55), GGSG (SEQ ID NO: 56), AGGG (SEQ ID NO: 57), SGGG (SEQ ID NO: 58), GAGA (SEQ ID NO: 59), GSGS (SEQ ID NO: 60), GAGAGA (SEQ ID NO: 61), GSGSGS (SEQ ID NO: 62), GAGAGAGA (SEQ ID NO: 63), GSGSGSGS (SEQ ID NO: 64), GAGAGAGAGA (SEQ ID NO: 65), GSGSGSGSGS (SEQ ID NO: 66), GAGAGAGAGAGA (SEQ ID NO: 67), GSGSGSGSGSGS (SEQ ID NO: 68), GGAGGA (SEQ ID NO: 69), GGSGGS (SEQ ID NO: 70), GGAGGAGGA (SEQ ID NO: 71), GGSGGSGGS (SEQ ID NO: 72), GGAGGAGGAGGA (SEQ ID NO: 73), GGSGGSGGSGGS (SEQ ID NO: 74), GGAGGGAG (SEQ ID NO: 75), GGSGGGSG (SEQ ID NO: 76), GGAGGGAGGGAG (SEQ ID NO: 77), GGSGGGSGGGSG (SEQ ID NO: 78), GGGGAGGGGAGGGGA (SEQ ID NO: 79), GGGGSGGGGSGGGGS (SEQ ID NO: 80), AAAL (SEQ ID NO: 84), AAAK (SEQ ID NO: 85), AAAR (SEQ ID NO: 86), EGKSSGSGSESKST (SEQ ID NO: 87), GSAGSAAGSGEF (SEQ ID NO: 88), AEAAAKEAAAKA (SEQ ID NO: 89), KESGSVSSEQLAQFRSLD (SEQ ID NO: 90), GENLYFQSGG (SEQ ID NO: 91), SACYCELS (SEQ ID NO: 92), RSIAT (SEQ ID NO: 93), RPACKIPNDLKQKVMNH (SEQ ID NO: 94), GGSAGGSGSGSSGGSSGASGTGTAGGTGSGSGTGSG (SEQ ID NO: 95), AAANSSIDLISVPVDSR (SEQ ID NO: 96), GGSGGGSEGGGSEGGGSEGGGSEGGGSEGGGSGGGS (SEQ ID NO: 97), EAAAK (SEQ ID NO: 98), or PAPAP (SEQ ID NO: 99).

[1025] 113 The polypeptide of any one of rows 1-112, wherein the polypeptide has a serum half-life of at least 7 days.

[1026] 114 The polypeptide of any one of rows 1-113, wherein the polypeptide binds to activin A, activin B, and / or myostatin and has reduced or weak binding to human BMP9.

[1027] 115 The polypeptide of row 114, wherein the polypeptide does not substantially bind to human BMP9. 116 The polypeptide of any one of rows 1-115, wherein the polypeptide binds to human activin A with a KD of 800 pM or less.

[1028] 117 The polypeptide of any one of rows 1-116, wherein the polypeptide binds to human activin A with a KD of 100 pM or less.

[1029] 118 The polypeptide of any one of rows 1-117, wherein the polypeptide binds to human activin A with a KD of 50 pM or less.

[1030] 119 The polypeptide of any one of rows 1-118, wherein the polypeptide has an IC50 of 200 ng / mL or less in a cellular assay that measures inhibition of activin A signaling.

[1031] 120 The polypeptide of any one of rows 1-119, wherein the polypeptide has an IC50 of 150 ng / mL or less in a cellular assay that measures inhibition of activin A signaling.

[1032] 121 The polypeptide of any one of rows 1-120, wherein the polypeptide binds to human activin B with a KD of 800 pM or less.

[1033] 122 The polypeptide of any one of rows 1-121, wherein the polypeptide binds to human activin B with a KD of 50 pM or less.

[1034] 123 The polypeptide of any one of rows 1-122, wherein the polypeptide has an IC50 of about 200 ng / mL or less in a cellular assay that measures inhibition of activin B signaling.

[1035] 124 The polypeptide of any one of rows 1-123, wherein the polypeptide has an IC50 of about 50 ng / mL or less in a cellular assay that measures inhibition of activin B signaling.

[1036]

[1037] PATENT

[1038] ATTORNEY DOCKET NO.: 51184-064WO2

[1039] Row Composition

[1040] 125 The polypeptide of any one of rows 1 -124, wherein the polypeptide binds to human GDF-11 with a KD of 0.5 pM or higher.

[1041] 126 A nucleic acid molecule encoding a polypeptide of any one of rows 1 -125.

[1042] 127 A vector comprising the nucleic acid molecule of row 126.

[1043] 128 A host cell that expresses a polypeptide of any one of rows 1-125, wherein the host cell comprises a nucleic acid molecule of row 126 or a vector of row 127, wherein the nucleic acid molecule or vector is expressed in the host cell.

[1044] 129 A pharmaceutical composition comprising a polypeptide of any one of rows 1-125, a nucleic acid molecule of row 126, or a vector of row 127, and one or more pharmaceutically acceptable carriers or excipients.

[1045] 130 The pharmaceutical composition of row 129, wherein the polypeptide is in a therapeutically effective amount.

[1046] 131 A construct comprising two identical polypeptides (e.g., a homodimer), each comprising an extracellular ActRIIB variant of any one of rows 1-97 (e.g., an ActRIIB variant having a sequence of any one of SEQ ID NOs: 269-283) fused (e.g., linked using an amino acid spacer) to the N- or C-terminus of an Fc domain monomer (e.g., the sequence of SEQ ID NO: 48, SEQ ID NO: 100, SEQ ID NO: 264, or SEQ ID NO: 285). The two Fc domain monomers in the two polypeptides interact to form an Fc domain in the construct.

[1047] 132 A construct comprising two different polypeptides (e.g., a heterodimer), each comprising an extracellular ActRIIB variant of any one of rows 1-97 (e.g., an ActRIIB variant having a sequence of any one of SEQ ID NOs: 269-283) fused (e.g., linked using an amino acid spacer) to the N- or C-terminus of an Fc domain monomer (e.g., the sequence of SEQ ID NO: 48, SEQ ID NO: 100, SEQ ID NO: 264, or SEQ ID NO: 285). The two Fc domain monomers in the two polypeptides interact to form an Fc domain in the construct.

[1048]

[1049] Examples

[1050] The following examples are provided to further illustrate some embodiments of the present invention but are not intended to limit the scope of the invention; it will be understood by their exemplary nature that other procedures, methodologies, or techniques known to those skilled in the art may alternatively be used.

[1051] Example 1 - Effect of ActRIIB 2.12-mFc and Chimera 1 / 2b-mFc in a mouse model for ADPKD The effect of ActRIIB 2.12-mFc (a homodimer of SEQ ID NO: 283 linked to a mouse Fc domain monomer by a GGG linker) and Chimera 1 / 2b-mFc (a homodimer of SEQ ID NO: 41 fused to a mouse Fc domain monomer by way of a GGG linker) on ADPKD disease progression was evaluated in an inducible mouse model of ADPKD. Compared to Chimera 1 / 2b-mFc, ActRIIB 2.12-mFc shows lower binding affinity for activin A (KD of 120 pM for ActRIIB 2.12-mFc vs. KD of 48 pM for Chimera 1 / 2b-mFc), reduced activity in a cellular assay that measures inhibition of activin A signaling (IC50 of 6797 ng / ml for ActRIIB 2.12-mFc vs. IC50 of 31 .54 ng / ml for Chimera 1 / 2b-mFc), and reduced activity in a cellular assay that measures inhibition of activin B signaling (IC50 of 154 ng / ml for ActRIIB 2.12-mFc vs. IC50 of 11 .72 ng / ml for Chimera 1 / 2b-mFc).PATENT

[1052] ATTORNEY DOCKET NO.: 51184-064WO2

[1053] One-month old doxycycline inducible PKD1 knockout (KO) mice (Pkd1 f / f; Pax8+; Tet-O-Cre+) received doxycycline at 1 month of age to induce disruption of the Pkd1 gene and KO of polycystin-1 (PC1) protein to trigger initiation and moderate disease progression. Immediately following doxycycline administration, mice were dosed subcutaneously (5 mL / kg) with 10 mg / kg ActRIIB 2.12-mFc (n=5 mice), 3 mg / kg Chimera 1 / 2b-mFc (n=5 mice), or Tris-buffered saline (TBS) control (n=4 mice) twice weekly for twelve weeks. Body weights were collected at the time of dosing. At the end of the 12-week dosing period, mice were sacrificed and kidneys weighed to estimate cystic burden. Kidney weights were evaluated using one way ANOVA with Dunnett’s post-hoc test for multiple comparisons (GRAPHPAD PRISM™ version 11.0).

[1054] Kidney weight results (left kidney weight, right kidney weight, total kidney weight, and kidney / body weight (2KBW)) are shown in FIGS. 1 A-1D. The left, right and total kidney weights of mice treated with ActRIIB 2.12-mFc were not significantly different from TBS treated control mice. Whereas left, right and total kidney weights of Chimera 1 / 2b-mFc treated mice were -31.0%, -34.8% and -34.7% lighter than TBS treated mice, respectively. Only the right and total kidney weights from Chimera 1 / 2b-mFc treated mice were significantly lighter (p<0.05) than corresponding ActRIIB 2.12-mFc treated mice. When normalizing total kidney weights to terminal body weights (2KBW), ActRIIB 2.12-mFc 2KBW were not significantly different from TBS treated controls. 2KBW of mice treated with Chimera 1 / 2b-mFc were 1.25% and 2KBW of mice treated with TBS were 1.98%, a significant reduction of -37.2% (p<0.05). The decrease in kidney weights and 2KBW of Chimera 1 / 2b-mFc treated mice compared to TBS treated controls is consistent with a significant reduction in cystic burden.

[1055] Example 2 - Treatment of ADPKD by administration of an extracellular ActRII variant According to the methods disclosed herein, a physician of skill in the art can treat ADPKD in a subject, such as a human patient, in need thereof so as to reduce kidney fibrosis or slow the progression of kidney fibrosis, reduce kidney inflammation or slow the progression of kidney inflammation, or improve kidney function or slow the decline of kidney function. To treat the subject, a physician of skill in the art can administer to the subject a composition containing a polypeptide including an extracellular ActRII variant (e.g., a polypeptide including extracellular ActRII chimera having the sequence of any one of SEQ ID NOs: 1-43 (e.g., SEQ ID NOs: 22-43) or a polypeptide including an extracellular ActRIIB variant having the sequence of any one of SEQ ID NOs: 269-283 (e.g., SEQ ID NOs: 270-283), such as a polypeptide containing an extracellular ActRII chimera or an extracellular ActRIIB variant linked to an Fc domain monomer (e.g., a polypeptide that is in the form of a homodimer of an extracellular ActRIIB variant or an extracellular ActRII chimera linked to an Fc domain monomer, which forms an Fc domain in the dimer)). The composition containing the extracellular ActRII variant may be administered to the subject, for example, by parenteral injection (e.g., intravenous or subcutaneous injection) to treat ADPKD. The polypeptide containing an extracellular ActRII variant is administered in a therapeutically effective amount, such as from 0.01 to 500 mg / kg (e.g., 0.01 , 0.1 , 0.2, 0.3, 0.325, 0.35, 0.375, 0.4, 0.5, 0.75, 1 , 1.25, 1.5, 1.75, 2, 2.25, 2.5, 2.75, 3, 3.25, 3.5, 3.75, 4, 4.25, 4.5, 4.75, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 100, 150, 200, 250, 300, 350, 400, 450, or 500 mg / kg). In some embodiments, the extracellular ActRII variant is administered once every sixteen weeks, quarterly, once every twelve weeks, bimonthly, once every eight weeks, once a month, once every four weeks, once every two weeks, or at least once a weekPATENT

[1056] ATTORNEY DOCKET NO.: 51184-064WO2

[1057] or more (e.g., 1 , 2, 3, 4, 5, 6, or 7 times a week or more). The extracellular ActRII variant is administered in an amount sufficient to increase reduce kidney fibrosis or slow the progression of kidney fibrosis, reduce kidney inflammation or slow the progression of kidney inflammation, improve GFR or slow a decline in GFR, and / or slow progression of the disease.

[1058] Following administration of the composition to a patient, a practitioner of skill in the art can monitor the patient’s improvement in response to the therapy by a variety of methods. For example, a physician can monitor the patient’s kidney function using blood tests, urine tests, and imaging tests. A finding that the patient’s kidney function is improving or that the disease is progressing more slowly following administration of the composition compared to test results prior to administration of the composition indicates that the patient is responding favorably to the treatment. Subsequent doses can be determined and administered as needed.

[1059] Example 3 - Treatment of lupus nephritis by administration of an extracellular ActRII variant According to the methods disclosed herein, a physician of skill in the art can treat lupus nephritis in a subject, such as a human patient, in need thereof so as to reduce kidney fibrosis or slow the progression of kidney fibrosis, reduce kidney inflammation, slow the progression of kidney inflammation, improve kidney function, or slow the decline of kidney function. To treat the subject, a physician of skill in the art can administer to the subject a composition containing a polypeptide including an extracellular ActRII variant (e.g., a polypeptide including extracellular ActRII chimera having the sequence of any one of SEQ ID NOs: 1 -43 (e.g., SEQ ID NOs: 22-43) or a polypeptide including an extracellular ActRIIB variant having the sequence of any one of SEQ ID NOs: 269-283 (e.g., SEQ ID NOs: 270-283), such as a polypeptide containing an extracellular ActRII chimera or an extracellular ActRIIB variant linked to an Fc domain monomer (e.g., a polypeptide that is in the form of a homodimer of an extracellular ActRIIB variant or an extracellular ActRII chimera linked to an Fc domain monomer, which forms an Fc domain in the dimer)). The composition containing the extracellular ActRII variant may be administered to the subject, for example, by parenteral injection (e.g., intravenous or subcutaneous injection) to treat lupus nephritis. The polypeptide containing an extracellular ActRII variant is administered in a therapeutically effective amount, such as from 0.01 to 500 mg / kg (e.g., 0.01 , 0.1 , 0.2, 0.3, 0.325, 0.35, 0.375, 0.4, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 2.75, 3, 3.25, 3.5, 3.75, 4, 4.25, 4.5, 4.75, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 100, 150, 200, 250, 300, 350, 400, 450, or 500 mg / kg). In some embodiments, the extracellular ActRII variant is administered once every sixteen weeks, quarterly, once every twelve weeks, bimonthly, once every eight weeks, once a month, once every four weeks, once every two weeks, or at least once a week or more (e.g., 1 , 2, 3, 4, 5, 6, or 7 times a week or more). The extracellular ActRII variant is administered in an amount sufficient to increase reduce kidney fibrosis or slow the progression of kidney fibrosis, reduce kidney inflammation or slow the progression of kidney inflammation, improve GFR or slow a decline in GFR, and / or slow progression of the disease.

[1060] Following administration of the composition to a patient, a practitioner of skill in the art can monitor the patient’s improvement in response to the therapy by a variety of methods. For example, a physician can monitor the patient’s kidney function using blood tests, urine tests, and imaging tests. A finding that the patient’s kidney function is improving or that the disease is progressing more slowly following administration of the composition compared to test results prior to administration of thePATENT

[1061] ATTORNEY DOCKET NO.: 51184-064WO2

[1062] composition indicates that the patient is responding favorably to the treatment. Subsequent doses can be determined and administered as needed.

[1063] Example 4 - Treatment of Antineutrophil Cytoplasmic Antibody (ANCA)-associated vasculitis by administration of an extracellular ActRII variant

[1064] According to the methods disclosed herein, a physician of skill in the art can treat ANCA-associated vasculitis in a subject, such as a human patient, in need thereof so as to reduce kidney fibrosis or slow the progression of kidney fibrosis, reduce kidney inflammation or slow the progression of kidney inflammation, or improve kidney function or slow the decline of kidney function. To treat the subject, a physician of skill in the art can administer to the subject a composition containing a polypeptide including an extracellular ActRII variant (e.g., a polypeptide including extracellular ActRII chimera having the sequence of any one of SEQ ID NOs: 1-43 (e.g., SEQ ID NOs: 22-43) or a polypeptide including an extracellular ActRIIB variant having the sequence of any one of SEQ ID NOs: 269-283 (e.g., SEQ ID NOs: 270-283), such as a polypeptide containing an extracellular ActRII chimera or an extracellular ActRIIB variant linked to an Fc domain monomer (e.g., a polypeptide that is in the form of a homodimer of an extracellular ActRIIB variant or an extracellular ActRII chimera linked to an Fc domain monomer, which forms an Fc domain in the dimer)). The composition containing the extracellular ActRII variant may be administered to the subject, for example, by parenteral injection (e.g., intravenous or subcutaneous injection) to treat ANCA-associated vasculitis. The polypeptide containing an extracellular ActRII variant is administered in a therapeutically effective amount, such as from 0.01 to 500 mg / kg (e.g., 0.01 , 0.1 , 0.2, 0.3, 0.325, 0.35, 0.375, 0.4, 0.5, 0.75, 1 , 1.25, 1.5, 1.75, 2, 2.25, 2.5, 2.75, 3, 3.25, 3.5, 3.75, 4, 4.25, 4.5, 4.75, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 100, 150, 200, 250, 300, 350, 400, 450, or 500 mg / kg). In some embodiments, the extracellular ActRII variant is administered once every sixteen weeks, quarterly, once every twelve weeks, bimonthly, once every eight weeks, once a month, once every four weeks, once every two weeks, or at least once a week or more (e.g., 1 , 2, 3, 4, 5, 6, or 7 times a week or more). The extracellular ActRII variant is administered in an amount sufficient to increase reduce kidney fibrosis or slow the progression of kidney fibrosis, reduce kidney inflammation or slow the progression of kidney inflammation, improve GFR or slow a decline in GFR, and / or slow progression of the disease.

[1065] Following administration of the composition to a patient, a practitioner of skill in the art can monitor the patient’s improvement in response to the therapy by a variety of methods. For example, a physician can monitor the patient’s kidney function using blood tests, urine tests, and imaging tests. A finding that the patient’s kidney function is improving or that the disease is progressing more slowly following administration of the composition compared to test results prior to administration of the composition indicates that the patient is responding favorably to the treatment. Subsequent doses can be determined and administered as needed.

[1066] Example 5 - Treatment of IgA nephropathy by administration of an extracellular ActRII variant According to the methods disclosed herein, a physician of skill in the art can treat IgA nephropathy in a subject, such as a human patient, in need thereof so as to reduce kidney fibrosis or slow the progression of kidney fibrosis, reduce kidney inflammation or slow the progression of kidney inflammation, or improve kidney function or slow the decline of kidney function. To treat the subject, aPATENT

[1067] ATTORNEY DOCKET NO.: 51184-064WO2

[1068] physician of skill in the art can administer to the subject a composition containing a polypeptide including an extracellular ActRII variant (e.g., a polypeptide including extracellular ActRII chimera having the sequence of any one of SEQ ID NOs: 1-43 (e.g., SEQ ID NOs: 22-43) or a polypeptide including an extracellular ActRIIB variant having the sequence of any one of SEQ ID NOs: 269-283 (e.g., SEQ ID NOs: 270-283), such as a polypeptide containing an extracellular ActRII chimera or an extracellular ActRIIB variant linked to an Fc domain monomer (e.g., a polypeptide that is in the form of a homodimer of an extracellular ActRIIB variant or an extracellular ActRII chimera linked to an Fc domain monomer, which forms an Fc domain in the dimer)). The composition containing the extracellular ActRII variant may be administered to the subject, for example, by parenteral injection (e.g., intravenous or subcutaneous injection) to treat IgA nephropathy. The polypeptide containing an extracellular ActRII variant is administered in a therapeutically effective amount, such as from 0.01 to 500 mg / kg (e.g., 0.01 , 0.1 , 0.2, 0.3, 0.325, 0.35, 0.375, 0.4, 0.5, 0.75, 1 , 1 .25, 1 .5, 1 .75, 2, 2.25, 2.5, 2.75, 3, 3.25, 3.5, 3.75, 4, 4.25, 4.5, 4.75, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 100, 150, 200, 250, 300, 350, 400, 450, or 500 mg / kg). In some embodiments, the extracellular ActRII variant is administered once every sixteen weeks, quarterly, once every twelve weeks, bimonthly, once every eight weeks, once a month, once every four weeks, once every two weeks, or at least once a week or more (e.g., 1 , 2, 3, 4, 5, 6, or 7 times a week or more). The extracellular ActRII variant is administered in an amount sufficient to increase reduce kidney fibrosis or slow the progression of kidney fibrosis, reduce kidney inflammation or slow the progression of kidney inflammation, improve GFR or slow a decline in GFR, and / or slow progression of the disease.

[1069] Following administration of the composition to a patient, a practitioner of skill in the art can monitor the patient’s improvement in response to the therapy by a variety of methods. For example, a physician can monitor the patient’s kidney function using blood tests, urine tests, and imaging tests. A finding that the patient’s kidney function is improving or that the disease is progressing more slowly following administration of the composition compared to test results prior to administration of the composition indicates that the patient is responding favorably to the treatment. Subsequent doses can be determined and administered as needed.

[1070] Other Embodiments

[1071] While the invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modifications and this application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure come within known or customary practice within the art to which the invention pertains and may be applied to the essential features hereinbefore set forth.

[1072] All publications, patents, and patent applications are herein incorporated by reference in their entirety to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference in its entirety.

[1073] Other embodiments are within the following claims.

Claims

1. PATENTATTORNEY DOCKET NO.: 51184-064WO2CLAIMS1. A method of treating autosomal dominant polycystic kidney disease (ADPKD) in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a composition of Table 7 or a composition of Table 8.

2. The method of claim 1 , wherein the method reduces kidney cyst volume, hepatic cyst volume, or pancreatic cyst volume.

3. The method of claim 1 or 2, wherein the subject has a mutation in polycystin 1 (PKD1) or polycystin 2 (PKD2).

4. The method of any one of claims 1-3, wherein the method slows or inhibits progression of cardiovascular disease.

5. The method of claim 4, wherein the cardiovascular disease is hypertension, an aneurysm, mitral valve prolapse, aortic dissection, atrial fibrillation, left ventricular hypertrophy, aortic calcification, soft tissue calcification, cardiomyopathy, vasculitis, or left-sided heart failure.

6. The method of any one of claims 1-5, wherein the method slows or inhibits progression of bone disease.

7. The method of claim 6, wherein the bone disease is osteoporosis, bone pain, bone fracture, soft tissue calcification, osteopenia, osteopetrosis, bone cancer or cancer metastasis-related bone loss, Paget’s disease, renal osteodystrophy, treatment-related bone loss, osteogenesis imperfecta, neuromuscular disease-related bone loss, burn-induced bone loss, anorexia-related bone loss, diet-related bone loss, bone loss associated with the treatment of obesity, low gravity-related bone loss, or immobility-related bone loss.

8. The method of claim 7, wherein the cancer is multiple myeloma, osteosarcoma, breast cancer, prostate cancer, lung cancer, or kidney cancer.

9. The method of any one of claims 1 -8, wherein the method slows or inhibits progression of diverticular disease.

10. The method of any one of claims 1 -9, wherein the method prevents urinary tract infections or decreases the frequency or severity of urinary tract infections.

11. The method of any one of claims 1 -10, wherein the method reduces kidney weight.

12. The method of any one of claims 1-11, wherein the method reduces expression of a SMAD2 / 3 target gene.PATENTATTORNEY DOCKET NO.: 51184-064WO213. The method of claim 12, wherein the SMAD2 / 3 target gene is Colled , Fn1 (EDA), or PAH .

14. A method of treating lupus nephritis in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a composition of Table 7 or a composition of Table 8.

15. The method of claim 14, wherein the method slows or inhibits progression of cardiovascular disease.

16. The method of claim 15, wherein the cardiovascular disease is hypertension or left ventricular hypertrophy.

17. The method of any one of claims 14-16, wherein the method slows or inhibits progression of bone disease.

18. The method of claim 17, wherein the bone disease is osteoporosis, bone pain, bone fracture, soft tissue calcification, osteopenia, osteopetrosis, bone cancer or cancer metastasis-related bone loss, Paget’s disease, renal osteodystrophy, treatment-related bone loss, osteogenesis imperfecta, neuromuscular disease-related bone loss, burn-induced bone loss, anorexia-related bone loss, diet-related bone loss, bone loss associated with the treatment of obesity, low gravity-related bone loss, or immobility-related bone loss.

19. The method of claim 18, wherein the cancer is multiple myeloma, osteosarcoma, breast cancer, prostate cancer, lung cancer, or kidney cancer.

20. A method of treating antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a composition of Table 7 or a composition of Table 8.

21. The method of claim 20, wherein the method slows or inhibits progression of cardiovascular disease.

22. The method of claim 21 , wherein the cardiovascular disease is hypertension or left ventricular hypertrophy.

23. The method of any one of claims 20-22, wherein the method slows or inhibits progression of bone disease.

24. The method of claim 23, wherein the bone disease is osteoporosis, bone pain, bone fracture, soft tissue calcification, osteopenia, osteopetrosis, bone cancer or cancer metastasis-related bone loss, Paget’s disease, renal osteodystrophy, treatment-related bone loss, osteogenesis imperfecta, neuromuscular disease-related bone loss, burn-induced bone loss, anorexia-related bone loss, diet-related bone loss, bone loss associated with the treatment of obesity, low gravity-related bone loss, or immobility-related bone loss.PATENTATTORNEY DOCKET NO.: 51184-064WO225. The method of claim 24, wherein the cancer is multiple myeloma, osteosarcoma, breast cancer, prostate cancer, lung cancer, or kidney cancer.

26. A method of treating immunoglobulin A (IgA) nephropathy in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a composition of Table 7 or a composition of Table 8.

27. The method of claim 26, wherein the method slows or inhibits progression of cardiovascular disease.

28. The method of claim 27, wherein the cardiovascular disease is hypertension or left ventricular hypertrophy.

29. The method of any one of claims 26-28, wherein the method slows or inhibits progression of bone disease.

30. The method of claim 29, wherein the bone disease is osteoporosis, bone pain, bone fracture, soft tissue calcification, osteopenia, osteopetrosis, bone cancer or cancer metastasis-related bone loss, Paget’s disease, renal osteodystrophy, treatment-related bone loss, osteogenesis imperfecta, neuromuscular disease-related bone loss, burn-induced bone loss, anorexia-related bone loss, diet-related bone loss, bone loss associated with the treatment of obesity, low gravity-related bone loss, or immobility-related bone loss.

31. The method of claim 30, wherein the cancer is multiple myeloma, osteosarcoma, breast cancer, prostate cancer, lung cancer, or kidney cancer.

32. The method of any one of claims 1 -31 , wherein the subject is male.

33. The method of any one of claims 1 -31 , wherein the subject is female.

34. The method of any one of claims 1 -33, wherein the method reduces kidney fibrosis or slows or inhibits progression of kidney fibrosis.

35. The method of any one of claims 1-34, wherein the method reduces kidney inflammation or slows or inhibits progression of kidney inflammation.

36. The method of any one of claims 1-35, wherein the method improves kidney function or slows or inhibits a decline in kidney function.

37. The method of claim 36, wherein improving kidney function or slowing or inhibiting a decline in kidney function results in improved glomerular filtration rate (GFR) or slowing or stopping a progressive decline in GFR, improved protein-to-creatinine ratio (PCR), albumin-to-creatinine ratio (ACR), or urinary albumin-PATENTATTORNEY DOCKET NO.: 51184-064WO2creatinine-ratio (UACR) or slowing or stopping a progressive increase in PCR, ACR or UACR, reduced blood urea nitrogen, reduced creatinine in blood, improved creatinine clearance, reduced proteinuria, reduced hematuria, or reduced albuminuria.

38. The method of claim 37, wherein the method improves GFR or slows or inhibits a decline in GFR.

39. The method of any one of claims 1-38, wherein the method delays or prevents the onset of end stage renal disease.

40. The method of any one of claims 1 -39, wherein the method delays or prevents a need for dialysis, continuous renal replacement therapy, or a kidney transplant.

41. The method of any one of claims 1-40, wherein the method improves life expectancy for the subject.

42. The method of any one of claims 1 -41 , wherein the method comprises administering to the subject a therapeutically effective amount of a composition of Table 7.

43. The method of any one of claims 1 -41 , wherein the method comprises administering to the subject a therapeutically effective amount of a composition of Table 8.